documents incorporated referencepart iii portions registrants proxy statement annual meeting shareholders filed within days close registrants fiscal year proxy statement incorporated reference report reportitem p art business general segments b usiness geographic reas raw aterials patents trademarks seasonality competition environment regulation employees h uman c apital anagement available nformation risk f actors b unresolved taff c omments c cybersecurity properties legal p roceedings mine afety isclosures executive fficers r egistrant p art ii market r egistrants c ommon e quity r elated tockholder atters ssuer p urchases e quity ecurities reserved managements iscussion nalysis r esults perations f inancial c ondition quantitative q ualitative isclosures bout arket r sk cautionary note regarding forwardlooking statements annual report johnson johnsons publicly available documents contain forwardlooking statements within meaning safe harbor provisions united states private securities litigation reform act management representatives johnson johnson subsidiaries company also may time time make forwardlooking statements forwardlooking statements relate strictly historical current facts reflect managements assumptions views plans objectives projections future forwardlooking statements may identified use words plans expects anticipates estimates words similar meaning conjunction among things discussions future operations expected operating results financial performance impact planned acquisitions dispositions impact timing restructuring initiatives including associated cost savings benefits companys strategy growth product development activities regulatory approvals market position expenditures forwardlooking statements based current beliefs expectations assumptions regarding future events subject uncertainties risks changes difficult predict many outside companys control investors realize underlying assumptions prove inaccurate known unknown risks uncertainties materialize companys actual results financial condition could vary materially expectations projections expressed implied forwardlooking statements investors therefore cautioned rely forwardlooking statements risks uncertainties include limited risks related product development market success competition challenges uncertainties inherent innovation development new improved products technologies companys continued growth success depend including uncertainty clinical outcomes additional analysis existing clinical data obtaining regulatory approvals health plan coverage customer access initial continued commercial success challenges companys ability obtain protect adequate patent intellectual property rights new existing products technologies united states important markets impact patent expirations typically followed introduction competing generic biosimilar products resulting revenue market share losses increasingly aggressive frequent challenges companys patents competitors others seeking launch competing generic biosimilar products increased receptivity courts united states patent trademark office decision makers challenges potentially resulting loss market exclusivity rapid decline sales relevant product sooner expected competition research development new improved products processes technologies result product process obsolescence competition reach agreement third parties collaboration licensing development marketing agreements products technologies competition based costeffectiveness product performance technological advances patents attained competitors allegations companys products infringe patents intellectual property rights third parties could adversely affect companys ability sell products question require payment money damages future royalties risks related product liability litigation regulatory activity product efficacy safety concerns whether based scientific evidence potentially resulting product withdrawals recalls regulatory action part united states food drug administration us fda international counterparts declining sales reputational damage increased litigation expense share price impact impact including declining sales reputational damage significant litigation government action adverse company including product liability claims allegations related pharmaceutical marketing practices contracting strategies impact adverse judgment settlement adequacy reserves related legal proceedings including patent litigation product liability personal injury claims securities class actions government investigations employment legal proceedings increased scrutiny healthcare industry government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties including limited debarment government business failure meet compliance obligations compliance agreements governments government agencies could result significant sanctions potential changes applicable laws regulations affecting united states international operations including relating approval new products licensing patent rights sales promotion healthcare products access reimbursement pricing healthcare products services environmental protection sourcing raw materials compliance local regulations laws may restrict companys ability manufacture sell products relevant markets including requirements comply medical device reporting regulations requirements european unions medical devices regulation changes domestic international tax laws regulations increasing audit scrutiny tax authorities around world exposures additional tax liabilities potentially excess existing reserves issuance new revised accounting standards financial accounting standards board regulations securities exchange commission risks related companys strategic initiatives healthcare market trends realization benefits separation companys consumer health business pricing pressures resulting trends toward healthcare cost containment including continued consolidation among healthcare providers market participants trends toward managed care shift toward governments increasingly becoming primary payors healthcare expenses significant new entrants healthcare markets seeking reduce costs government pressure companies voluntarily reduce costs price increases restricted spending patterns individual institutional governmental purchasers healthcare products services due economic hardship budgetary constraints challenges companys ability realize strategy growth including externally sourced innovations development collaborations strategic acquisitions licensing marketing agreements potential heightened costs external arrangements due competitive pressures potential expected strategic benefits opportunities planned completed acquisition divestiture company may realized may take longer realize expected potential expected benefits opportunities related past ongoing restructuring actions may realized may take longer realize expected companys ability divest companys remaining ownership interest kenvue inc kenvue realize anticipated benefits separation kenvue 's ability succeed standalone publicly traded company risks related economic conditions financial markets operating internationally risks associated global operations company customers suppliers including foreign governments countries company operates impact inflation fluctuations interest rates currency exchange rates potential effect fluctuations revenues expenses resulting margins potential changes exportimport trade laws regulations policies united states countries including increased trade restrictions tariffs potential drug reimportation legislation impact international operations financial instability international economies sovereign risk possible imposition governmental controls restrictive economic policies unstable international governments legal systems impact global public health crises pandemics changes global climate extreme weather natural disasters could affect demand companys products services cause disruptions manufacturing distribution networks alter availability goods services within supply chain affect overall design integrity companys products operations impact global economic changes events including global tensions war impact armed conflicts terrorist attacks united states parts world including social economic disruptions instability financial markets risks related supply chain operations difficulties delays manufacturing internally thirdparty providers otherwise within supply chain may lead voluntary involuntary business interruptions shutdowns product shortages withdrawals suspensions products market potential regulatory action interruptions breaches companys information technology systems companys vendors could result reputational competitive operational business harm well financial costs regulatory action reliance global supply chains production distribution processes complex subject increasing regulatory requirements may adversely affect supply sourcing pricing materials used companys products potential expected benefits opportunities related restructuring actions may realized may take longer realize expected including due required approvals applicable regulatory authorities investors also carefully read risk factors described item annual report description certain risks could among things cause companys actual results differ materially expressed forwardlooking statements investors understand possible predict identify factors consider risks described item complete statement potential risks uncertainties company undertake publicly update forwardlooking statement may made time time whether result new information future events developmentspart item business general johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products healthcare field johnson johnson holding company operating companies conducting business virtually countries world companys primary focus products related human health wellbeing johnson johnson incorporated state new jersey executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities company 's two business segments innovative medicine previously referred pharmaceutical medtech within strategic parameters provided committee senior management groups us international operating companies responsible strategic plans daytoday operations companies subsidiary within business segments limited exceptions managed residents country located segments business following completion separation consumer health business kenvue august company organized two business segments innovative medicine medtech additional information required item incorporated herein reference narrative tabular descriptions segments operating results item managements discussion analysis results operations financial condition report note segments business geographic areas notes consolidated financial statements included item report innovative medicine innovative medicine segment focused following therapeutic areas immunology eg rheumatoid arthritis psoriatic arthritis inflammatory bowel disease psoriasis infectious diseases eg hivaids neuroscience eg mood disorders neurodegenerative disorders schizophrenia oncology eg prostate cancer hematologic malignancies lung cancer bladder cancer cardiovascular metabolism eg thrombosis diabetes macular degeneration pulmonary hypertension eg pulmonary arterial hypertension medicines segment distributed directly retailers wholesalers distributors hospitals healthcare professionals prescription use key products innovative medicine segment include remicade infliximab treatment number immunemediated inflammatory diseases simponi golimumab subcutaneous treatment adults moderate severe rheumatoid arthritis active psoriatic arthritis active ankylosing spondylitis moderately active severely active ulcerative colitis simponi aria golimumab intravenous treatment adults moderate severe rheumatoid arthritis active psoriatic arthritis active ankylosing spondylitis active polyarticular juvenile idiopathic arthritis pjia people years age older stelara ustekinumab treatment adults children moderate severe plaque psoriasis adults active psoriatic arthritis adults moderately severely active crohn 's disease treatment moderately severely active ulcerative colitis tremfya guselkumab treatment adults moderate severe plaque psoriasis active psoriatic arthritis edurant rilpivirine prezista darunavir prezcobixrezolsta darunavircobicistat antiretroviral medicines treatment human immunodeficiency virus hiv combination antiretroviral products symtuza darunavircobicistatemtricitabine tenofovir alafenamide oncedaily single tablet regimen treatment hiv concerta methylphenidate hcl extended release tablets cii treatment attention deficit hyperactivity disorder invega sustennaxeplion paliperidone palmitate treatment schizophrenia schizoaffective disorder adults invega trinzatrevicta paliperidone palmitate treatment schizophrenia patients adequately treated invega sustenna least four months spravato esketamine nasal spray used along oral antidepressant treat adults treatmentresistant depression trd depressive symptoms adults major depressive disorder mdd suicidal thoughts actions carvykti ciltacabtagene autoleucel chimeric antigen receptor cartcell therapy treatment patients withrelapsedrefractory multiple myeloma zytiga abiraterone annual report acetate treatment patients prostate cancer erleada apalutamide next generation androgen receptor inhibitor treatment patients prostate cancer imbruvica ibrutinib treatment certain bcell malignancies blood cancers chronic graft versus host disease darzalex daratumumab treatment multiple myeloma darzalex faspro daratumumab hyaluronidasefihj treatment multiple myeloma light chain al amyloidosis xarelto rivaroxaban oral anticoagulant prevention deep vein thrombosis dvt may lead pulmonary embolism pe patients undergoing hip knee replacement surgery reduce risk stroke systemic embolism patients nonvalvular atrial fibrillation treatment reduction risk recurrence dvt pe reduce risk major cardiovascular events patients coronary artery disease cad peripheral artery disease pad treatment secondary prevention thromboembolism pediatric patients thromboprophylaxis pediatric patients following fontan procedure opsumit macitentan monotherapy combination indicated longterm treatment pulmonary arterial hypertension pah uptravi selexipag approved oral intravenous selective ip receptor agonist targeting prostacyclin pathway pah many medicines developed collaboration strategic partners licensed companies maintain active lifecycle development programs medtech medtech segment includes broad portfolio products used interventional solutions orthopaedics surgery vision categories interventional solutions include electrophysiology products biosense webster treat heart rhythm disorders heart recovery portfolio abiomed includes technologies treat severe coronary artery disease requiring highrisk pci ami cardiogenic shock neurovascular care cerenovus treats hemorrhagic ischemic stroke orthopaedics portfolio depuy synthes includes products enabling technologies support hips knees trauma spine sports surgery portfolios include advanced general surgery technologies ethicon well solutions focus breast aesthetics mentor ear nose throat acclarent procedures johnson johnson vision products include acuvue brand contact lenses tecnis intraocular lenses cataract surgery products distributed wholesalers hospitals retailers used predominantly professional fields physicians nurses hospitals eye care professionals clinics geographic areas johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products healthcare field company conducts business virtually countries world primary focus products related human health wellbeing products made sold international business include many described segments business innovative medicine medtech however principal markets products methods distribution international business vary country culture products sold international business include developed us subsidiaries abroad investments activities countries outside us subject higher risks comparable us activities investment commercial climate may influenced financial instability international economies restrictive economic policies political legal system uncertainties raw materials raw materials essential company 's business generally readily available multiple sources exceptions temporary unavailability raw materials would likely material adverse effect financial results company patents company 's subsidiaries made practice obtaining patent protection products processes possible licensed significant number patents us countries relating products product uses formulations manufacturing processes aggregate believed material importance company operation businesses companys subsidiaries face patent challenges third parties including challenges seeking manufacture market generic biosimilar versions company 's key pharmaceutical products prior expiration applicable patents covering products significant legal proceedings claims involving company 's patent intellectual property described note legal proceedingsintellectual property notes consolidated financial statements included item report sales companys largest product stelara ustekinumab accounted approximately company 's total revenues fiscal accordingly patents related product believed material company janssen biotech inc whollyowned subsidiary johnson johnson owns patents specifically related stelara latest expiring united states composition matter patent expired result settlements agreements third parties company anticipate launch biosimilar version stelara january united states latest expiring european composition matter patent supplementary protection certificate expires sales companys second largest product collectively darzalex daratumumab darzalex faspro daratumumab hyaluronidasefihj accounted approximately company 's total revenues fiscal accordingly patents related product believed material company genmab owns two patent families related darzalex janssen biotech inc exclusive license patent families two patent families expire united states europe compound patent protection select countries extends janssen biotech inc owns separate patent portfolio related darzalex faspro trademarks companys subsidiaries made practice selling products trademarks obtaining protection trademarks available means trademarks protected registration us countries products marketed company considers trademarks aggregate material importance operation businesses seasonality worldwide sales reflect significant degree seasonality however spending typically heavier fourth quarter year quarters reflects increased spending decisions principally research development activity competition product lines company 's subsidiaries compete companies locally globally competition exists product lines without regard number size competing companies involved competition research internally externally sourced involving development improvement new existing products processes particularly significant development new innovative products well protecting underlying intellectual property companys product portfolio important company 's success areas business competitive environment requires substantial investments continuing research environment company subject variety environmental laws regulations united states jurisdictions company believes operations comply material respects applicable environmental laws regulations companys compliance requirements expected material effect upon capital expenditures cash flows earnings competitive position annual report regulation companys businesses subject varying degrees governmental regulation countries operations conducted general trend toward increasingly stringent regulation enforcement company subject costly complex us foreign laws governmental regulations adverse regulatory action may materially adversely affect company 's financial condition business operations us pharmaceutical product medical technology industries long subject regulation various federal state agencies primarily product safety efficacy manufacturing advertising labeling safety reporting exercise broad regulatory powers us food drug administration us fda continues result increases amounts testing documentation required us fda approval new drugs devices corresponding increase expense product introduction similar trends also evident major markets outside us new medical device regulatory framework evolving privacy data localization emerging cyber security laws regulations around world examples increased regulation within us increasing number us states enacted comprehensive privacy laws federal regulators eg us fda ftc hhs continue stress intersection health privacy compliance enforcement priority eu multiple directives laws including nis ehds data act cyber resilience act ai act rapidly changing privacy cybersecurity compliance requirements introducing new enforcement risks addition china introduced broad personal information protection data security regulations anticipated thereby increasing chinas scrutiny company compliance data transfer practices jurisdictions enacting similar privacy laws local data protection authorities force greater accountability collection access use personal data healthcare industry laws also restrict transfers data across borders potentially impacting datadriven health care solutions developed deployed globally compliant manner moreover result broad scale release availability artificial intelligence ai technologies generative ai global trend towards comprehensive nuanced regulation eg white houses executive order safe secure trustworthy development use artificial intelligence eu ai act ensure ethical use privacy security ai underway includes standards transparency accountability fairness require compliance developments enhancements regulatory agencies whose purview company operates administrative powers may subject actions product withdrawals recalls seizure products civil criminal sanctions cases companys subsidiaries may deem advisable initiate product recalls regardless whether required directed us fda regulatory agencies around globe also increasing enforcement activities us fda conclude compliance applicable laws regulations pharmaceutical products medical technologies ineffective pose unreasonable health risk us fda could ban products detain seize adulterated misbranded products order recall repair replacement refund products refuse grant pending applications marketing authorization require certificates foreign governments exports andor require us notify health professionals others products present unreasonable risks substantial harm public health us fda may also assess civil criminal penalties us officers employees impose operating restrictions companywide basis enjoin andor restrain certain conduct resulting violations applicable law us fda may also recommend prosecution us department justice adverse regulatory action depending magnitude may restrict us effectively marketing selling products limit ability obtain future clearances approvals could result substantial modification business practices operations equivalent enforcement mechanisms exist different countries conduct business costs human healthcare continue subject study investigation regulation governmental agencies legislative bodies around world us attention focused states regulatory agencies congress prices profits overutilization quality costs healthcare generally laws regulations enacted require adherence strict compliance standards prevent fraud abuse healthcare industry increased focus interactions financial relationships healthcare companies healthcare providers various state federal transparency laws regulations require disclosures payments transfers value made certain healthcare practitioners including physicians teaching hospitals certain nonphysician practitioners federal foreign laws governing international business practices require strict compliance antibribery standards certain prohibitions respect payments foreign government official payors pharmacy benefit managers pbms potent force marketplace increased attention paid impact pbm practices healthcare cost access us business continues affected federal state legislation alters pricing coverage andreimbursement landscape federal level august president biden signed law inflation reduction act ira includes provisions effectively authorize government establish prices certain highspend singlesource drugs biologics reimbursed medicare program starting medicare part drugs medicare part b drugs august centers medicare medicaid services cms published first selected drug list includes xarelto stelara well imbruvica developed collaboration cocommercialized us pharmacyclics llc abbvie company selected drug list also included medicines targeting disease states prevalent medicare population remains uncertainty however regarding federal government establish prices selected products ira specifies ceiling price minimum price event anticipate selected products subjected governmentestablished price medicare population ira also contains provisions impose rebates certain prices increase rate outpaces rate inflation beginning october medicare part drugs january medicare part b drugs separate ira provisions redesign medicare part benefit various ways including shifting greater portion costs manufacturers within certain coverage phases replacing part coverage gap discount program new manufacturer discounting program failure comply ira provisions may subject manufacturers various penalties including civil monetary penalties july janssen pharmaceuticals inc janssen filed litigation us department health human services well centers medicare medicaid services challenging constitutionality inflation reduction acts ira medicare drug price negotiation program litigation requests declaration ira violates janssens rights first amendment fifth amendment constitution therefore janssen subject iras mandatory pricing scheme impact ira business broader pharmaceutical industry remains uncertain litigation filed janssen pharmaceutical companies remains ongoing cms yet publicly announce maximum fair price selected drugs additionally expect continued scrutiny drug pricing government price reporting congress agencies bodies federal state levels may result additional regulations mechanisms increase pricing transparency controls number additional bills pending congress healthcare reform proposals state level would affect drug pricing including medicare medicaid programs changing legal landscape positive negative impacts us healthcare industry much remaining uncertain various provisions federal state law potential modification repeal laws ultimately affect industry ira federal state legislative change could affect pricing market conditions products addition business practices healthcare industry come increased scrutiny particularly us government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties note increased enforcement activity data protection authorities various jurisdictions particularly european union significant fines levied companies data breaches violations privacy requirements unlawful crossborder data transfers us federal trade commission stepped enforcement data privacy several significant settlements including settlements concerning downstream sharing personal information use disclosure personal health data material increase classaction lawsuits linked collection use biometric data use tracking technologies company relies global supply chains production distribution processes complex subject increasing regulatory requirements may affect sourcing supply pricing materials used company 's products processes also subject complex lengthy regulatory approvals annual report employees human capital management december number employees approximately employees fulltime equivalent fte positions employee defined individual working fulltime parttime excluding fixed term employees interns coop employees employee data may include full population recently acquired companies individuals longterm disability excluded contingent workers contractors subcontractors also excluded fte represents total number fulltime equivalent positions reflect total number individual employees work parttime employees region percentages strategy company believes employees critical continued success essential element longterm strategy management responsible ensuring policies processes reflect reinforce company 's desired corporate culture including policies processes related strategy risk management ethics compliance companys human capital management strategy built three fundamental focus areas attracting recruiting best talent developing retaining talent empowering inspiring talent underpinning focus areas ongoing efforts cultivate foster culture built diversity equity inclusion dei innovation health wellbeing safety company 's employees encouraged succeed professionally personally helping company achieve business goals culture employee engagement company employees guided credo sets forth company 's responsibilities patients consumers customers healthcare professionals employees communities shareholders employees worldwide must adhere companys code business conduct sets basic requirements serves foundation company policies procedures guidelines provide additional guidance expected employee behaviors every market operates company conducts global surveys offer employees ability provide feedback valuable insight help address potential human resources risks identify opportunities improve global employees across countries participated credo survey offered languages growth development lead changing healthcare landscape crucial company continue attract retain top talent company 's voluntary turnover rate company believes employees must equipped right knowledge skills provided opportunities grow develop careers accordingly professional development programs educational resources available employees company 's objective foster learning culture helps shape persons unique career path creating robust pipeline talent deliver companys longterm strategies furtherance objective company deploys global approach ensure development everyone regardless career journey prioritize learning company recently held johnson johnson 's first global learning day employees encouraged set aside full day explore skillbuilding courses across five areas leadership business skills digital upskilling dei wellbeing jj learn company 's new learning platform diversity equity inclusion dei company committed workplace diversity cultivating fostering advancing culture equity inclusion companys evidencedbased global enterprise diversity equity inclusion strategy recognizes dei accelerates company 's ability meet changing needs communities company serves outlined credo companys dei vision change world company 's dei mission make diversity equity inclusion work everyday company 's enterprise dei strategy aligned dei vision mission rests four core pillars build workforce individuals diverse backgrounds cultures abilities perspectives foster culture inclusion every individual belongs transform talent business processes achieve equitable opportunities drive innovation growth business serve diverse markets around world company 's dei strategy guided internal external insights global best practices continual employee feedback recognizes diversity changes location inclusion everywhere annual report compensation benefits part company 's total rewards philosophy company offers competitive compensation benefits attract retain top talent company committed fairness equitable treatment compensation benefits employees levels company observes legal minimum wage provisions exceeds possible company 's total rewards offerings include array programs support employees ' wellbeing including annual performance incentive opportunities pension retirement savings programs health welfare benefits paid time leave programs flexible work schedules employee assistance programs recognition companys commitment help employees balance personal professional responsibilities company enhanced caregiver bereavement volunteer paid leave benefits effective july health wellness safety companys investment employee health wellbeing safety built conviction advancing health humanity starts advancing health employees right awareness focus practices tools company ensures employees around world well temporary contractors visitors company 's sites work safely company continuously expanded health wellbeing programs throughout company across globe incorporating new thinking technologies keep offerings bestinclass help employees achieve personal health goals programs practices company advances total healthphysical mental emotional financialensure employee health protection emerging health risks company continues address employees needs jj flex hybrid model empowers companys officebased employees find right productivity balance inperson remote work available information companys main corporate website address wwwjnjcom company makes sec filings available companys website wwwinvestorjnjcomfinancialssecfilings soon reasonably practicable electronically filed furnished sec company 's sec filings also available secs website wwwsecgov investors public note company also announces information wwwfactsaboutourprescriptionopioidscom wwwfactsabouttalccom wwwlltmanagementinformationcom use websites communicate investors public products litigation matters possible information post websites could deemed material information therefore encourage investors others interested company review information posted websites conjunction wwwjnjcom company 's sec filings press releases public conference calls webcasts addition amended restated certificate incorporation bylaws written charters audit committee compensation benefits committee nominating corporate governance committee regulatory compliance sustainability committee science technology committee special committee board directors companys principles corporate governance code business conduct employees code business conduct ethics members board directors executive officers corporate governance materials available wwwinvestorjnjcomgovernancecorporategovernanceoverview company 's website provided without charge shareholder submitting written request provided information wwwjnjcom wwwfactsaboutourprescriptionopioidscom wwwfactsabouttalccom wwwlltmanagementinformationcom deemed part report incorporated filings company makes sec item risk factors investment companys common stock debt securities involves risks uncertainties company seeks identify manage mitigate risks business uncertainties risks difficult predict many outside companys control therefore eliminated addition information report companys filings sec investors consider carefully factors set forth investors aware possible predict identify factors following meant complete discussion potential risks uncertainties known unknown risks uncertainties materialize companys business results operations financial condition could adversely affected potentially material way risks related business industry operations companys businesses operate highly competitive product markets competitive pressures could adversely affect companys earnings company faces substantial competition two operating segments geographic markets companys businesses compete companies sizes basis costeffectiveness technological innovations intellectual property rights product performance real perceived product advantages pricing availability rate reimbursement company also competes market participants securing rights acquisitions collaborations licensing agreements third parties competition rights product candidates technologies may result significant investment acquisition costs onerous agreement terms company competitors development effective less costly products andor ability secure patent intellectual property rights successfully market products ahead company could negatively impact sales companys existing products well ability bring new products market despite significant prior investment related product development company may also experience operational financial risk connection acquisitions unable fully identify potential risks liabilities associated acquired businesses products successfully integrate operations employees successfully identify realize synergies existing businesses containing acquisitionrelated strain management operations financial resources companys innovative medicine businesses loss patent exclusivity product often followed substantial reduction sales competitors gain regulatory approval generic competing products enter market similar competition triggered loss exclusivity biological product companys medtech businesses technological innovation product quality reputation customer service especially important competitiveness development companies new improved products processes technologies could threaten make companys products technologies less desirable less economical obsolete companys business operations negatively impacted unable introduce new products technological advances safe effective effectively marketed otherwise outperform competitors interruptions delays manufacturing operations could adversely affect companys business sales reputation companys manufacturing products requires timely delivery sufficient amounts complex highquality components materials companys subsidiaries operate manufacturing facilities well sourcing thousands suppliers around world company past may future face unanticipated interruptions delays manufacturing internal external supply chain manufacturing disruptions occur many reasons including regulatory action production quality deviations safety issues labor disputes labor shortages sitespecific incidents fires natural disasters hurricanes severe weather events raw material shortages political unrest terrorist attacks epidemics pandemics delays difficulties manufacturing result product shortages declines sales reputational impact well significant remediation related costs associated addressing shortage company relies third parties manufacture supply certain products failure loss thirdparty manufacturer supplier could result delays increased costs may adversely affect business company relies third parties manufacture supply certain raw materials component parts products depend thirdparty manufacturers allocate us portion manufacturing capacity sufficient meet needs produce products acceptable quality acceptable manufacturing yields deliver products us timely basis acceptable prices however guarantee thirdparty manufacturers able meet nearterm longterm manufacturing requirements could result lost sales adverse effect business annual report risks associated reliance third parties manufacture products include reliance third party regulatory compliance quality assurance misappropriation companys intellectual property limited ability manage inventory possible breach manufacturing agreement third party possible termination nonrenewal manufacturing agreement third party time costly inconvenient us moreover third party manufacturers suffers damage facilities loses benefits material agreements experiences power outages encounters financial difficulties unable secure necessary raw materials suppliers suffers reduction efficiency company may experience significant business disruption event disruption company would need seek source qualified thirdparty manufacturers likely resulting delays increased costs could affect business adversely counterfeit versions products could harm patients negative impact revenues earnings reputation business industry continues challenged vulnerability distribution channels illegal counterfeiting presence counterfeit products growing number markets internet third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards distributors patients counterfeit products may visually indistinguishable authentic version counterfeit medicines pose risk patient health safety conditions manufactured often unregulated unlicensed uninspected unsanitary sites well lack regulation contents industrys failure mitigate threat counterfeit medicines could adversely impact business reputation impacting patient confidence authentic products potentially resulting lost sales product recalls increased threat litigation addition diversion products authorized market channels may result reduced revenues negatively affect profitability global health crises pandemics epidemics outbreaks could adversely disrupt impact certain aspects companys business results operations financial condition subject risks associated global health crises epidemics pandemics outbreaks incidents health crisis health crises example covid pandemic adversely impacted certain aspects companys business results operations financial condition including lower sales reduced customer demand usage certain products spread health crises may cause company modify business practices take actions may required government authorities company determines best interests patients customers employees business partners circumstances company robust business continuity plans place across global supply chain network designed help mitigate impact health crises efforts may completely prevent business adversely affected event health crisis health crises could adversely impact companys operations including among things manufacturing operations supply chain thirdparty suppliers sales marketing clinical trial operations factors could adversely affect companys business financial results global economic conditions generally risks related government regulation legal proceedings global sales companys innovative medicine medtech segments may negatively impacted healthcare reforms increasing pricing pressures sales companys innovative medicine medtech products significantly affected reimbursements third party payors government healthcare programs private insurance plans managed care organizations part various efforts contain healthcare costs payors putting downward pressure prices products reimbursed us increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries part due continued consolidation among healthcare providers could result pricing pressures addition recent legislation ongoing political scrutiny pricing coverage reimbursement could result additional pricing pressures specifically inflation reduction act ira may subject certain products governmentestablished pricing potentially impose rebates subject manufacturers fail adhere government 's interpretations law penalties increased thirdparty utilization b federal drug discount program expanded interpretations statute may negative impact company 's financial performance outside us numerous major markets including eu united kingdom japan china pervasive government involvement funding healthcare regard directly indirectly impose price controls limit access reimbursement companys products reduce value intellectual property protectionwe subject increasing number costly complex governmental regulations countries operations conducted may materially adversely affect companys financial condition business operations described item business company subject increasing number extensive government laws regulations investigations legal action national state local government agencies us countries operates example changes us fdas timing requirements approval clearance products may negative impact ability bring new products market new laws regulations may also impose deadlines company thirdparty suppliers manufacturers partners providers may insufficient time implement changes comply new regulations may result manufacturing delays supply chain constraints company unable identify ways mitigate delays constraints may adverse effect sales access products company subject significant legal proceedings result significant expenses fines reputational damage ordinary course business johnson johnson subsidiaries subject numerous claims lawsuits involving various issues product liability patent disputes claims product sales marketing pricing practices violate various antitrust unfair trade practices andor consumer protection laws companys significant legal proceedings described note legal proceedings notes consolidated financial statements included item report litigation general securities derivative action class action multidistrict litigation particular expensive disruptive matters may include thousands plaintiffs may involve parties seeking large andor indeterminate amounts including punitive exemplary damages may remain unresolved several years example company defendant numerous lawsuits arising use body powders containing talc primarily johnsons baby powder companys sale manufacturing marketing opioids company believes substantial defenses matters feasible predict ultimate outcome litigation company could future required pay significant amounts result settlements judgments matters potentially excess accruals including matters company could held jointly severally liable among defendants resolution increase accruals one matters reporting period could material adverse effect companys results operations cash flows period company purchase thirdparty product liability insurance however company utilizes wholly owned captive insurance company subject certain limits product reliability safety effectiveness concerns significant negative impacts sales results operations lead litigation cause reputational damage concerns product safety whether raised internally litigants regulators consumer advocates whether based scientific evidence result safety alerts product recalls governmental investigations regulatory action part us fda counterpart countries private claims lawsuits payment fines settlements declining sales reputational damage circumstances also result damage brand image brand equity consumer trust companys products product recalls past could future prompt government investigations inspections shutdown manufacturing facilities continued product shortages related sales declines significant remediation costs reputational damage possible civil penalties criminal prosecution company faces significant regulatory scrutiny imposes significant compliance costs exposes company government investigations legal actions penalties rapid increase new government laws regulations imposes significant compliance costs company failure company timely implement changes comply new laws may expose company investigations legal actions penalties regulatory issues regarding compliance current good manufacturing practices cgmp comparable quality regulations foreign countries manufacturers drugs devices lead fines penalties product recalls product shortages interruptions production delays new product approvals litigation addition marketing pricing sale companys products subject regulation investigations legal actions including federal food drug cosmetic act medicaid rebate program federal state false claims acts state unfair trade practices acts consumer protection laws scrutiny healthcare industry business practices government agencies state attorneys general us resulting investigations prosecutions carry risk significant civil criminal penalties including limited debarment participation government healthcare programs debarment could material adverse effect companys business results operations significant current investigations litigation brought government agencies described note legal proceedingsgovernment proceedings notes consolidated financial statements included item report annual report changes tax laws exposures additional tax liabilities could negatively impact companys operating results changes tax laws regulations around world including us led organization economic cooperation development recent enactment certain eu noneu countries anticipated enactment additional countries global minimum tax could negatively impact companys effective tax rate results operations change statutory tax rate certain international tax provisions country would result revaluation companys deferred tax assets liabilities related particular jurisdiction period new tax law enacted change would result expense benefit recorded companys consolidated statement earnings company closely monitors proposals arise countries operates changes tax laws regulations may occur time related expense benefit recorded may material fiscal quarter year law change enacted see note income taxes notes consolidated financial statements included item report additional information company conducts business files tax returns numerous countries addressing tax audits disputes many tax authorities connection various government initiatives companies required disclose information tax authorities operations around world may lead greater audit scrutiny profits earned countries company regularly assesses likely outcomes tax audits disputes determine appropriateness tax reserves however tax authority could take position tax treatment contrary companys expectations could result tax liabilities excess reserves risks related intellectual property company faces increased challenges intellectual property rights central business company owns licenses significant number patents proprietary rights relating products manufacturing processes rights essential companys businesses materially important companys results operations public policy within outside us become increasingly unfavorable toward intellectual property rights company certain obtain adequate patent protection new products technologies united states important markets protections granted last long originally anticipated competitors routinely challenge validity extent companys owned licensed patents proprietary rights litigation interferences oppositions proceedings inter partes review ipr proceedings united states patent trademark office uspto proceedings absorb resources protracted well unpredictable addition challenges companys products infringe patents third parties could result injunction andor need pay past damages future royalties adversely affect competitive position sales products question company faced increasing patent challenges third parties seeking manufacture market generic biosimilar versions companys key pharmaceutical products prior expiration applicable patents covering products us manufacturers generic versions innovative human pharmaceutical products may challenge validity claim noninfringement innovator products abbreviated new drug application anda process us fda related anda litigation biologics price competition innovation act bpcia enacted created new regulatory pathway approval us fda biosimilar alternatives innovatordeveloped biological products also created mechanisms biosimilar applicants challenge patents innovator biologics ipr process uspto also used competitors challenge patents asserted litigation event company successful defending patents challenges upon atrisk launch generic biosimilar firm product company lose major portion revenues referenced product short period time current legal proceedings involving companys patents intellectual property rights described note legal proceedingsintellectual property notes consolidated financial statements included item report risks related product development regulatory approval commercialization significant challenges delays companys innovation development implementation new products technologies indications could adverse impact companys longterm success companys continued growth success depends ability innovate develop new differentiated products services address evolving healthcare needs patients providers consumers development successful products technologies also necessary offset revenue losses companys existing products lose market share due various factors competition loss patent exclusivity new products introduced within past five years accounted approximately sales company certain whether able develop license otherwise acquire companies products technologies whether particular product candidates granted regulatory approval approved whether products commercially successful company pursues product development internal research development well collaborations acquisitions joint ventures licensing arrangements third parties contexts developing new products particularly pharmaceutical biotechnology products medical devices requires significant investment resources many years biopharmaceutical research development programs result commercially viable products process depends many factors including ability discern patients healthcare providers future needs develop promising new compounds strategies technologies achieve successful clinical trial results secure effective intellectual property protection obtain regulatory approvals timely basis reach market successfully differentiate companys products competing products approaches treatment new products enhancements existing products may accepted quickly significantly marketplace due product price competition changes customer preferences healthcare purchasing patterns resistance healthcare providers uncertainty thirdparty reimbursement even following initial regulatory approval success product adversely impacted safety efficacy findings larger realworld patient populations well market entry competitive products company leverages use data science machine learning forms ai emerging technologies across varying parts business operations introduction incorporation ai may result unintended consequences new expanded risks liabilities ai technology continuously evolving ai technologies develop adopt may become obsolete earlier planned investments technologies may result benefits anticipate enable us obtain maintain competitive advantage application machine learning ai business emerging evolving alongside new laws regulations may entail significant costs ultimately limit ability continue use technologies technologies also carry inherent risks related data privacy security described risks related financial economic market conditions company faces variety financial economic legal social political risks associated conducting business internationally companys extensive operations business activity throughout world accompanied certain financial economic legal social political risks including listed foreign currency exchange fiscal approximately companys sales occurred outside us approximately europe western hemisphere excluding us asiapacific africa region changes nonus currencies relative us dollar impact companys revenues expenses company uses financial instruments mitigate impact fluctuations currency exchange rates cash flows unhedged exposures continue subject currency fluctuations addition weakening strengthening us dollar may result significant favorable unfavorable translation effects operating results companys nonus business activity translated us dollars inflation currency devaluation risks company faces challenges maintaining profitability operations economies experiencing high inflation rates specifically company accounted operations argentina turkey venezuela highly inflationary prior threeyear cumulative inflation rate surpassed company strives maintain profit margins areas cost reduction programs productivity improvements periodic price increases mightexperience operating losses result continued inflation addition impact currency devaluations annual report countries experiencing high inflation rates significant currency exchange fluctuations could negatively impact companys operating results illegal importation pharmaceutical products illegal importation pharmaceutical products countries government price controls market dynamics result lower prices may adversely affect companys sales profitability us countries company operates exception limited quantities prescription drugs personal use foreign imports pharmaceutical products illegal current us law however volume illegal imports continues rise ability patients customers obtain lowerpriced imports grown significantly antibribery regulations company subject various federal foreign laws govern international business practices respect payments government officials laws include us foreign corrupt practices act fcpa prohibits us publicly traded companies promising offering giving anything value foreign officials corrupt intent influencing foreign official purpose helping company obtain retain business gain improper advantage companys business heavily regulated therefore involves significant interaction foreign officials also many countries outside us healthcare providers prescribe human pharmaceuticals employed government purchasers human pharmaceuticals government entities therefore companys interactions prescribers purchasers subject regulation fcpa addition us application enforcement fcpa various jurisdictions company operates laws regulations including uk bribery act aimed preventing penalizing corrupt anticompetitive behavior enforcement activities laws could subject company additional administrative legal proceedings actions could include claims civil penalties criminal sanctions administrative remedies including exclusion healthcare programs financial economic legal social political risks risks inherent conducting business globally include local regional economic environments policies markets serve including interest rates monetary policy inflation economic growth recession commodity prices currency controls limitations ability expatriate cash protective economic policies taken governments trade protection measures increased antitrust reporting requirements enforcement activity importexport licensing requirements compliance local regulations laws including countries regulatory requirements restricting companys ability manufacture sell products relevant market diminished protection intellectual property contractual rights certain jurisdictions potential nationalization expropriation companys foreign assets political social upheavals economic instability repression human rights issues geopolitical events including natural disasters disruptions markets due war armed conflict terrorism epidemics pandemics due international nature company 's business geopolitical economic changes events including global tensions war could adversely affect business results operations financial condition described company extensive operations business activity throughout world global tensions conflict andor war among countries conduct business distribute products may result foreign currency volatility decreased demand products affected countries challenges global supply chain related increased costs materials inputs products suppliers recently experienced expect continue experience impacts company 's business resulting russiaukraine war rising conflict middle east well increasing tensions us china response heightened conflict russiaukraine war governments may impose export controls broad financial economic sanctions business operations may impacted imposition trade protection measures policies adopted country favor domestic companies technologies foreign competitors additional sanctions measures may imposed global community including limited limitations ability file prosecute maintain patents trademarks intellectual property rights furthermore countries russia action may taken allows companies individuals exploit inventions owned patent holders united states many countries without consent compensation may able prevent third parties practicing company 's inventions russia selling importing products russia weak financial performance failure maintain satisfactory credit rating disruptions financial markets could adversely affect liquidity capital position borrowing costs access capital markets currently maintain investment grade credit ratings moodys investors service standard poors ratings services rating agencies routinely evaluate us ratings longterm shortterm debt based number factors downgrade credit ratings credit rating agency whether result actions factors beyond control increase cost borrowing indebtedness may incur reduce market capacity commercial paper require posting additional collateral derivative contracts assurance able maintain credit ratings additional actual anticipated changes downgrades credit ratings including announcement ratings review downgrade may negative impact liquidity capital position access capital markets risks business depends ability recruit retain talented highly skilled employees diverse workforce continued growth requires us recruit retain talented employees representing diverse backgrounds experiences skill sets market highly skilled workers leaders industry extremely competitive ability compete depends ability hire develop motivate highly skilled personnel areas organization maintaining brand reputation well diverse equitable inclusive work environment enables us attract top talent less successful recruiting efforts retain highly skilled workers key leaders ability develop deliver successful products services may adversely affected addition effective succession planning important longterm success unsuccessful implementation succession plans failure ensure effective transfer knowledge smooth transitions involving key employees could adversely affect business financial condition results operations climate change legal regulatory market measures address climate change may negatively affect business results operations climate change resulting increased concentrations carbon dioxide greenhouse gases atmosphere could present risks operations including adverse impact global temperatures weather patterns frequency severity extreme weather natural disasters natural disasters extreme weather conditions hurricane tornado earthquake wildfire flooding may pose physical risks facilities disrupt operation supply chain impacts changing climate water resources may result water scarcity limiting ability access sufficient highquality water certain locations may increase operational costs concern climate change may also result new additional legal regulatory requirements designed reduce greenhouse gas emissions andor mitigate effects climate change environment laws regulations stringent current legal regulatory obligations may experience disruption increase costs associated sourcing manufacturing distribution products may adversely affect business results operations financial condition impacts climate change influence customer preferences failure provide climatefriendly products could potentially result loss market share information security incident including cybersecurity breach could negative impact companys business reputation meet business objectives company relies internal information technology systems networks third parties vendors process store sensitive data including confidential research business plans financial information intellectual property personal data may subject legal protection ensure continuity companys supply chain operations extensive information security cybersecurity threats affect companies globally pose risk security availability systems networks including customer products connected rely systems networks confidentiality integrity availability companys sensitive data company assesses threats makes investments increase internal protection detection response capabilities well ensure companys thirdparty providers required capabilities controls address risk frequently changing attack techniques along increased volume sophistication attacks potential company adversely impacted impact could result reputational competitive operational business harm well financial costs regulatory action also increasing use ai could increase risks company maintains cybersecurity insurance event information security cyber incident however coverage may sufficient cover financial legal business reputational losses annual report result increased global tensions company expects continue increased risk information security cybersecurity incidents including cyberattacks perpetrated adversaries countries company maintains operations given potential sophistication attacks company may able address threat information security cybersecurity incidents proactively implement adequate preventative measures may able detect address disruption security breach promptly could adversely affect business results operations financial condition moreover threats could also impact thirdparty partners resulting compromise company 's systems networks data could negatively affect company breach privacy laws unauthorized access loss misuse personal data could negative impact companys business reputation company subject privacy data protection laws across globe impose broad compliance obligations collection use storage access transfer protection personal data breach requirements could result substantial fines penalties private right actions claims damage reputation business new privacy laws expected territories together greater privacy enforcement governmental authorities globally particularly data localization requirements international data flows company established privacy compliance programs controls businesses worldwide required comply many technology datadriven initiatives prioritized across company involving multiple vendors third parties potential risks controls imposed cross border data flows unauthorized access loss personal data internal external threats could impact business operations research activities company may unable achieve anticipated strategic financial benefits following separation kenvue inc kenvue including respect companys remaining ownership interest company incurred significant expenses connection kenvue separation separation addition company may able achieve full strategic financial benefits expected result separation anticipated benefits separation based number assumptions may prove incorrect company holds ownership interest kenvue company predict trading price shares kenvues common stock market value kenvue shares subject market volatility factors outside companys control company intends divest ownership interest kenvue assurance regarding ultimate timing divestiture unanticipated developments could delay prevent otherwise adversely affect divestiture including limited financial market conditions separation could result substantial tax liability company received private letter ruling irs taxfree nature separation us internal revenue code amended notwithstanding private letter ruling opinions tax advisors irs determines certain steps transaction qualify taxfree treatment us federal income tax purposes resulting tax liability company shareholders could substantial separation may also qualify taxfree treatment countries around world result may trigger substantial tax liability company item b unresolved staff comments applicable item c cybersecurity risk management strategy company documented cybersecurity policies standards assesses risks cybersecurity threats monitors information systems potential cybersecurity issues protect companys information systems cybersecurity threats company uses various security tools supporting protection detection response capabilities company maintains cybersecurity incident response plan help ensure timely consistent response actual attempted cybersecurity incidents impacting company company also identifies assesses thirdparty risks within enterprise company 's use thirdparty service providers across range areas including data security supply chain structured thirdparty risk management program company maintains formal information security training program employees includes training matters phishing email security best practices employees also required complete mandatory training data privacy evaluate enhance cybersecurity program company periodically utilizes thirdparty experts undertake maturity assessments companys information security program date company aware cybersecurity incident reasonably likely material impact companys business operations however frequently changing attack techniques along increased volume sophistication attacks potential company adversely impacted impact could result reputational competitive operational business harm well financial costs regulatory action refer risk factor captioned information security incident including cybersecurity breach could negative impact companys business reputation part item risk factors additional description cybersecurity risks potential related impacts company governance managements responsibility company takes riskbased approach cybersecurity implemented cybersecurity controls designed address cybersecurity threats risks chief information officer cio member companys executive committee chief information security officer ciso responsible assessing managing cybersecurity risks including prevention mitigation detection remediation cybersecurity incidents companys ciso coordination cio responsible leading companys cybersecurity program management cybersecurity risk current ciso twentyfive years experience information security background includes technical experience strategy architecture focused roles cyber threat experience various leadership roles governance board oversight companys board directors oversees overall risk management process including cybersecurity risks directly committees regulatory compliance sustainability committee rcsc board primarily responsible oversight risk cybersecurity threats oversees compliance applicable laws regulations company policies related among others privacy cybersecurity rcsc meetings include discussions specific risk areas throughout year including among others relating cybersecurity ciso provides least two updates year rcsc cybersecurity matters reports include overview cybersecurity threat landscape key cybersecurity initiatives improve companys risk posture changes thelegal regulatory landscape relative cybersecurity overviews certain cybersecurity incidents occurred within company within industry annual report item properties company 's subsidiaries operate manufacturing facilities occupying approximately million square feet floor space manufacturing facilities used industry segments companys business approximately follows square feet segment thousands innovative medicine medtech worldwide total within us five facilities used innovative medicine segment medtech segment outside us facilities used innovative medicine segment medtech segment locations manufacturing facilities major geographic areas world follows number square feet geographic area facilities thousands united states europe western hemisphere excluding us africa asia pacific worldwide total addition manufacturing facilities discussed company maintains numerous office warehouse facilities throughout world company 's subsidiaries generally seek rather lease manufacturing facilities although principally nonus locations leased office warehouse facilities often leased company also engages contract manufacturers company committed maintaining properties good operating condition segment information additions property plant equipment contained note segments business geographic areas notes consolidated financial statements included item report item legal proceedings information called item incorporated herein reference information set forth note legal proceedings notes consolidated financial statements included item report item mine safety disclosures applicable executive officers registrant listed executive officers company family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors executive officers elected board hold office one year respective successors elected qualified earlier resignation removal name age position vanessa broadhurst member executive committee executive vice president global corporate affairs joaquin duato chairman board chief executive officer b peter fasolo phd member executive committee executive vice president chief human resources officer c elizabeth forminard member executive committee executive vice president general counsel william n hait md ph member executive committee executive vice president chief external innovation medical officer e john c reed md phd member executive committee executive vice president innovative medicine rd f tim schmid member executive committee executive vice president worldwide chairman medtech g james swanson member executive committee executive vice president chief information officer h jennifer l taubert member executive committee executive vice president worldwide chairman innovative medicine kathryn e wengel member executive committee executive vice president chief technical operations risk officer j joseph j wolk member executive committee executive vice president chief financial officer k ms v broadhurst named executive vice president global corporate affairs appointed executive committee ms broadhurst rejoined company appointed company group chairman global commercial strategy organization held general manager roles amgen inflammation cardiovascular cardiovascular bone prior roles amgen served various leadership roles company b mr j duato became chairman board directors january subsequent appointments chief executive officer director january mr duato appointed executive committee named executive vice president worldwide chairman pharmaceuticals subsequently served vice chairman executive committee mr duato first joined company janssenfarmaceutica sa spain subsidiary company held executive positions increasing responsibility business sectors across multiple geographies functions c dr p fasolo appointed executive committee named executive vice president chief human resources officer first joined company worldwide vice president human resources medtech segment subsequently served companys chief talent officer left johnson johnson join kohlberg kravis roberts co chief talent officer returned company vice president global human resources ms e forminard appointed executive vice president general counsel member executive committee october ms forminard joined company serving roles increasing responsibility including general counsel medical devices diagnostics general counsel consumer group supply chain worldwide vice president corporate governance immediate past role general counsel pharmaceuticals e dr w hait appointed executive vice president chief external innovation medical safety global public health officer member executive committee first joined company served number leadership roles including annual report global head janssen research development global head johnson johnson global external innovation f dr j c reed joined company executive vice president innovative medicine rd member executive committee prior joining company dr reed held executive leadership positions sanofi roche serving respective executive committees also served ceo sanfordburnham medical research institute sanford burnham prebys established multiple therapeutic areaaligned research centers platform technology centers g mr schmid named executive vice president worldwide chairman medtech appointed executive committee october joined company served leadership positions throughout johnson johnson medtech including chief strategic customer officer president ethicon recently served company group chairman medtech asia pacific h mr j swanson appointed executive vice president chief information officer member executive committee rejoined company chief information officer johnson johnson bayer crop science served member executive leadership team chief information officer head digital transformation mr swanson held positions increasing responsibility company including project manager director sr director vice president chief information officer ms j l taubert appointed executive vice president worldwide chairman innovative medicine formerly pharmaceuticals member executive committee joined company worldwide vice president held several executive positions increasing responsibility pharmaceuticals sector including company group chairman north america company group chairman americas j ms k e wengel appointed executive vice president chief technical operations risk officer subsequent appointment executive committee named executive vice president chief global supply chain officer ms wengel first joined company project engineer engineering supervisor janssen subsidiary company tenure company held variety strategic leadership executive positions including roles within operations quality engineering new products information technology technical business functions k mr j j wolk appointed executive vice president chief financial officer member executive committee july first joined company finance manager business development orthomcneil subsidiary company tenure company held variety senior leadership roles several segments functions across company 's subsidiaries including vice president finance chief financial officer janssen pharmaceutical companies vice president investor relations part ii item market registrants common equity related stockholder matters issuer purchases equity securities february record holders common stock company additional information called item incorporated herein reference following sections report note common stock stock option plans stock compensation agreements notes consolidated financial statements included item item security ownership certain beneficial owners management related stockholder matters equity compensation plan information issuer purchases equity securities september company announced board directors approved share repurchase program authorizing company purchase billion company 's common stock repurchase program completed fiscal first quarter following table provides information respect common stock purchases company fiscal fourth quarter common stock purchases open market made part systematic plan meet needs companys compensation programs repurchases also include stockforstock option exercises settled fiscal fourth quarter total number shares maximum number approximate total number avg price units purchased part dollar value shares units shares paid per publicly announced may yet purchased fiscal period purchased share plans programs plans programs october october october november november december total fiscal fourth quarter company repurchased aggregate shares johnson johnson common stock openmarket transactions purchased part systematic plan meet needs companys compensation programs item reserved annual report item managements discussion analysis results operations financial condition organization business segments description company business segments johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products healthcare field company conducts business virtually countries world primary focus products related human health wellbeing company organized two business segments innovative medicine medtech innovative medicine segment focused following therapeutic areas including immunology infectious diseases neuroscience oncology pulmonary hypertension cardiovascular metabolic diseases products segment distributed directly retailers wholesalers distributors hospitals healthcare professionals prescription use medtech segment includes broad portfolio products used orthopaedic surgery interventional solutions vision fields products distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities innovative medicine medtech business segments product lines company competes companies locally globally throughout world competition exists product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new innovative products well protecting underlying intellectual property company 's product portfolio important companys success areas business competitive environment requires substantial investments continuing research managements objectives credo foundation companys purpose blend heart science ingenuity profoundly impact health humanity company believes health everything company 's strength healthcare innovation empowers us build world complex diseases prevented treated cured treatments smarter less invasive solutions personal company 's expertise innovative medicine medtech company uniquely positioned innovate across full spectrum healthcare solutions today deliver breakthroughs tomorrow profoundly impact health humanity new products introduced within past five years accounted approximately sales billion invested research development reflecting managements commitment create lifeenhancing innovations create value partnerships profoundly impact health humanity critical driver companys success diversity employees worldwide employees empowered inspired lead credo purpose guides allows every employee use companys reach size advance companys purpose also lead agility urgency leveraging extensive resources across enterprise enables company innovate execute excellence ensures company remain focused addressing unmet needs society every day invest enduring impact ultimately delivering value patients consumers healthcare professionals employees communities shareholders research acquisitions development net cash acquired includes acquisitions process research development assets accounted business combination dividends paid per share results operations analysis consolidated sales discussion results operations financial condition pertaining fiscal years see companys annual report fiscal year ended january item management 's discussion analysis results operations financial condition prior periods disclosed herein recast reflect continuing operations company worldwide sales increased billion compared increase sales changes consisted following sales increasedecrease due volume price currency total net impact acquisitions divestitures worldwide sales growth positive impact impact sales us companies billion billion represents increases sales international companies billion billion represents increase decrease fiveyear compound annual growth rates worldwide us international sales respectively tenyear compound annual growth rates worldwide us international sales respectively sales companies europe experienced decline compared prior year included operational decline positive currency impact fiscal net impact covid vaccine loss exclusivity zytiga european regions change operational sales negative sales companies western hemisphere excluding us achieved growth compared prior year included operational growth negative currency impact sales companies asiapacific africa region achieved growth compared prior year including operational growth negative currency impact annual report company utilized three wholesalers distributing products segments represented approximately total consolidated revenues company three wholesalers distributing products segments represented approximately total consolidated revenues sales geographic region billions sales segment billions note values may rounded analysis sales business segments innovative medicine segment innovative medicine segment sales billion increase included operational growth negative currency impact us sales billion increase international sales billion decrease included operational decline negative currency impact acquisitions divestitures net negative impact operational sales growth worldwide innovative medicine segmentmajor innovative medicine therapeutic area sales total operations currency dollars millions change change change total immunology remicade simponisimponi aria stelara tremfya immunology total infectious diseases covid vaccine edurantrilpivirine prezista prezcobixrezolsta symtuza infectious diseases total neuroscience concertamethylphenidate invega sustennaxeplioninvega trinzatrevicta spravato neuroscience total oncology carvykti darzalex erleada imbruvica zytiga abiraterone acetate oncology total pulmonary hypertension opsumit uptravi pulmonary hypertension total cardiovascular metabolism xarelto total innovative medicine sales percentage greater meaningful previously referred pharmaceutical inclusive risperdal consta previously disclosed separately inclusive invokana previously disclosed separately annual report immunology products achieved sales billion representing increase compared prior year increased sales stelara ustekinumab primarily driven patient mix market growth continued strength inflammatory bowel disease growth tremfya guselkumab due market growth continued strength psopsa psoriasis psoriatic arthritis patient mix additionally simponisimponi aria growth driven growth outside us lower sales remicade infliximab due biosimilar competition biosimilar versions remicade introduced united states certain markets outside united states additional competitors continue enter market continued infliximab biosimilar competition result reduction sales remicade sales stelara united states approximately billion fiscal third parties filed abbreviated biologics license applications fda seeking approval market biosimilar versions stelara company settled certain litigation biosimilar price competition innovation act result settlements agreements separate third parties company anticipate launch biosimilar version stelara january united states infectious disease products sales billion decline compared prior year primarily driven decline covid vaccine revenue loss exclusivity prezista neuroscience products sales billion representing increase compared prior year growth spravato esketamine driven ongoing launches well increased physician confidence patient demand growth partially offset declines risperdalrisperdal consta paliperidone longacting injectables outside us due xeplion loss exclusivity european union oncology products achieved sales billion representing increase compared prior year sales darzalex daratumumab driven continued share gains regions market growth growth erleada apalutamide due continued share gains market growth metastatic castration resistant prostate cancer sales carvykti ciltacabtagene autoleucel driven ongoing launch share gains capacity improvement additionally sales launch tecvayli teclistamabcqyv talvey talquetamabtgvs included oncology contributed growth growth partially offset zytiga abiraterone acetate due loss exclusivity imbruvica ibrutinib due global competitive pressures pulmonary hypertension products sales billion representing increase compared prior year sales growth due favorable patient mix share gains market growth uptravi selexipag opsumit macitentan partially offset declines pulmonary hypertension cardiovascularmetabolismother products sales billion decline compared prior year decline xarelto rivaroxaban sales primarily driven unfavorable patient mix access changes company maintains policy end customer permitted direct delivery product location billing location policy impacts contract pharmacy transactions involving nongrantee b covered entities companys drugs subject multiple exceptions grantee nongrantee covered entities maintain certain contract pharmacy arrangements policy exceptions company continue offer b discounts covered entities covered outpatient drugs believes policy improve ability identify inappropriate duplicate discounts diversion prohibited b statute b drug pricing program us federal government program requiring drug manufacturers provide significant discounts covered outpatient drugs covered entities policy discount implications positively impacted sales customers company advanced pipeline several regulatory submissions approvals new drugs additional indications existing drugs follows product name us eu us eu chemical name indication approval approval filing filing akeega niraparib firstandonly dual action tablet treatment abiraterone acetate patients brcapositive metastatic castration resistant prostate cancer magnitude balversa erdafitinib treatment patients locally advanced metastatic urothelial carcinoma selected fibroblast growth factor receptor gene alterations thor carvykti ciltacabtagene treatment relapsed refactor multiple myeloma autoleucel pl cartitude edurant rilpivirine treatment pediatric patients years old hiv erleada tablet reduction apalutamide opsumit macitentan treatment pediatric pulmonary arterial hypertension opsynvi treatment pulmonary arterial hypertension mecitentantadalafil stct rybrevant combination chemotherapy firstline amivantamab treatment adult patients advanced nonsmall cell lung cancer activating egfr exon insertion mutations papillon rybrevant lazertinib treatment nonsmall cell lung cancer l mariposa rybrevant lazertinib treatment nonsmall cell lung cancer l mariposa tecvayli teclistamab treatment patients relapsed refractory multiple myeloma biweekly dosing talvey talquetamab treatment patients relapsed refractory multiple myeloma annual report medtech segment medtech segment sales billion increase included operational growth negative currency impact us sales billion increase compared prior year international sales billion increase compared prior year included operational growth negative currency impact net impact acquisitions divestitures medtech segment worldwide operational sales growth positive primarily related abiomed acquisition major medtech franchise sales total operations currency dollars millions change change change surgery advanced general orthopaedics hips knees trauma spine sports interventional solutions electrophysiology abiomed interventional solutions vision contact lensesother surgical total medtech sales percentage greater meaningful surgery franchise sales billion representing increase growth advanced surgery primarily driven biosurgery global procedure growth strength portfolio well uptake new products endocutters energy growth partially offset competitive pressures volumebased procurement impacts endocutters energy growth general surgery primarily driven increased procedures coupled technology penetration benefits differentiated wound closure portfolio orthopaedics franchise sales billion representing increase growth hips reflects global procedure growth continued strength portfolio partially offset volumebased procurement impacts russia sanctions growth knees primarily driven procedures benefits recent product additions attune portfolio pull related velys robotic assisted solution partially offset stocking dynamics primarily outside us growth trauma driven global procedures adoption recently launched products partially offset volumebased procurement impacts growth spine sports primarily driven digital solutions shoulders sports craniomaxillofacial products partially offset russia sanctions supply constraints primarily outside us interventional solutions franchise achieved sales billion representing increase includes sales abiomed acquired december electrophysiology grew double digits due global procedure growth new product performance commercial execution partially offset impacts volumebased procurement china abiomed sales reflect strength commercialized regions continued adoption impella impella rp vision franchise achieved sales billion representing increase contact lensesother growth primarily driven continued strong performance acuvue oasys day family including recent launches commercial execution partially offset impacts us stocking dynamics russia sanctions impacts strategic portfolio decisions supply challenges surgical operational growth primarily driven cataract procedure growth continued strength recent innovations reduction prior year stocking outside us partiallyoffset softer refractive premium iol markets russia sanctions analysis consolidated earnings provision taxes income consolidated earnings provision taxes income billion billion years respectively percent sales consolidated earnings provision taxes income respectively earnings provision taxes dollars billions percentages chart percent total sales cost products sold selling marketing administrative expenses cost products soldselling marketing administrative dollars billions percentages chart percent total sales cost products sold cost products sold increased percent sales driven commodity inflation unfavorable product mix restructuring related excess inventory costs abiomed amortization medtech business partially offset favorable patient mix lower onetime covid vaccine manufacturing related exit costs innovative medicine business intangible asset amortization expense included cost products sold billion billion fiscal years respectively annual report selling marketing administrative expense selling marketing administrative expenses decreased slightly percent sales driven leveraging selling marketing expenses innovative medicine medtech businesses partially offset increase administrative costs research development expense research development expense segment business follows dollars millions amount sales amount sales innovative medicine medtech total research development expense percent increasedecrease prior year percent segment sales research development activities represent significant part company 's business expenditures relate processes discovering testing developing new products upfront payments developmental milestones improving existing products well ensuring product efficacy regulatory compliance prior launch company remains committed investing research development aim delivering high quality innovative products research development flat percent sales primarily driven higher milestone payments innovative medicine business acquired inprocess research development asset laminar acquisition medtech business fiscal year offset portfolio prioritization innovative medicine business inprocess research development impairments iprd fiscal year company recorded charge approximately billion included billion related market dynamics associated nonstrategic asset acquired part acquisition momenta pharmaceuticals fiscal year company recorded intangible asset impairment charge approximately billion related inprocess research development asset bermekimab jnj investigational drug treatment atopic dermatitis ad hidradenitis suppurativa hs additional information regarding efficacy ad indication hs indication became available led company decision terminate development bermekimab ad hs company acquired rights bermekimab xbiotech inc fiscal year income expense net income expense net account company records gains losses related sale writedown certain investments equity securities held johnson johnson innovation jjdc inc jjdc changes fair value securities investment incomeloss related employee benefit programs gains losses divestitures certain transactional currency gains losses acquisition divestiture related costs litigation accruals settlements well royalty income income expense net fiscal year unfavorable billion compared prior year primarily due following dollars billionsincomeexpense change litigation related changes fair value securities covid vaccine manufacturing exit related costs acquisition integration divestiture related employee benefit plan related total income expense net primarily related approximately billion charge talc see note consolidated financial statements details favorable intellectual property related litigation settlements approximately billion primarily related pelvic mesh fiscal includes billion related unfavorable change fair value remaining stake kenvue billion related partial impairment idorsia convertible debt change fair value idorsia equity securities held primarily related impairment ponvory onetime integration costs related acquisition abiomed primarily costs related acquisition abiomed interest income expense interest income fiscal year billion compared interest income billion fiscal year primarily due higher rates interest earned cash balances interest expense fiscal year billion compared interest expense billion fiscal year primarily due higher interest rates debt balances cash cash equivalents marketable securities totaled billion end averaged billion compared cash cash equivalents marketable securities total billion billion average balance total debt balance end billion average debt balance billion compared billion end average debt balance billion lower average cash cash equivalents marketable securities primarily due acquisition abiomed late december lower average debt balance primarily due repayment commercial paper income tax segment income loss tax segment business follows income tax segment sales percent segment sales dollars millions innovative medicine medtech segment earnings tax less expenses allocated segments worldwide income tax see note consolidated financial statements details amounts allocated segments include interest income expense general corporate income expense fiscal includes approximately billion charge related talc matters approximately billion unfavorable change fair value retained stake kenvue annual report innovative medicine segment innovative medicine segment income tax percent sales versus increase income tax percent sales primarily driven following lower onetime covid vaccine related exit costs billion versus billion lower inprocess research development impairments billion versus billion unfavorable changes fair value securities billion compared billion lower litigation related expense billion leveraging selling marketing expenses rd portfolio prioritization partially offset restructuring charges billion versus billion impairment ponvory higher milestone payments medtech segment medtech segment income tax percent sales versus decrease income tax percent sales primarily driven following higher amortization expense billion related abiomed expense billion acquired process research development asset laminar acquisition commodity inflation partially offset income litigation settlements billion versus expense billion lower integrationacquisition costs related abiomed billion versus billion leveraging selling marketing expenses restructuring fiscal year company completed prioritization research development rd investment within innovative medicine segment focus promising medicines greatest benefit patients resulted exit certain programs within therapeutic areas rd program exits primarily infectious diseases vaccines including discontinuation respiratory syncytial virus rsv adult vaccine program hepatitis hiv development pretax restructuring charge approximately billion fiscal year million recorded restructuring million recorded cost products sold consolidated statement earnings included termination partnered nonpartnered program costs asset impairments fiscal year company initiated restructuring program orthopaedics franchise within medtech segment streamline operations exiting certain markets product lines distribution network arrangements pretax restructuring expense billion fiscal year million recorded restructuring million recorded cost products sold consolidated statement earnings primarily included inventory instrument charges related market product exits company recorded pretax charge billion related restructuring program global supply chain global supply chain program announced second quarter completed fiscal fourth quarter see note consolidated financial statements additional details related restructuring programs provision taxes income worldwide effective income tax rate continuing operations december european union eu member states formally adopted eus pillar two directive generally provides minimum effective tax rate established organization economic cooperation development oecd pillar two framework supported countries worldwide december several eu noneu countries enacted pillar legislation initial effective date january aspects law effective later company estimating result legislation effective tax rate increase approximately basis points compared fiscal legislation guidance regulations may issued fiscal well business events may impact estimate discussion related fiscal provision taxes refer note consolidated financial statements liquidity capital resources liquidity cash flows cash cash equivalents billion end compared billion end primary sources uses cash contributed billion increase dollars billions q cash cash equivalents balance cash generated operating activities net cash investing activities net cash used financing activities effect exchange rate rounding q cash cash equivalents balance addition company billion marketable securities end fiscal year billion end fiscal year see note consolidated financial statements additional details cash cash equivalents marketable securities cash flow operations billion result dollars billions net earnings gain kenvue separation net gain sale assetsbusinesses deferred tax provision partially offset noncash expenses adjustments primarily depreciation amortization stockbased compensation asset writedowns charge purchase process research development assets increase current noncurrent liabilities increase current noncurrent assets increase accounts payable accrued liabilities increase accounts receivable inventories cash flow operations annual report cash flow investing activities billion primarily due dollars billions additions property plant equipment proceeds disposal assetsbusinesses net purchases inprocess research development assets net sales investments credit support agreements activity net net cash investing activities cash flow used financing activities billion primarily due dollars billions dividends shareholders repurchase common stock net repayment short long term debt proceeds stock options exercisedemployee withholding tax stock awards net credit support agreements activity net proceeds short longterm debt net issuance cost related debt transferred kenvue separation proceeds kenvue initial public offering cash transferred kenvue separation rounding net cash used financing activities december company 's notes payable longterm debt excess cash cash equivalents marketable securities december net debt position billion compared prior year billion debt balance end billion compared billion considering recent market conditions company reevaluated operating cash flows liquidity profile foresee significant incremental risk company anticipates operating cash flows ability raise funds external sources borrowing capacity existing committed credit facilities access commercial paper markets continue provide sufficient resources fund operating needs including company 's remaining balance paid agreement settle opioid litigation approximately billion establishment approximately billion reserve talc matters see note consolidated financial statements additional details addition company monitors global capital markets ongoing basis time time may raise capital market conditions favorable may kenvue completed initial public offering ipo resulting issuance shares common stock par value per share kenvue common stock initial public offering per share net proceeds billion excess net proceeds ipo net book value johnson johnson divested interest billion recorded additional paidin capital closing ipo johnson johnson owned approximately total outstanding shares kenvue common stock july noncontrolling interest billion associated kenvue reflected equity attributable noncontrolling interests consolidated balance sheet august johnson johnson completed disposition additional ownership kenvue common stock exchange offer resulted johnson johnson acquiring shares companys common stock exchange shares kenvue common stock billion johnson johnson common stock received exchange offer recorded treasury stock following exchange offer company owns total outstanding shares kenvue common stock recorded assets within continuing operations fair market value billion august billion december johnson johnson divested net assets billion august accumulated comprehensive loss attributable consumer health business date billion additionally date exchange offer johnson johnson decreased noncontrolling interest billion record deconsolidation kenvue resulted gain exchange offer billion recorded net earnings discontinued operations net taxes consolidated statements earnings fiscal third quarter onetime gain includes gain billion kenvue common stock retained johnson johnson gain exchange offer qualifies taxfree transaction us federal income tax purposes september company announced board directors approved share repurchase program authorizing company purchase billion companys common stock fiscal year approximately billion repurchased program fiscal year billion repurchased repurchase program completed following table summarizes companys material contractual obligations aggregate maturities december satisfy obligations company intends use cash operations tax legislation interest dollars millions tcja debt obligations debt obligations total total tax matters see note consolidated financial statements annual report financing market risk company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value certain foreign currency assets liabilities hedge future foreign currency transactions primarily related product costs gains losses contracts offset gains losses underlying transactions appreciation us dollar december market rates would increase unrealized value companys forward contracts billion conversely depreciation us dollar december market rates would decrease unrealized value companys forward contracts billion either scenario gain loss forward contract would offset gain loss underlying transaction therefore would impact future anticipated earnings cash flows company hedges exposure fluctuations currency exchange rates effect certain assets liabilities foreign currency entering currency swap contracts change spread us foreign interest rates companys interest rate sensitive financial instruments would either increase decrease unrealized value companys swap contracts approximately billion either scenario maturity gain loss swap contract would offset gain loss underlying transaction therefore would impact future anticipated cash flows company enter financial instruments trading speculative purposes company policy entering contracts parties least investment grade credit rating counterparties contracts major financial institutions significant concentration exposure one counterparty management believes risk loss remote company entered credit support agreements csa certain derivative counterparties establishing collateral thresholds based respective credit ratings netting agreements see note consolidated financial statements additional details credit support agreements company invests fixed rate floating rate interest earning securities carry degree interest rate risk fair market value fixed rate securities may adversely impacted due rise interest rates floating rate securities may produce less income predicted interest rates fall basis points change spread companys interest rate sensitive investments would either increase decrease unrealized value cash equivalents current marketable securities less billion company access substantial sources funds numerous banks worldwide september company secured new day credit facility billion expires september company early terminated additional day revolving credit facility billion expiration november interest charged borrowings credit line agreement based either secured overnight financing rate sofr reference rate applicable market rate allowed plus applicable margins commitment fees agreement material total borrowings end billion billion respectively decrease debt balance due repayment commercial paper net debt cash current marketable securities net debt billion compared net debt billion total debt represented total capital shareholders equity total debt total capital shareholders equity per share end compared yearend summary borrowings found note consolidated financial statements dividends company increased dividend st consecutive year cash dividends paid per share per share january board directors declared regular cash dividend per share payable march shareholders record february information critical accounting policies estimates managements discussion analysis results operations financial condition based companys consolidated financial statements prepared accordance accounting principles generally accepted us gaap preparation financial statements requires management make estimates assumptions affect amounts reported revenues expenses assets liabilities related disclosures actual results may may differ estimates company believes understanding certain key accounting policies estimates essential achieving insight companys operating results financial condition key accounting policies include revenue recognition income taxes legal selfinsurance contingencies valuation longlived assets assumptions used determine amounts recorded pensions employee benefit plans accounting stock based awards revenue recognition company recognizes revenue product sales obligations terms contract customer satisfied generally occurs transfer control goods customers company 's global payment terms typically days provisions certain rebates sales incentives trade promotions coupons product returns discounts customers governmental clawback provisions accounted variable consideration recorded reduction sales product discounts granted based terms arrangements direct indirect market participants well market conditions including consideration competitor pricing rebates estimated based contractual terms historical experience patient outcomes trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall sales returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns innovative medicine segments almost exclusively resalable sales returns certain franchises medtech segment typically resalable material company infrequently exchanges products inventory returned products sales returns reserve total company less annual net trade sales fiscal years promotional programs product listing allowances recorded period related sales include volumebased sales incentive programs volumebased incentive programs based estimated sales volumes incentive period recorded products sold arrangements evaluated determine appropriate amounts deferred recorded reduction revenue company also earns profitshare payments collaborative arrangements certain products included sales customers profitshare payments less total revenues fiscal year less total revenues fiscal year included sales customers addition company enters collaboration arrangements contain multiple revenue generating activities amounts due collaborative partners arrangements recognized activity performed delivered based relative selling price upfront fees received part arrangements deferred recognized performance period see note consolidated financial statements additional disclosures collaborations reasonably likely changes assumptions used calculate accruals rebates returns promotions anticipated material effect financial statements company currently discloses impact changes assumptions quarterly annual filing material financial statement impact annual report tables show progression accrued rebates returns promotions reserve doubtful accounts reserve cash discounts segment business fiscal years ended december january innovative medicine segment balance balance beginning payments end dollars millions period accruals credits period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million january recorded contra asset includes prior period adjustments medtech segment balance balance beginning payments end dollars millions period accruals credits period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million january recorded contra asset income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based enacted tax regulations rates future changes tax laws rates may affect recorded deferred tax assets liabilities company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position company recorded deferred tax liabilities undistributed earnings prior december international subsidiaries company provided deferred taxes undistributed earnings subsequent january certain international subsidiaries earnings considered indefinitely reinvested company intends continue reinvest earnings international operations company decides later date repatriate earnings us company would required provide net tax effects amounts company estimates tax effect repatriation would approximately billion currently enacted tax laws regulations current currency exchange rates amount include possible benefit us foreign tax credits may substantially offset cost see note note consolidated financial statements information regarding income taxes legal self insurance contingencies company records accruals various contingencies including legal proceedings product liability claims arise normal course business accruals based managements judgment probability losses applicable actuarially determined estimates company self insurance whollyowned captive insurance company addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated annual report see notes consolidated financial statements information regarding product liability legal proceedings longlived intangible assets company assesses changes qualitatively quantitatively economic conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets assumptions estimates may change time may may necessary company record impairment charges employee benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide plans based assumptions discount rate expected return plan assets mortality rates expected salary increases healthcare cost trend rates attrition rates see note consolidated financial statements details rates stock based compensation company recognizes compensation expense associated issuance equity instruments employees services based type equity instrument fair value estimated date grant using either blackscholes option valuation model combination blackscholes option valuation model monte carlo valuation model expensed financial statements service period input assumptions used determining fair value expected life expected volatility riskfree rate expected dividend yield performance share units fair market value calculated two component goals date grant adjusted operational earnings per share relative total shareholder return fair values earnings per share goal performance share unit estimated date grant using fair market value shares time award discounted dividends paid performance share units vesting period fair value relative total shareholder return goal performance share unit estimated date grant using monte carlo valuation model see note consolidated financial statements additional information new accounting pronouncements refer note consolidated financial statements recently adopted accounting pronouncements recently issued accounting pronouncements yet adopted december economic market factors company aware products used environment decade policymakers consumers businesses expressed concerns rising cost healthcare response concerns company longstanding policy pricing products responsibly period us weighted average compound annual growth rate companys net price increases healthcare products prescription overthecounter drugs hospital professional products us consumer price index cpi company operates certain countries economic conditions continue present significant challenges company continues monitor situations take appropriate actions inflation rates continue effect worldwide economies consequently way companies operate company accounted operations argentina venezuela turkey beginning fiscal second quarter highly inflationary prior threeyear cumulative inflation rate surpassed material impact company 's results period face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases december argentine government devalued peso approximately company recorded charge approximately million related operations argentina due application highly inflationary accounting december companys argentine subsidiaries represented less company 's consolidated assets liabilities revenues profits continuing operations therefore effect change exchange rate expected material adverse effect company 's fullyear results july janssen pharmaceuticals inc janssen filed litigation us department health human services well centers medicare medicaid services challenging constitutionality inflation reduction acts ira medicare drug price negotiation program litigation requests declaration ira violates janssens rights first amendment fifth amendment constitution therefore janssen subject iras mandatory pricing scheme russiaukraine war although longterm implications russias invasion ukraine difficult predict time financial impact conflict fiscal year including accounts receivable inventory reserves material fiscal years ending december january business companys russian subsidiaries represented less companys consolidated assets represented revenues company maintain ukraine subsidiaries subsequent kenvue separation early march company took steps suspend advertising enrollment clinical trials additional investment russia company continues supply products relied upon patients healthcare purposes conflict middle east although longterm implications israel 's conflict difficult predict time financial impact conflict fiscal year including accounts receivable inventory reserves material fiscal year ending december business companys israel subsidiaries represented companys consolidated assets represented less revenues company exposed fluctuations currency exchange rates change value us dollar compared foreign currencies company sales income expense would increased decreased translation foreign sales approximately billion net income approximately billion governments around world consider various proposals make changes tax laws may include increasing decreasing existing statutory tax rates connection various government initiatives companies required disclose information tax authorities operations around world may lead greater audit scrutiny profits earned countries change statutory tax rate country would result revaluation companys deferred tax assets liabilities related particular jurisdiction period new tax law enacted change would result expense benefit recorded companys consolidated statement earnings company closely monitors proposals arise countries operates changes statutory tax rate may occur time related expense benefit recorded may material fiscal quarter year law change enacted company faces various worldwide healthcare changes may continue result pricing pressures include healthcare cost containment government legislation relating sales promotions pricing reimbursement healthcare products changes behavior spending patterns purchasers healthcare products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing healthcare insurance coverage may continue impact companys businesses annual report company also operates environment increasingly hostile intellectual property rights firms filed abbreviated new drug applications biosimilar biological product applications us fda otherwise challenged coverage andor validity company 's patents seeking market generic biosimilar forms many companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending patent claims challenged resulting lawsuits generic biosimilar versions products issue introduced market resulting potential substantial market share revenue losses products may result noncash impairment charge associated intangible asset also risk one competitors could launch generic biosimilar version product issue following regulatory approval even though one valid patents place legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial employment indemnification matters governmental investigations legal proceedings arise time time ordinary course business company records accruals loss contingencies associated legal matters probable liability incurred amount loss reasonably estimated december company determined liabilities associated certain litigation matters probable reasonably estimated company accrued matters continue monitor related legal issue adjust accruals might warranted based new information developments accordance asc contingencies litigation regulatory matters discussed loss probable reasonably possible company unable estimate possible loss range loss beyond amounts accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions including timing related payments ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability number potential claims ability achieve comprehensive multiparty settlements complexity related crossclaims counterclaims andor numerous parties involved extent adverse awards judgments verdicts rendered company company record accrual loss determined probable reasonably estimated company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued company 's balance sheet expected material adverse effect company 's financial position however resolution increase accruals one matters reporting period may material adverse effect company 's results operations cash flows period see note consolidated financial statements included item report information regarding legal proceedings common stock companys common stock listed new york stock exchange symbol jnj february record holders common stock company item quantitative qualitative disclosures market risk information called item incorporated herein reference item managements discussion analysis results operations financial condition liquidity capital resources financing market risk report note summary significant accounting policies financial instruments notes consolidated financial statements included item report item financial statements supplementary data index audited consolidated financial statements consolidated b alance heets consolidated tatements e arnings consolidated tatements c omprehensive ncome consolidated tatements e quity consolidated tatements c ash f lows notes c onsolidated f inancial tatements report ndependent r egistered p ublic ccounting f irm pcaob id managements r eport nternal c ontrol ver f inancial r eporting annual report johnson johnson subsidiaries consolidated balance sheets december january dollars millions except share per share amounts note assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances inventories notes prepaid expenses receivables current assets discontinued operations note total current assets property plant equipment net notes intangible assets net notes goodwill notes deferred taxes income note assets noncurrent assets discontinued operations note total assets liabilities shareholders equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued compensation employee related obligations accrued taxes income note current liabilities discontinued operations note total current liabilities longterm debt note deferred taxes income note employee related obligations notes longterm taxes payable note liabilities noncurrent liabilities discontinued operations note total liabilities commitments contingencies note shareholders equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares accumulated comprehensive income loss note retained earnings additionalpaidincapital less common stock held treasury cost note shares shares total shareholders equity total liabilities shareholders equity see notes consolidated financial statements johnson johnson subsidiaries consolidated statements earnings dollars shares millions except per share amounts note sales customers cost products sold gross profit selling marketing administrative expenses research development expense inprocess research development impairments interest income interest expense net portion capitalized note income expense net restructuring note earnings provision taxes income provision taxes income note net earnings continuing operations net earnings discontinued operations net tax note net earnings net earnings per share notes continuing operations basic discontinued operations basic total net earnings per share basic continuing operations diluted discontinued operations diluted total net earnings per share diluted average shares outstanding notes basic diluted see notes consolidated financial statements annual report johnson johnson subsidiaries consolidated statements comprehensive income dollars millions note net earnings comprehensive income loss net tax foreign currency translation securities unrealized holding gain loss arising period reclassifications earnings net change employee benefit plans prior service credit cost net amortization gain loss net amortization consumer settlement curtailment effect exchange rates net change derivatives hedges unrealized gain loss arising period reclassifications earnings net change comprehensive income loss comprehensive income tax effects comprehensive income fiscal years respectively foreign currency translation million million million employee benefit plans million million million derivatives hedges million million million see notes consolidated financial statements amounts presented recast exclude discontinued operations johnson johnson subsidiaries consolidated statements equity dollars millions note retained accumulated common earnings stock treasury additional comprehensive issued stock total paidin capital income loss amount amount balance january net earnings cash dividends paid per share employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance january net earnings cash dividends paid per share employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance january net earnings cash dividends paid per share employee compensation stock option plans repurchase common stock kenvue separation ipo note comprehensive income loss net tax balance december see notes consolidated financial statements annual report johnson johnson subsidiaries consolidated statements cash flows dollars millions note cash flows operating activities net earnings adjustments reconcile net earnings cash flows operating activities depreciation amortization property intangibles stock based compensation asset writedowns charge purchase inprocess research development assets gain kenvue separation net gain sale assetsbusinesses deferred tax provision credit losses accounts receivable allowances changes assets liabilities net effects acquisitions divestitures increase accounts receivable increase inventories increase accounts payable accrued liabilities increasedecrease current noncurrent assets increasedecrease current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assetsbusinesses net acquisitions net cash acquired note purchases inprocess research development assets note purchases investments sales investments credit support agreements activity net including capitalized licenses milestones net cash fromused investing activities cash flows financing activities dividends shareholders repurchase common stock proceeds shortterm debt repayment shortterm debt proceeds longterm debt net issuance costs repayment longterm debt proceeds exercise stock optionsemployee withholding tax stock awards net credit support agreements activity net proceeds short longterm debt net issuance cost related debt transferred kenvue separation proceeds kenvue initial public offering cash transferred kenvue separation net cash used financing activities effect exchange rate changes cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents continuing operations beginning period cash cash equivalents discontinued operations beginning period cash cash equivalents beginning year note cash cash equivalents continuing operations end period cash cash equivalents discontinued operations end period cash cash equivalents end year note supplemental cash flow data cash paid year interest interest net amount capitalized income taxes inclusive discontinued operations supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds employee withholding tax stock awards acquisitions fair value assets acquired fair value liabilities assumed net cash paid acquisitions note see notes consolidated financial statements amounts presented recast exclude discontinued operations annual report notes consolidated financial statements summary significant accounting policies principles consolidation consolidated financial statements include accounts johnson johnson subsidiaries company intercompany accounts transactions eliminated columns rows within tables may add due rounding percentages calculated using actual nonrounded figures description company business segments company approximately employees worldwide engaged research development manufacture sale broad range products healthcare field company conducts business virtually countries world primary focus products related human health wellbeing kenvue iposeparation discontinued operations may kenvue completed initial public offering ipo resulting issuance shares common stock par value per share kenvue common stock initial public offering per share net proceeds billion excess net proceeds ipo net book value johnson johnson divested interest billion recorded additional paidin capital closing ipo johnson johnson owned approximately total outstanding shares kenvue common stock july noncontrolling interest billion associated kenvue reflected equity attributable noncontrolling interests consolidated balance sheet fiscal second quarter august johnson johnson completed disposition additional ownership shares kenvue exchange offer following exchange offer company owns shares kenvue accounted equity investment carried fair value within continuing operations historical results consumer health business previously represented consumer health business segment reflected discontinued operations companys consolidated financial statements date exchange offer see note additional details unless otherwise indicated information notes consolidated financial statements refer johnson johnsons continuing operations business segments following completion exchange offer company organized two business segments innovative medicine medtech innovative medicine segment focused following therapeutic areas including immunology infectious diseases neuroscience oncology pulmonary hypertension cardiovascular metabolic diseases products segment distributed directly retailers wholesalers distributors hospitals healthcare professionals prescription use medtech segment includes broad portfolio products used orthopaedic surgery interventional solutions vision fields products distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics new accounting standards recently adopted accounting standards asu liabilitiessupplier finance programs topic disclosure supplier finance program obligations company adopted standard beginning fiscal year requires buyer supplier finance program disclose additional information program financial statement users company agreements supplier finance programs thirdparty financial institutions programs provide participating suppliers ability finance payment obligations company thirdparty financial institutions company party arrangements suppliers thirdparty financial institutions companysobligations suppliers including amounts due scheduled payment dates general payment terms days affected participating suppliers decision participate program december january billion valid obligations program obligations presented accounts payable consolidated balance sheets recently issued accounting standards adopted december asu segment reporting topic improvements reportable segment disclosures update requires expanded annual interim disclosures significant segment expenses regularly provided chief operating decision maker included within reported measure segment profit loss update effective fiscal years beginning december applied retrospectively periods presented financial statements early adoption permitted accounting standard impacts disclosures material impact companys consolidated financial statements asu income taxes topic improvements income tax disclosures update standardizes categories effective tax rate reconciliation requires disaggregation income taxes additional income taxrelated disclosures update required effective company fiscal periods beginning december accounting standard impacts disclosures material impact companys consolidated financial statements cash equivalents company classifies highly liquid investments stated maturities three months less date purchase cash equivalents highly liquid investments stated maturities greater three months date purchase current marketable securities company policy making investments commercial institutions least investment grade credit rating company invests cash primarily government securities obligations corporate debt securities money market funds reverse repurchase agreements rras rras collateralized deposits form government securities obligations amount less value company record asset liability company permitted sell repledge associated collateral company policy collateral least equivalent credit rating company utilizes third party custodian manage exchange funds ensure collateral received maintained value rras daily basis rras stated maturities greater three months date purchase classified marketable securities investments investments classified held maturity investments reported amortized cost realized gains losses reported earnings investments classified availableforsale debt securities carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income availableforsale securities available current operations classified current assets otherwise classified long term management determines appropriate classification investment debt equity securities time purchase reevaluates determination balance sheet date company reviews investments impairment adjusts investments fair value earnings required property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets years building building equipment years land leasehold improvements years machinery equipment company capitalizes certain computer software development costs included machinery equipment incurredin connection developing obtaining computer software internal use capitalized software costs amortized estimated useful lives software generally range years company reviews longlived assets assess recoverability using undiscounted cash flows certain events changes operating economic conditions occur impairment assessment may performed recoverability annual report carrying value assets asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows revenue recognition company recognizes revenue product sales obligations terms contract customer satisfied generally occurs transfer control goods customers company 's global payment terms typically days provisions certain rebates sales incentives trade promotions coupons product returns discounts customers governmental clawback provisions accounted variable consideration recorded reduction sales liability recognized within accrued rebates returns promotions consolidated balance sheet product discounts granted based terms arrangements direct indirect market participants well market conditions including consideration competitor pricing rebates estimated based contractual terms historical experience patient outcomes trend analysis projected market conditions various markets served significant portion liability related rebates sale company 's pharmaceutical products within us primarily managed care medicare medicaid programs amounted billion billion december january respectively company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall sales returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns innovative medicine segments almost exclusively resalable sales returns certain franchises medtech segment typically resalable material company infrequently exchanges products inventory returned products sales returns reserve total company less annual net trade sales fiscal years promotional programs product listing allowances recorded period related sales include volumebased sales incentive programs volumebased incentive programs based estimated sales volumes incentive period recorded products sold arrangements evaluated determine appropriate amounts deferred recorded reduction revenue company also earns profitshare payments collaborative arrangements certain products included sales customers profitshare payments less total revenues fiscal year less total revenues fiscal years included sales customers see note consolidated financial statements disaggregation revenue shipping handling shipping handling costs incurred billion billion billion fiscal years respectively included selling marketing administrative expense amount revenue received shipping handling less sales customers periods presented inventories inventories stated lower cost net realizable value determined firstin firstout method intangible assets goodwill authoritative literature us gaap requires goodwill intangible assets indefinite lives assessed annually impairment company completed annual impairment test fiscal fourth quarter future impairment tests performed annually fiscal fourth quarter sooner warranted purchased inprocess research development accounted indefinite lived intangible asset underlying project completed point intangible asset accounted definite lived intangible asset warranted purchased inprocess research development could written partially impaired depending underlying program intangible assets finite useful lives continue amortized useful lives reviewed impairment warranted economic conditions see note details intangible assets goodwill financial instruments required us gaap derivative instruments recorded balance sheet fair value fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value level highest priority level lowest changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposures impact companys financial performance protect companys cash flow adverse movements foreign exchange rates ensure appropriateness financial instruments manage enterprise risk associated financial institutions see note additional information financial instruments leases company determines whether arrangement lease contract inception establishing contract conveys right control use identified property plant equipment period time exchange consideration right use rou assets lease liabilities operating leases included assets accrued liabilities liabilities consolidated balance sheet rou assets represent right use underlying asset lease term lease liabilities represent obligation make lease payments arising lease commitments finance leases significant included property plant equipment loans notes payable longterm debt consolidated balance sheet rou assets lease liabilities recognized lease commencement date based present value minimum lease payments lease term company uses incremental borrowing rate based information available commencement date determining present value lease payments implicit rate readily determinable lease terms may include options extend terminate lease options included lease term reasonably certain company exercise option operating lease expense recognized straightline basis lease term company elected following policy elections adoption use portfolio approach leases assets master service agreements exclusion short term leases balance sheet separating lease nonlease components company primarily operating lease space vehicles manufacturing equipment data processing equipment rou asset pertaining leases continuing operation billion fiscal years lease liability continuing operations billion fiscal years operating lease costs continuing operations billion fiscal years cash paid amounts included measurement lease liabilities continuing operations billion fiscal years product liability accruals product liability claims recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information actuarially determined estimates applicable accruals adjusted periodically additional information becomes available company accrues estimate legal defense costs needed defend matter costs probable reasonably estimated extent adverse verdicts rendered company company record accrual loss determined probable reasonably estimated annual report company self insurance whollyowned captive insurance company addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated research development research development expenses expensed incurred accordance asc research development upfront milestone payments made third parties connection research development collaborations expensed incurred point regulatory approval payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangibles net accumulated amortization company enters collaborative arrangements typically pharmaceutical biotechnology companies develop commercialize drug candidates intellectual property arrangements typically involve two parties active participants collaboration exposed significant risks rewards dependent commercial success activities collaborations usually involve various activities one parties including research development marketing selling distribution often collaborations require upfront milestone royalty profit share payments contingent upon occurrence certain future events linked success asset development amounts due collaborative partners related development activities generally reflected reduction research development expense performance contract development services central companys operations general income statement presentation collaborations follows naturetype collaboration statement earnings presentation thirdparty sale product profit share payments received sales customers royaltiesmilestones paid collaborative partner post cost products sold regulatory approval royalties received collaborative partner income expense net upfront payments milestones paid collaborative partner research development expense preregulatory approval research development payments collaborative partner research development expense research development payments received reduction research development expense collaborative partner government entity milestones capitalized intangible assets amortized cost products sold useful life years presented individual project represented greater total annual consolidated research development expense company number products compounds developed collaboration strategic partners including xarelto codeveloped bayer healthcare ag imbruvica developed collaboration comarketed pharmacyclics llc abbvie company separately company number licensing arrangements products compounds including darzalex licensed genmab advertising costs associated advertising expensed year incurred included selling marketing administrative expenses advertising expenses worldwide comprised television radio print media internet advertising billion billion billion fiscal years respectively income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based enacted tax regulations rates future changes tax laws rates may affect recorded deferred tax assets liabilities future company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position united states enacted law new us tax legislation us tax cuts jobs act tcja law included provisions comprehensive overhaul corporate income tax code including reduction statutory corporate tax rate effective january tcja included provision tax previously undistributed earnings us companies located foreign jurisdictions undistributed earnings form cash cash equivalents taxed rate earnings taxed rate tax payable years accrue interest payments began continue remaining balance end approximately billion billion classified noncurrent reflected longterm taxes payable companys balance sheet tcja also includes provisions tax global intangible lowtaxed income gilti gilti described excess us shareholders total net foreign income deemed return tangible assets provided tcja january fasb issued guidance allows companies elect accounting policy whether record tax effects gilti period tax liability generated ie period cost provide deferred tax assets liabilities related basis differences exist expected effect amount gilti inclusion future years upon reversal ie deferred method company elected account gilti deferred method deferred tax amounts recorded based evaluation temporary differences expected reverse gilti incurred future periods company recorded deferred tax liabilities undistributed earnings prior december international subsidiaries company provided deferred taxes undistributed earnings subsequent january certain international subsidiaries earnings considered indefinitely reinvested company intends continue reinvest earnings international operations company decides later date repatriate earnings us company would required provide net tax effects amounts company estimates tax effect repatriation would approximately billion currently enacted tax laws regulations current currency exchange rates amount include possible benefit us foreign tax credits may substantially offset cost see note consolidated financial statements information regarding income taxes net earnings per share basic earnings per share computed dividing net earnings available common shareholders weighted average number common shares outstanding period diluted earnings per share reflects potential dilution could occur securities exercised converted common stock using treasury stock method use estimates preparation consolidated financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect amounts reported estimates used accounting sales discounts rebates allowances incentives product liabilities income taxes withholding taxes depreciation amortization employee benefits contingencies intangible asset liability valuations actual results may may differ estimates company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated best estimate loss within range accrued however estimate range better minimum amount accrued annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years fiscal year consists weeks therefore includes additional shipping days case fiscal year case fiscal year annual report cash cash equivalents current marketable securities end fiscal year cash cash equivalents current marketable securities comprised current carrying unrecognized estimated cash cash marketable dollars millions amount loss fair value equivalents securities cash nonus sovereign securities us reverse repurchase agreements corporate debt securities money market funds time deposits subtotal us gov't securities us gov't agencies sovereign securities corporate debt securities subtotal available sale total cash cash equivalents current marketable securities current carrying unrecognized estimated cash cash marketable dollars millions amount loss fair value equivalents securities cash us reverse repurchase agreements corporate debt securities money market funds time deposits subtotal us gov't securities us gov't agencies corporate debt securities subtotal available sale total cash cash equivalents current marketable securities held maturity investments reported amortized cost realized gains losses reported earnings available sale debt securities reported fair value unrealized gains losses reported net taxes comprehensive income fair value government securities obligations corporate debt securities estimated using quoted broker prices significant observable inputs contractual maturities available sale debt securities december follows dollars millions cost basis fair value due within one year due one year five years due five years ten years total debt securities company invests excess cash deposits major banks throughout world highquality money market instruments company policy making investments commercial institutions least investment grade credit rating inventories end fiscal years inventories comprised dollars millions raw materials supplies goods process finished goods total inventories property plant equipment end fiscal years property plant equipment cost accumulated depreciation dollars millions land land improvements buildings building equipment machinery equipment construction progress total property plant equipment gross less accumulated depreciation total property plant equipment net company capitalizes interest expense part cost construction facilities equipment interest expense capitalized fiscal years million million million respectively depreciation expense including amortization capitalized interest fiscal years billion billion billion respectively upon retirement disposal property plant equipment costs related amounts accumulated depreciation amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds recorded earnings annual report intangible assets goodwill end fiscal years gross net amounts intangible assets dollars millions intangible assets definite lives patents trademarks gross less accumulated amortization patents trademarks net customer relationships intangibles gross less accumulated amortization customer relationships intangibles net intangible assets indefinite lives trademarks purchased inprocess research development total intangible assets indefinite lives total intangible assets net majority comprised customer relationships goodwill december january allocated segment business follows innovative dollars millions medicine medtech total goodwill january goodwill related acquisitions goodwill related divestitures currency translationother goodwill january goodwill related acquisitions goodwill related divestitures currency translationother goodwill december includes purchase price allocation adjustments abiomed weighted average amortization period patents trademarks approximately years weighted average amortization period customer relationships intangible assets approximately years amortization expense amortizable assets included cost products sold billion billion billion tax fiscal years ended december january january respectively intangible asset writedowns included income expense net estimated amortization expense related intangible assets approved products tax five succeeding years approximately dollars millions see note consolidated financial statements additional details related acquisitions divestitures fair value measurements company uses forward foreign exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future intercompany products thirdparty purchases materials denominated foreign currency company uses cross currency interest rate swaps manage currency risk primarily related borrowings types derivatives designated cash flow hedges additionally company primarily uses interest rate swaps instrument manage interest rate risk related fixed rate borrowings derivatives designated fair value hedges company uses cross currency interest rate swaps forward foreign exchange contracts designated net investment hedges additionally company uses forward foreign exchange contracts offset exposure certain foreign currency assets liabilities forward foreign exchange contracts designated hedges therefore changes fair values derivatives recognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities company enter derivative financial instruments trading speculative purposes contain credit risk related contingent features company maintains credit support agreements csa certain derivative counterparties establishing collateral thresholds based respective credit ratings netting agreements december january total amount cash collateral paid company csa amounted billion billion net respectively related net investment cash flow hedges ongoing basis company monitors counterparty credit ratings company considers credit nonperformance risk low company primarily enters agreements commercial institutions least investment grade credit rating refer table significant financial assets liabilities measured fair value contained footnote receivables payables commercial institutions december company notional amounts outstanding forward foreign exchange contracts cross currency interest rate swaps interest rate swaps billion billion billion respectively january company notional amounts outstanding forward foreign exchange contracts cross currency interest rate swaps interest rate swaps billion billion billion respectively derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction designation cash flow hedge made entrance date derivative contract inception derivatives expected highly effective foreign exchange contracts designated cash flow hedges accounted forward method gainslosses associated contracts recognized income statement hedged item impacts earnings changes fair value derivatives recorded accumulated comprehensive income underlying transaction affects earnings reclassified earnings account hedged transaction gains losses associated interest rate swaps changes fair value hedged debt attributable changes interest rates recorded interest expense period occur gains losses net investment hedges accounted currency translation account within accumulated comprehensive income portion excluded effectiveness testing recorded interest income expense using spot method ongoing basis company assesses whether derivative continues highly effective offsetting changes hedged items derivative longer expected highly effective hedge accounting discontinued company designated euro denominated notes issued may due dates ranging net investment hedge company 's investments certain international subsidiaries use euro functional currency order reduce volatility caused changes exchange rates december balance deferred net loss derivatives included accumulated comprehensive income million aftertax additional information see consolidated statements comprehensive income note company expects substantially amounts related forward foreign exchange contracts reclassified earnings next months result transactions expected occur period maximum length time company hedging transaction exposure months excluding interest rate contracts net investment hedges amount ultimately realized earnings may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative annual report following table summary activity related derivatives hedges fiscal years ended december january net tax december january cost interest cost interest products rd income income products rd income income dollars millions sales sold expense expense expense sales sold expense expense expense effects fair value net investment cash flow hedging gain loss fair value hedging relationship interest rate swaps contracts hedged items derivatives designated hedging instruments gain loss net investment hedging relationship cross currency interest rate swaps contracts amount gain loss recognized income derivative amount excluded effectiveness testing amount gain loss recognized aoci gain loss cash flow hedging relationship forward foreign exchange contracts amount gain loss reclassified aoci income amount gain loss recognized aoci cross currency interest rate swaps contracts amount gain loss reclassified aoci income amount gain loss recognized aoci december january following amounts recorded consolidated balance sheet related cumulative basis adjustment fair value hedges cumulative amount fair value hedging line item consolidated balance sheet adjustment included carrying hedged item included carrying amount hedged liability amount hedged liability dollars millions december january december january longterm debt following table effect derivatives designated hedging instrument fiscal years ended december january location gain loss gainloss recognized income recognized dollars millions derivative income derivative derivatives designated hedging instruments december january foreign exchange contracts income expense following table effect net investment hedges fiscal years ended december january location gain loss gainloss reclassified accumulated gainloss reclassified recognized comprehensive income accumulated oci accumulated oci income income december january december january dollars millions debt interest income expense cross currency interest interest income expense rate swaps company holds equity investments readily determinable fair values equity investments without readily determinable fair values company measures equity investments readily determinable fair values cost minus impairment plus minus changes resulting observable price changes orderly transactions identical similar investment issuer following table summary activity related equity investments fiscal years ended december january january december changes fair sales value reflected non current purchasesother dollars millions carrying value net income carrying value assets equity investments readily determinable value equity investments without readily determinable value annual report january january changes fair sales value reflected non current purchasesother dollars millions carrying value net income carrying value assets equity investments readily determinable value equity investments without readily determinable value recorded incomeexpense includes impact currency includes remaining stake kenvue billion unfavorable change fair value investment separation date end fiscal year fiscal years ended december january equity investments without readily determinable market values million million respectively changes fair value reflected net income result impairments offsetting impacts million million respectively changes fair value reflected net income due changes observable prices gains disposal investments fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability accordance asc threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described level highest priority level lowest fair value derivative financial instrument ie forward foreign exchange contracts interest rate contracts aggregation currency future cash flows discounted present value prevailing market interest rates subsequently converted us dollar current spot foreign exchange rate company believe fair values derivative instruments materially differ amounts could realized upon settlement maturity changes fair value material effect companys results operations cash flows financial position company also holds equity investments classified level debt securities classified level company holds acquisition related contingent liabilities based upon certain regulatory commercial events classified level whose values determined using discounted cash flow methodologies similar techniques determination fair value requires significant judgment estimations following three levels inputs used measure fair value level quoted prices active markets identical assets liabilities level significant observable inputs level significant unobservable inputs companys significant financial assets liabilities measured fair value fiscal year ended december january follows dollars millions level level level total total derivatives designated hedging instruments assets forward foreign exchange contracts interest rate contracts total liabilities forward foreign exchange contracts interest rate contracts total derivatives designated hedging instruments assets forward foreign exchange contracts liabilities forward foreign exchange contracts available sale investments equity investments debt securities liabilities contingent consideration gross net derivative reconciliation dollars millions total gross assets credit support agreements csa total net asset total gross liabilities credit support agreements csa total net liabilities annual report summarized information changes liabilities contingent consideration follows dollars millions beginning balance changes estimated fair value additions paymentsother ending balance assets liabilities classified level exception equity investments million classified level contingent consideration million classified level includes cross currency interest rate swaps interest rate swaps classified noncurrent assets classified cash equivalents current marketable securities includes million million million classified noncurrent liabilities december january january respectively includes million million classified current liabilities january january respectively fiscal year company recorded million contingent consideration related abiomed see notes financial assets liabilities held carrying amount consolidated balance sheet borrowings components longterm debt follows effective effective rate rate dollars millions debentures due notes due notes due notes due mm euro mm euro notes due mm gbp mm gbp notes due notes due notes due notes due notes due notes due mm euro mm euro notes due notes due notes due debentures due notes due notes due b euro b euro notes due notes due notes due debentures due notes due debentures due notes due notes due notes due notes due notes due notes due notes due notes due subtotal less current portion total longterm debt weighted average effective rate annual report translation rate december translation rate january excess carrying value fair value debt billion billion end fiscal year fiscal year respectively fair value longterm debt estimated using market prices corroborated quoted broker prices significant observable inputs company access substantial sources funds numerous banks worldwide september company secured new day credit facility billion expires september company early terminated additional day revolving credit facility billion expiration november interest charged borrowings credit line agreement based either term sofr reference rate applicable market rates allowed terms agreement plus applicable margins commitment fees agreements material throughout fiscal years company continued access liquidity commercial paper market shortterm borrowings current portion longterm debt amounted approximately billion billion end fiscal years respectively current portion long term debt billion billion respectively remainder commercial paper local borrowing international subsidiaries current debt balance december includes billion commercial paper weighted average interest rate weighted average maturity approximately two months current debt balance january includes billion commercial paper weighted average interest rate weighted average maturity approximately two months aggregate maturities longterm debt obligations commencing dollars millions income taxes provision taxes income consists dollars millions currently payable us taxes international taxes total currently payable deferred us taxes international taxes total deferred provision taxes income comparison income tax expense us statutory rate fiscal years companys effective tax rate follows dollars millions us international earnings taxes income tax rates us statutory rate international operations us tax settlements us taxes international income tax benefits loss capital assets tax benefits sharebased compensation effective rate international operations reflect impacts operations jurisdictions statutory tax rates different us particularly ireland switzerland belgium puerto rico favorable impact effective tax rate compared us statutory rate includes impact gilti tax foreignderived intangible income deduction foreign income taxable us tax code amount includes impact certain provisions tcja became effective fiscal amount includes impact certain foreign subsidiaries deferred tax remeasurements legislative elections amounts include reorganization international subsidiaries described fiscal year effective tax rate decreased compared fiscal year effective tax rate company recorded certain nonrecurring favorable tax items fiscal year compared prior fiscal year fiscal fourth quarter company settled us internal revenue service audit tax years resulted favorable impact rate settlement partially offset company recording billion decrease expected us foreign tax credits unfavorable effective rate impact reflected current tax expense us taxes international income companys effective tax rate reconciliation fiscal year company certain nonrecurring impacts result legislative tax elections made certain international subsidiaries resulted change companys tax basis certain assets resulting deferred tax remeasurements net impact nonrecurring items net benefit companys annual effective tax rate comprised following items approximately billion tax benefit local deferred tax assets record remeasurement increased tax basis benefit reflected international operations companys effective tax rate reconciliation benefit offset approximately billion us deferred tax expense gilti deferred tax liability resulting remeasurement deferred tax assets reflected us tax international income companys effective tax rate reconciliation approximately billion us deferred tax benefit gilti deferred tax result international subsidiary making election change treatment local deferred tax asset refundable tax credit reflected us taxes international income companys effective tax rate reconciliation companys tax rates benefited certain provisions tax cuts jobs act became effective fiscal company also lower income higher tax jurisdictions vs fiscal year primarily us company recorded approximately billion charge related talc matters united states effective tax rate information see note consolidated financial statements fiscal year effective tax rate increased compared fiscal year effective tax rate company recorded certain nonrecurring favorable tax items fiscal year resulted unfavorable impact companys fiscal effective tax rate compared prior fiscal year items described companys tax rate also benefited impairment bermekimab ad iprd changes fair value securities companys investment portfolio recorded us statutory rate annual report fiscal year company reorganized ownership structure certain whollyowned international subsidiaries part reorganization company increased tax basis certain assets fair value accordance applicable local regulations net impact restructuring approximately billion net benefit benefit companys annual effective tax rate comprised following items approximately billion local deferred tax assets record remeasurement tax basis assets fair value benefit reflected international operations companys effective tax rate reconciliation approximately billion us deferred tax expense relating gilti deferred tax liability resulting remeasurement deferred tax assets expense reflected us taxes international income companys effective tax rate reconciliation also fiscal fourth quarter company recognized loss certain us affiliates related previously impaired book value certain intangibles reduced effective tax rate approximately reflected tax benefits loss capital assets effective tax rate reconciliation additionally fiscal impacts rate primarily driven litigation acquisition related items follows company accrued additional legal expenses approximately billion talc effective tax rate billion risperdal gynecomastia settlements effective tax rate see note consolidated financial statements details company recorded partial iprd charge billion ottava intangible asset acquired auris health acquisition effective rate temporary differences carryforwards end fiscal years follows deferred tax deferred tax dollars millions asset liability asset liability employee related obligations stock based compensation depreciation property plant equipment goodwill intangibles rd capitalized tax reserves liabilities income reported tax purposes net realizable operating loss carryforwards undistributed foreign earnings global intangible lowtaxed income miscellaneous international miscellaneous us total deferred income taxes fiscal company changed presentation income taxes accrued intercompany profits inventory still owned company part prepaid expenses consolidated balance sheet net valuation allowances billion billion change valuation allowance driven approximately billion acquisition related activity remainder due normal operations fiscal year company whollyowned international subsidiaries cumulative net losses company believes likely subsidiaries generate future taxable income sufficient utilize deferred tax assets however certain jurisdictions valuation allowances recorded deferred tax assets loss carryforwards likely realized following table summarizes activity related unrecognized tax benefits continuing operations dollars millions beginning year increases related current year tax positions increases related prior period tax positions decreases related prior period tax positions settlements lapse statute limitations end year december company approximately billion unrecognized tax benefits company conducts business files tax returns numerous countries currently tax audits progress number tax authorities respect united states internal revenue service completed audit tax years major jurisdictions company conducts business years remain open tax audits go back year company believes possible tax audits may completed next twelve months taxing authorities jurisdictions including united states however company able provide reasonably reliable estimate timing future tax payments change uncertain tax positions company classifies liabilities unrecognized tax benefits related interest penalties longterm liabilities interest expense penalties related unrecognized tax benefits classified income tax expense company recognized tax interest expense million million million fiscal years respectively total amount accrued interest million million fiscal years respectively employee related obligations end fiscal fiscal employee related obligations recorded consolidated balance sheets dollars millions pension benefits postretirement benefits postemployment benefits deferred compensation total employee obligations less current benefits payable employee related obligations noncurrent prepaid employee related obligations million million respectively included assets consolidated balance sheets annual report pensions benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily healthcare eligible us retired employees dependents many international employees covered governmentsponsored programs cost company significant us nonunion pension benefits employees hired january primarily based employees compensation last five years retirement number years service final average pay formula us pension benefits employees hired calculated using different formula based employee compensation total years service retirement value formula january company announced effective january eligible us nonunion employees regardless hire date earn benefits retirement value formula amendment affect benefits accrued final average pay formula service january international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided company fund retiree healthcare benefits advance right modify plans future company used december december respectively measurement date us international retirement benefit plans net periodic benefit costs companys defined benefit retirement plans benefit plans include following components retirement plans benefit plans dollars millions service cost interest cost expected return plan assets amortization prior service cost recognized actuarial losses gains curtailments settlements net periodic benefit cost credit service cost component net periodic benefit cost presented line items consolidated statement earnings employee compensation costs reported including cost products sold research development expense selling marketing administrative expenses net earnings discontinued operations net taxes related separation kenvue components net periodic benefit cost presented part income expense net consolidated statement earnings exception certain amounts curtailments settlements reported net earnings discontinued operations net taxes related separation kenvue noted unrecognized gains losses us pension plans amortized average remaining future service plan plans active employees amortized average life expectancy amortization gains losses us benefit plans determined using corridor greater market value assets accumulated postretirement benefit obligation total unamortized gains losses excess corridor amortized average remaining future service prior service costsbenefits us pension plans amortized average remaining future service plan participants time plan amendment prior service costbenefit us benefit plans amortized average remaining service full eligibility age plan participants time plan amendment following table represents weightedaverage actuarial assumptions retirement plans benefit plans worldwide benefit plans net periodic benefit cost service cost discount rate interest cost discount rate rate increase compensation levels expected longterm rate return plan assets benefit obligation discount rate rate increase compensation levels companys discount rates determined considering current yield curves representing high quality longterm fixed income instruments resulting discount rates consistent duration plan liabilities company 's methodology determining service interest cost uses duration specific spot rates along yield curve plans ' liability cash flows expected rates return plan asset assumptions represent company 's assessment longterm returns diversified investment portfolios globally assessment determined using projections external financial sources longterm historical averages actual returns asset class various asset class allocations market following table displays assumed healthcare cost trend rates individuals healthcare plans healthcare cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend year rate reaches ultimate trend rate excludes ongoing negotiations regarding healthcare cost service providers following table sets forth information related benefit obligation fair value plan assets fiscal yearend companys defined benefit retirement plans postretirement plans retirement plans benefit plans dollars millions change benefit obligation projected benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial gains losses divestitures acquisitions curtailments settlements restructuring benefits paid plan effect exchange rates projected benefit obligation end year annual report change plan assets plan assets fair value beginning year actual return loss plan assets company contributions plan participant contributions settlements divestitures acquisitions benefits paid plan assets effect exchange rates plan assets fair value end year funded status end year amounts recognized companys balance sheet consist following noncurrent assets current liabilities noncurrent liabilities total recognized consolidated balance sheet end year amounts recognized accumulated comprehensive income consist following net actuarial loss prior service cost credit unrecognized net transition obligation total tax effects accumulated benefit obligations end year actuarial gainslosses retirement plans primarily driven changes discount rates primarily driven kenvue separation includes approximately million transferred group annuity contract issued thirdparty insurer us salaried pension plan retirement plans benefit plans dollars millions amounts recognized net periodic benefit cost comprehensive income net periodic benefit cost credit net actuarial gain loss amortization net actuarial loss prior service cost credit amortization prior service cost credit effect exchange rates total lossincome recognized comprehensive income tax total recognized net periodic benefit cost comprehensive income company plans continue fund us qualified plans comply pension protection act international plans funded accordance local regulations additional discretionary contributions made deemed appropriate meet longterm obligations plans certain plans funding common practice funding provides economic benefit consequently company several pension plans funded company contributed million million us international pension plans respectively following table displays funded status company 's us qualified nonqualified pension plans international funded unfunded pension plans december december respectively us plans international plans qualified plans nonqualified plans funded plans unfunded plans dollars millions plan assets projected benefit obligation accumulated benefit obligation funded status projected benefit obligation accumulated benefit obligation plans accumulated benefit obligations excess plan assets accumulated benefit obligation projected benefit obligation plan assets billion billion billion respectively end billion billion billion respectively end following table displays projected future benefit payments companys retirement benefit plans dollars millions projected future benefit payments retirement plans benefit plans following table displays projected future minimum contributions unfunded retirement plans amounts include discretionary contributions company may elect make future dollars millions projected future contributions pension plan overseen local committee board responsible overall administration investment pension plans determining investment policies strategies goals committee board considers factors including local pension rules regulations local tax regulations availability investment vehicles separate accounts commingled accounts insurance funds etc funded status plans ratio actives retirees duration liabilities relevant factors including diversification liquidity local markets liquidity base currency majority companys pension funds open new entrants expected ongoing plans permitted investments primarily liquid andor listed little reliance illiquid nontraditional investments hedge funds companys retirement plan asset allocation end target allocations follows annual report percent target plan assets allocation worldwide retirement plans equity securities debt securities total plan assets determination fair value plan assets plan established welldocumented process determining fair values fair value based upon quoted market prices available listed prices quotes available fair value based upon models primarily use inputs marketbased independently sourced market parameters including yield curves interest rates volatilities equity debt prices foreign exchange rates credit curves plan believes valuation methods appropriate consistent market participants use different methodologies assumptions determine fair value certain financial instruments could result different estimate fair value reporting date valuation hierarchy authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described table level highest priority level lowest net asset value nav based value underlying assets owned fund minus liabilities divided number shares outstanding financial instruments categorization within valuation hierarchy based upon lowest level input significant fair value measurement following description valuation methodologies used investments measured fair value shortterm investment funds cash quoted shortterm instruments valued closing price amount held deposit custodian bank investments investment vehicles valued using nav provided administrator fund nav quoted price market active classified level government agency securities limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified within level valuation hierarchy quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows quoted market prices security available active market classified level debt instruments limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified level quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows classified level level debt instruments priced based unobservable inputs equity securities equity securities valued closing price reported major market individual securities traded substantially equity securities classified within level valuation hierarchy commingled funds investment vehicles valued using nav provided fund administrator assets level category quoted market price assets assets represented primarily limited partnerships investment vehicles valued using nav provided fund administrator assets exchange listed actively traded classified level inactively traded assets classified level following table sets forth retirement plans ' investments measured fair value december december quoted prices significant active significant investments markets observable unobservable measured net identical assets inputs inputs asset value level level level total assets dollars millions shortterm investment funds government agency securities debt instruments equity securities commingled funds assets investments fair value activity level assets significant years presented company 's benefit plans unfunded except us commingled funds level million million december december respectively fair value johnson johnson common stock directly held plan assets million total plan assets december million total plan assets december savings plan company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employees contributions consistent provisions plan employee eligible total company matching contributions plans million million million fiscal years respectively annual report capital treasury stock changes treasury stock treasury stock amounts millions except treasury stock shares thousands shares amount balance january employee compensation stock option plans repurchase common stock balance january employee compensation stock option plans repurchase common stock balance january employee compensation stock option plans repurchase common stock kenvue share exchange note balance december aggregate shares common stock issued approximately shares end fiscal years cash dividends paid per share fiscal year compared dividends per share fiscal year per share fiscal year january board directors declared regular cash dividend per share payable march shareholders record february september company announced board directors approved share repurchase program authorizing company purchase billion company 's shares common stock repurchase program completed fiscal first quarter accumulated comprehensive income loss components comprehensive income loss consist following total gain accumulated foreign gain loss currency loss employee derivatives comprehensive dollars millions translation securities benefit plans hedges income loss january net changes january net changes january net changes kenvue separationipo december amounts accumulated comprehensive income presented net related tax impact foreign currency translation adjusted income taxes relates permanent investments international subsidiaries additional details comprehensive income see consolidated statements comprehensive income details reclassifications accumulated comprehensive income gainloss securities reclassifications released income expense net employee benefit plans reclassifications included net periodic benefit cost see note additional details gainloss derivatives hedges reclassifications earnings recorded account hedged transaction see note additional details includes impact curtailments settlements connection separation kenvue international currency translation translation subsidiaries operating nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years substantial portion cash flows local currency majority company 's subsidiaries local currency functional currency consolidating international subsidiaries balance sheet currency effects recorded component accumulated comprehensive income current noncurrent assets line within statement cash flows includes impact foreign currency translation equity account includes results translating certain balance sheet assets liabilities current exchange rates accounts historical rates except located highly inflationary economies argentina venezuela beginning fiscal second quarter company also accounted operations turkey highly inflationary translation balance sheet accounts highly inflationary economies reflected operating results rollforward changes fiscal years foreign currency translation adjustments included note net currency transaction gains losses included income expense losses million million million fiscal years respectively annual report earnings per share following reconciliation basic net earnings per share diluted net earnings per share fiscal years ended december january january millions except per share amounts basic net earnings per share continuing operations basic net earnings per share discontinued operations total net earnings per share basic average shares outstanding basic potential shares exercisable stock option plans less shares repurchased treasury stock method adjusted average shares outstanding diluted diluted net earnings per share continuing operations diluted net earnings per share discontinuing operations total net earnings per share diluted diluted net earnings per share calculation fiscal year excluded million shares related stock options exercise price options greater average market value company 's stock diluted net earnings per share calculation fiscal years included shares related stock options exercise price options less average market value company 's stock common stock stock option plans stock compensation agreements december company one stockbased compensation plan shares outstanding contracts company 's longterm incentive plan longterm incentive plan longterm incentive plan expired april awards stock options restricted shares units performance share units granted subsequent date longterm incentive plan longterm incentive plan company may issue million shares common stock million shares common stock may issued subject stock options stock appreciation rights million shares common stock may issued subject full value awards awards generally counted basis share reserve provided million full value awards granted full value award excess million counted basis share reserve shares available future grants longterm incentive plan million end fiscal year compensation cost charged income plans million million million fiscal years respectively total income tax benefit recognized income statement sharebased compensation costs million million million fiscal years respectively company also recognized additional income tax benefits million million million fiscal years respectively options exercised restricted shares vested total unrecognized compensation cost million million million fiscal years respectively weighted average period cost recognized years years years fiscal years respectively sharebased compensation costs capitalized part inventory insignificant periods company settles employee benefit equity issuances treasury shares treasury shares replenished market purchases throughout year number shares used settle employee benefit equity issuances stock options stock options expire years date grant vest service periods range months years options granted longterm incentive plan granted average high low prices companys common stock new york stock exchange date grant options granted longterm incentive plan granted closing price companys common stock new york stock exchange date gran fair value option award estimated date grant using blackscholes option valuation model uses assumptions noted following table grants expected volatility represents blended rate year weekly historical overall volatility rate week average implied volatility rate based atthemoney traded johnson johnson options life years grants historical data used determine expected life option riskfree rate based us treasury yield curve effect time grant average fair value options granted fiscal years respectively fair value estimated based weighted average assumptions riskfree rate expected volatility expected life years expected dividend yield summary option activity plan december presented aggregate weighted intrinsic outstanding average exercise value shares thousands shares price dollars millions shares january options granted options exercised options canceledforfeited shares december total intrinsic value options exercised million million million fiscal years respectively includes shares options cancelled result conversion johnson johnson stock options held kenvue employees kenvue stock options annual report following table summarizes stock options outstanding exercisable december shares thousands outstanding exercisable weighted weighted average average exercise price range options average life exercise price options exercise price average contractual life remaining years stock options outstanding january january average life years average life years respectively stock options exercisable january january average price average price respectively restricted share units performance share units company grants restricted share units vest service periods range months years company also grants performance share units paid shares johnson johnson common stock end three year performance period performance shares granted two equallyweighted goals directly align help drive longterm total shareholder return adjusted operational earnings per share relative total shareholder return number shares actually earned end threeyear period vary based actual performance target number performance share units granted summary restricted share units performance share units activity plans december presented outstanding outstanding shares thousands restricted share units performance share units shares january granted issued canceledforfeitedadjusted shares december includes shares restricted share units shares performance share units cancelled result conversion johnson johnson restricted share units performance share units held kenvue employees kenvue restricted share units average fair value restricted share units granted fiscal years respectively using fair market value date grant fair value restricted share units discounted dividends paid restricted share units vesting period fair value restricted share units issued million million million respectively weighted average fair value performance share units granted fiscal years calculated using weighted average fair market value component goals date grant fair values earnings per share goals performance share unit estimated date grant using fair market value shares time award discounted dividends paid performance share units vesting period fair value relative total shareholder return goal performance share unit estimated date grant using monte carlo valuation model fair value performance share units issued million million million fiscal years respectively segments business geographic areas following separation consumer health business fiscal third quarter company organized two business segments innovative medicine formerly referred pharmaceutical medtech segment results recast periods reflect continuing operations company sales customers change dollars millions vs vs innovative medicine immunology us international worldwide remicade us us exports international worldwide simponi simponi aria us international worldwide stelara us international worldwide tremfya us international worldwide immunology us international worldwide infectious diseases us international worldwide covid vaccine us international worldwide annual report sales customers change dollars millions vs vs edurant rilpivirine us international worldwide prezista prezcobix rezolsta symtuza us international worldwide infectious diseases us international worldwide neuroscience us international worldwide concerta methylphenidate us international worldwide invega sustenna xeplion invega trinza trevicta us international worldwide spravato us international worldwide neuroscience us international worldwide oncology us international worldwide sales customers change dollars millions vs vs carvykti us international worldwide darzalex us international worldwide erleada us international worldwide imbruvica us international worldwide zytiga abiraterone acetate us international worldwide oncology us international worldwide pulmonary hypertension us international worldwide opsumit us international worldwide uptravi us international worldwide pulmonary hypertension us international worldwide annual report sales customers change dollars millions vs vs cardiovascular metabolism us international worldwide xarelto us international worldwide us international worldwide total innovative medicine us international worldwide medtech interventional solutions us international worldwide electrophysiology us international worldwide abiomed us international worldwide interventional solutions us international worldwide orthopaedics us international worldwide hips us international worldwide sales customers change dollars millions vs vs knees us international worldwide trauma us international worldwide spine sports us international worldwide surgery us international worldwide advanced us international worldwide general us international worldwide vision us international worldwide contact lenses us international worldwide surgical us international worldwide total medtech us international worldwide annual report sales customers change dollars millions vs vs worldwide us international worldwide percentage greater meaningful previously referred pharmaceutical inclusive risperdal consta previously disclosed separately inclusive invokana previously disclosed separately acquired december income tax identifiable assets dollars millions innovative medicine medtech total less expense allocated segments discontinued operations general corporate worldwide total additions property depreciation plant equipment amortization dollars millions innovative medicine medtech segments total discontinued operations general corporate worldwide total sales customers longlived assets dollars millions united states europe western hemisphere excluding us asiapacific africa segments total discontinued operations general corporate non longlived assets worldwide total see note description segments company operates export sales significant fiscal year company utilized three wholesalers distributing products segments represented approximately total consolidated revenues fiscal year company three wholesalers distributing products segments represented approximately total consolidated revenues fiscal year company three wholesalers distributing products three segments represented approximately total consolidated revenues amounts allocated segments include interest incomeexpense general corporate incomeexpense fiscal includes approximately billion charge related talc matters see note legal proceedings additional details billion related unfavorable change fair value retained stake kenvue general corporate includes cash cash equivalents marketable securities innovative medicine includes onetime covid vaccine manufacturing exit related costs billion restructuring related charge billion unfavorable changes fair value securities billion favorable litigation related items billion loss divestiture billion intangible asset impairment charge approximately billion related market dynamics associated nonstrategic asset acquired part acquisition momenta pharmaceuticals medtech includes acquired process research development asset billion related laminar acquisition restructuring related charge billion acquisition integration related costs billion primarily related acquisition abiomed medical device regulation charge billion income litigation settlements billion innovative medicine includes onetime covid vaccine manufacturing exit related costs billion intangible asset impairment charge approximately billion related inprocess research development asset bermekimab jnj investigational drug treatment atopic dermatitis ad hidradenitis suppurativa hs acquired acquisition xbiotech inc fiscal year additional information regarding efficacy ad hs indications became available led company decision terminate development bermekimab ad hs litigation expense billion unfavorable changes fair value securities billion restructuring related charge billion medtech includes litigation expense billion primarily pelvic mesh related costs restructuring related charge billion acquisition integration related costs billion primarily related acquisition abiomed medical device regulation charge billion innovative medicine includes litigation expense billion primarily related risperdal gynecomastia divestiture gains billion gains billion related change fair value securities restructuring related charge billion medtech includes inprocess research development expense billion related ottava restructuring related charge billion medical device regulation charge billion annual report litigation expense billion longlived assets include property plant equipment net fiscal years respectively intangible assets goodwill net fiscal years respectively acquisitions divestitures fiscal first quarter company announced entered definitive agreement acquire ambrx biopharma inc ambrx nasdaq amam clinicalstage biopharmaceutical company proprietary synthetic biology technology platform design develop nextgeneration antibody drug conjugates adcs allcash merger transaction total equity value approximately billion billion net estimated cash acquired company acquire outstanding shares ambrxs common stock per share merger ambrx subsidiary company closing transaction expected occur first half subject receipt ambrx shareholder approval well clearance hartscottrodino antitrust improvements act customary closing conditions company expects transaction accounted business combination results operations included innovative medicine segment acquisition date fiscal year company make acquisitions qualified business combination fiscal year asset acquisitions inprocess research development approximately billion cash primarily consisting acquisition laminar inc billion closed november laminar inc privatelyheld medical device company focused eliminating left atrial appendage laa patients nonvalvular atrial fibrillation afib fiscal year certain businesses acquired billion cash billion liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition excess purchase price estimated fair value tangible assets acquired amounted billion assigned identifiable intangible assets residual recorded goodwill fiscal year acquisitions primarily included abiomed inc abiomed remaining acquisitions material december company completed acquisition abiomed leading firsttomarket provider cardiovascular medical technology firstinkind portfolio treatment coronary artery disease heart failure also extensive innovation pipeline lifesaving technologies transaction broadens companys position growing cardiovascular innovator advancing standard care heart failure recovery one healthcares largest areas unmet need transaction accounted business combination results operations included medtech segment date acquisition acquisition completed tender offer outstanding shares consideration paid acquisition consisted upfront payment per share cash amounting billion net cash acquired well nontradeable contingent value right cvr entitling holder receive per share cash respect cvrs total approximately billion aggregate certain commercial clinical milestones achieved corresponding enterprise value without taking account cvrs approximately billion includes cash cash equivalents marketable securities acquired milestones cvr consist per share payable net sales abiomed products exceeds billion johnson johnsons fiscal second quarter fiscal first quarter threshold met period subsequently met rolling four quarter period end johnson johnsons fiscal first quarter per share b per share payable upon fda premarket application approval use impella products stelevated myocardial infarction stemi patients without cardiogenic shock january c per share payable upon first publication class recommendation use impella products high risk pci stemi without cardiogenic shock within four years respective clinical endpoint publication dates cases later december fiscal fourth quarter company finalized purchase price allocation fiscal purchase price allocation adjustments netting approximately billion offsetting increase goodwill fair value acquisition allocated assets acquired billion net billion cash acquired primarily goodwill billion amortizable intangible assets billion iprd billion marketable securities billion andliabilities assumed billion includes fair value contingent consideration mentioned billion deferred taxes billion goodwill primarily attributable commercial acceleration expansion portfolio expected deductible tax purposes contingent consideration recorded liabilities adjusted fair value fiscal year end consolidated balance sheet amortizable intangible assets primarily comprised already inmarket products impella platform average weighted life years iprd assets valued technology programs unapproved products value iprd calculated using probabilityadjusted cash flow projections discounted risk inherent projects probability success factor ranged discount rate applied company recorded acquisition related costs tax approximately billion primarily recorded incomeexpense company recorded acquisition related costs tax approximately billion recorded incomeexpense fiscal year company make material acquisitions qualified business combination accordance us gaap standards related business combinations goodwill intangible assets supplemental pro forma information fiscal years provided impact aforementioned acquisitions material effect companys results operations divestitures fiscal year company executed divestitures resulting approximately billion proceeds resulting gains losses material fiscal year end company held assets primarily intangibles consolidated balance sheet expects divest approximately billion primarily related acclarent ponvory fiscal year company make material divestitures fiscal year separate transactions company divested two brands outside us within innovative medicine segment company recognized pretax gain recorded income expense net approximately billion legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial indemnification matters governmental investigations legal proceedings arise time time ordinary course business company records accruals loss contingencies associated legal matters probable liability incurred amount loss reasonably estimated december company determined liabilities associated certain litigation matters probable reasonably estimated company accrued matters continue monitor related legal issue adjust accruals might warranted based new information developments accordance asc contingencies litigation regulatory matters discussed loss probable reasonably possible company unable estimate possible loss range loss beyond amounts accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions including timing related payments ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability number potential claims ability achieve comprehensive multiparty settlements complexity related crossclaims counterclaims andor numerous parties involved extent adverse awards judgments verdicts rendered company company record accrual loss determined probable reasonably estimated companys opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued companys balance sheet expected material adverse effect companys financial position however resolution increase accruals one matters reporting period may material adverse effect companys results operations cash flows period annual report matters concerning talc significant number personal injury claims alleging talc causes cancer asserted johnson johnson consumer inc successor ltl management llc known llt management llc company arising use body powders containing talc primarily johnsons baby powder talc cases previously gone trial company obtained number defense verdicts also verdicts company many reversed appeal june missouri court appeals reversed part affirmed part july verdict billion ingham v johnson johnson et al ed mo app reducing overall award billion application transfer case missouri supreme court subsequently denied june petition certiorari seeking review ingham decision united states supreme court denied june company paid award including interest totaled approximately billion facts circumstances including terms award unique ingham decision representative claims brought company company continues believe strong legal grounds contest talc verdicts appealed notwithstanding companys confidence safety talc products certain circumstances company settled cases october johnson johnson consumer inc old jjci implemented corporate restructuring corporate restructuring result restructuring old jjci ceased exist three new entities created ltl management llc north carolina limited liability company ltl debtor b royalty llc north carolina limited liability company direct subsidiary ltl ram c debtors direct parent johnson johnson consumer inc new jersey company new jjci debtor received certain old jjcis assets became solely responsible talcrelated liabilities old jjci including liabilities related way injury damage alleged injury damage sustained incurred purchase use exposure talc including talc contained product risk responsibility damage injury except liabilities exclusive remedy provided workers compensation statute act talcrelated liabilities october notwithstanding companys confidence safety talc products debtor filed voluntary petition united states bankruptcy court western district north carolina charlotte division seeking relief chapter bankruptcy code ltl bankruptcy case litigation ltl old jjci new jjci company corporate affiliates identified retailers insurance companies certain parties protected parties stayed although ltl agree lift stay small number appeals appeal bonds filed ltl bankruptcy case transferred united states bankruptcy court district new jersey claimants filed motions dismiss ltl bankruptcy case following multiple day hearing new jersey bankruptcy court denied motions march claimants subsequently filed notices appeal denial motions dismiss ltl bankruptcy case extension stay protected parties january third circuit reversed bankruptcy courts ruling remanded bankruptcy court dismiss ltl bankruptcy ltl filed petition rehearing third circuits decision denied march ltl subsequently filed motion third circuit stay mandate directing new jersey bankruptcy court dismiss ltl bankruptcy pending filing disposition petition writ certiorari united states supreme court third circuit denied motion stay mandate issued mandate april new jersey bankruptcy court dismissed ltl bankruptcy case effectively lifting stay parties returning talc litigation tort system ltl refiled united states bankruptcy court district new jersey seeking relief chapter bankruptcy code ltl bankruptcy case result new filing talc claims ltl automatically stayed pursuant section bankruptcy code additionally new jersey bankruptcy court issued temporary restraining order staying litigation ltl old jjci new jjci company identified retailers certain parties new protected parties also april new jersey bankruptcy court issued decision granted limited injunctive relief company new protected parties ltl preliminary injunction ltl preliminary injunction remained force late august following bankruptcy courts extension initial ltl preliminary injunction june ltl preliminary injunction except cases filed federal court ovarian cancer multidistrict litigation discovery personal injury wrongful death matters permitted proceed furthermore april talc claimants ' committee filed motion dismiss ltl bankruptcy followed similar motions claimants hearings motions dismiss occurred june july court dismissed ltl bankruptcy case day company stated intent appeal decision continue efforts obtain resolution talc claims september bankruptcy court entered order granting ltl leave seek direct appeal third circuit court appeals october third circuit granted ltls petition direct appeal briefing ongoingfollowing dismissal ltl new lawsuits filed cases across country stayed reactivated majority cases pending federal court organized multidistrict litigation mdl united states district court district new jersey mdl casespecific discovery proceeding expectation trial occur early separately discovery pretrial activity underway various individually filed set cases around country activity cases centralized new jersey california original bankruptcy case company agreed provide funding ltl payment amounts new jersey bankruptcy court determines owed ltl establishment billion trust furtherance purpose company established reserve approximately billion connection aforementioned trust bankruptcy proceedings ltl deconsolidated company ltl bankruptcy case company agreed contribute additional amount added prior billion would total reserve approximately billion payable years nominal value approximately billion discounted rate resolve current future talc claims approximate billion reserve encompasses actual contemplated settlements approximately onethird recorded current liability recorded amount remains companys best estimate probable loss dismissal parties yet reached resolution talc matters company unable estimate possible loss range loss beyond amount accrued class action advancing claims relating industrial talc filed company others new jersey state court may edley class action edley class action asserts among things company fraudulently defended past asbestos personal injury lawsuits arising exposure industrial talc mined milled manufactured january companys wholly owned subsidiary windsor minerals inc currently debtor imerys bankruptcy described hereafter company removed edley class action federal court district new jersey october company filed motions dismiss deny certification class pursue edley class action new jersey district court argument motions heard november thereafter company resolved matter february companys talc supplier imerys talc america inc two affiliates imerys talc vermont inc imerys talc canada inc collectively imerys filed voluntary petition relief chapter united states code bankruptcy code united states bankruptcy court district delaware imerys bankruptcy imerys bankruptcy relates imeryss potential liability personal injury exposure talcum powder sold imerys bankruptcy imerys alleges claims company indemnification rights joint insurance proceeds bankruptcy imerys proposed chapter plan imerys plan contemplated talcrelated claims channeled trust along alleged indemnification rights company following confirmation consummation plan trust would pay talc claims pursuant proposed trust distribution procedures tdp seek indemnification company february cyprus mines corporation cyprus owned certain imerys talc mines filed voluntary petition relief chapter bankruptcy code filed disclosure statement plan cyprus plan cyprus plan contemplates settlement imerys talc claimants cyprus would make monetary contribution trust established imerys plan exchange injunction talc claims asserted certain affiliated parties imerys plan proceeded solicitation early however imerys plan receive requisite number votes confirmed bankruptcy court ruled certain votes cast favor imerys plan disregarded imerys subsequently canceled confirmation hearing imerys imerys tort claimants committee imerys future claimants representative along cyprus cyprus tort claimants committee cyprus future claimants representative collectively mediation parties engaged mediation since shortly confirmation hearing canceled october september bankruptcy court entered order extending term mediation among mediation parties end december bankruptcy court also authorized imerys cyprus proceed mediation certain insurers end december september imerys cyprus filed amended plans reorganization amended plans contemplate similar construct prior imerys cyprus plans including talc claims imerys cyprus certain protected parties channeled trust along imeryss cypruss alleged indemnification rights company january imerys cyprus filed revised tdp february imerys cyprus filed certain motions related disclosure statement february securities class action lawsuit filed company certain named officers united states district court district new jersey alleging company violated federal securities laws failing disclose alleged asbestos contamination body powders containing talc primarily johnsons baby powder purchasers companys shares suffered losses result april company moved dismiss complaint annual report december court denied part motion dismiss april briefing plaintiffs motion class certification completed case stayed may pursuant ltl bankruptcy case reopened may december court granted plaintiffs motion class certification january defendants filed petition third circuit federal rule civil procedure f permission appeal courts order granting class certification fact discovery proceeding lawsuit brought company superior court california county san diego alleging violations californias consumer legal remedies act clra relating johnsons baby powder lawsuit plaintiffs allege company violated clra failing provide required proposition warnings july company filed notice removal united states district court southern district california plaintiffs filed second amended complaint shortly thereafter october company moved dismiss second amended complaint failure state claim upon relief may granted response motions plaintiffs filed third amended complaint december company moved dismiss third amended complaint failure state claim upon relief may granted april court granted motion dismiss granted leave amend may plaintiffs filed fourth amended complaint indicated would filing motion leave file fifth amended complaint plaintiffs filed fifth amended complaint august company moved dismiss fifth amended complaint failure state claim upon relief may granted january court issued order opinion ruling companys favor granting motion dismiss prejudice february plaintiffs filed notice appeal ninth circuit plaintiffs filed opening brief july company filed responsive brief october notice suggestion bankruptcy filed ninth circuit stay imposed court held reply deadline abeyance september stay lifted briefing complete court expected either schedule oral argument issue decision time june mississippi attorney general filed complaint chancery court first judicial district hinds county mississippi company johnson johnson consumer companies inc known johnson johnson consumer inc collectively jjci complaint alleges jjci violated mississippi consumer protection act failing disclose alleged health risks associated female consumers use talc contained johnsons baby powder johnsons shower shower product divested seeks injunctive monetary relief february trial court set case trial begin february however october ltl bankruptcy court issued order staying case march third circuit issued mandate dismiss ltl bankruptcy case april new jersey bankruptcy court dismissed ltl bankruptcy case effectively lifting stay matter state requested new trial setting later april trial court set new trial date april company filed summary judgment daubert motions state filed limited daubert motion parties agreed court 's request mediation pretrial conference set february trial scheduled april however company actively engaged resolution discussions concerning matter january state new mexico filed consumer protection case alleging company deceptively marketed sold talcum powder products making misrepresentations safety products presence carcinogens including asbestos march new mexico court denied companys motion compel state new mexico engage discovery state agencies denied companys request interlocutory appeal decision company filed petition writ superintending control request stay new mexico supreme court issue state new mexicos discovery obligations april view efforts resolve talcrelated claims ltl bankruptcy case company state agreed day stay matters except pending writ new mexico supreme court expired june thereafter company moved enjoin prosecution case ltl bankruptcy case october bankruptcy court issued order staying case december state filed appeal third circuit concerning stay order separately september new mexico supreme court granted company 's request stay pending briefing scope state new mexicos discovery obligations march third circuit issued mandate dismiss ltl bankruptcy case april new jersey bankruptcy court dismissed ltl bankruptcy case effectively lifting stay matter state notified new mexico supreme court lifted stay litigation april court taken action since notified lifting stay remains effect fortytwo states district columbia including mississippi new mexico commenced joint investigation companys marketing talcum powder products time multistate group asserted claims company five states issued civil investigative demands seeking documents information company produced documents arizona north carolina texas washington entered confidentiality agreements company received follow requests states march fortytwo states agreed mediation claims ltl bankruptcy case july new mexico mississippi indicated would longer voluntarily submit mediation ltl bankruptcy would proceed respective cases state court march mediation terminated january company reached agreement principle multistate group state attorneys general subject ongoing negotiation nonmonetary terms unique procedural history status new mexico mississippi matters specifically discussed abovein addition company received inquiries subpoenas requests produce documents regarding talc matters ltl bankruptcy case various governmental authorities company produced documents responded inquiries continue cooperate government inquiries matters concerning opioids beginning continuing present company janssen pharmaceuticals inc jpi along pharmaceutical companies named close lawsuits related marketing opioids including duragesic nucynta nucynta er majority cases filed state local governments similar lawsuits also filed private plaintiffs organizations including limited following individual plaintiffs behalf children born neonatal abstinence syndrome nas hospitals health insurerspayors date company jpi litigated two cases judgment prevailed either trial appeal october company announced proposed agreement principle negotiating committee state attorneys general settle remaining government opioid litigation claims nationwide final national settlement agreement announced july company agreed pay billion resolve opioid lawsuits future opioid claims states cities counties local school districts special districts tribal governments contingent sufficient participation eligible government entities credits back entities declined ineligible participate july company announced terms agreement settle state subdivision claims finalized approximately allin settlement paid end fiscal expected payment schedule provides approximately billion payments paid end fiscal agreement admission liability wrongdoing provides release opioidrelated claims company jpi affiliates including companys former subsidiaries tasmanian alkaloids pty ltd noramco inc january company jpi settled otherwise resolved opioid claims advanced government entity claimants except city baltimore number school districts claimants company jpi continue defend cases brought remaining government entity litigants well cases brought private litigants including nas claimants hospitals health insurerspayors counting private litigant cases approximately remaining opioid cases company jpi various state courts remaining cases ohio mdl additional cases federal courts cases dismissed appealed plaintiffs certain others scheduled trial addition province british columbia filed suit company canadian affiliate janssen inc many industry members canada seeking action certified opt class action behalf provincialterritorial federal governments canada additional proposed class actions filed canada company janssen inc many industry members behalf people used opioids personal injuries municipalities first nations bands actions allege variety claims related opioid marketing practices including false advertising unfair competition public nuisance consumer fraud violations deceptive acts practices false claims unjust enrichment adverse judgment lawsuits could result imposition large monetary penalties significant damages including punitive damages cost abatement substantial fines equitable remedies sanctions june december companys board directors received series shareholder demand letters alleging breaches fiduciary duties related marketing opioids board retained independent counsel investigate allegations demands april independent counsel delivered report board recommending company reject shareholder demands take steps necessary appropriate secure dismissal related derivative litigation board unanimously adopted recommendations independent counsels report november one shareholders sent demand filed derivative complaint company nominal defendant certain current former directors officers defendants superior court new jersey complaint alleges breaches fiduciary duties related marketing opioids company suffered damages result alleged breaches series additional derivative complaints making similar allegations similar defendants filed new jersey state federal courts two state court cases voluntarily dismissed february state court granted companys motion dismiss one two cases shareholder brought second case filed notice dismissal shareholder whose complaint dismissed filed motion reconsideration may state court held oral argument motion reconsideration subsequently denied motion shareholder appealed state courts dismissal order annual report product liability company certain subsidiaries involved numerous product liability claims lawsuits involving multiple products claimants cases seek substantial compensatory available punitive damages company believes substantial defenses feasible predict ultimate outcome litigation time time even substantial defenses company considers isolated settlements based variety circumstances company accrued matters continue monitor related legal issue adjust accruals might warranted based new information developments accordance asc contingencies company accrues estimate legal defense costs needed defend matter costs probable reasonably estimated certain matters company accrued additional amounts estimated costs associated settlements damages losses product liability accruals represent projected product liability thousands claims around world different litigation environments different fact patterns changes accruals may required future additional information becomes available table contains significant cases provides approximate number plaintiffs united states direct claims pending lawsuits regarding injuries allegedly due relevant product product category december product product category number plaintiffs body powders containing talc primarily johnsons baby powder depuy asr xl acetabular system depuy asr hip resurfacing system pinnacle acetabular cup system pelvic meshes ethicon physiomesh flexible composite mesh risperdal elmiron number pending lawsuits expected fluctuate certain lawsuits settled dismissed additional lawsuits filed may additional claims yet filed medtech depuy asr xl acetabular system asr hip resurfacing system august depuy orthopaedics inc depuy announced worldwide voluntary recall asr xl acetabular system depuy asr hip resurfacing system asr hip used hip replacement surgery claims personal injury made depuy company cases filed federal courts united states organized multidistrict litigation united states district court northern district ohio litigation also filed countries outside united states primarily united kingdom canada australia ireland germany india italy november depuy reached agreement courtappointed committee lawyers representing asr hip plaintiffs establish program settle claims eligible asr hip patients united states surgery replace asr hips known revision surgery august depuy reached additional agreements february march extended settlement program include asr hip patients revision surgeries august prior february settlement program resolved claims thereby bringing resolution significant asr hip litigation activity united states however lawsuits united states remain settlement program address litigation outside united states australia class action settlement reached resolved claims majority asr hip patients country canada company reached agreements settle class actions filed country company continues receive information respect potential additional costs associated recall worldwide basis company established accruals costs associated united states settlement program asr hiprelated product liability litigation depuy pinnacle acetabular cup system claims personal injury also made depuy orthopaedics inc company collectively depuy relating pinnacle acetabular cup system used hip replacement surgery product liability lawsuits continue filed company continues receive information respect potential costs anticipated number cases cases filed federal courts united states organized multidistrict litigation united statesdistrict court northern district texas texas mdl beginning june judicial panel multidistrict litigation ceased transfer new cases texas mdl cases pending federal court outside texas mdl litigation also filed state courts countries outside united states first quarter depuy established united states settlement program resolve cases part settlement program adverse verdicts settled company established accrual product liability litigation associated pinnacle acetabular cup system related settlement program ethicon pelvic mesh claims personal injury made ethicon inc ethicon company arising ethicons pelvic mesh devices used treat stress urinary incontinence pelvic organ prolapse company continues receive information respect potential costs additional cases cases filed federal courts united states organized multi district litigation mdl united states district court southern district west virginia march mdl court entered order closing mdl mdl court remanded cases trial jurisdictions case originally filed additional pelvic mesh lawsuits filed remain outside mdl company settled otherwise resolved majority united states cases estimated costs associated settlements remaining cases reflected companys accruals addition class actions individual personal injury cases claims seeking damages alleged injury resulting ethicons pelvic mesh devices commenced various countries outside united states including claims cases united kingdom netherlands belgium france ireland italy spain slovenia class actions israel australia canada south africa november federal court australia issued judgment regarding findings respect liability relation three lead applicants generally relation design manufacture pre postmarket assessments testing supply promotion devices australia used treat stress urinary incontinence pelvic organ prolapse september exhausting appeals company reached inprinciple agreement resolve two pelvic mesh class actions australia march federal court approved settlement class actions canada discontinued result settlement group cases agreement resolve israeli class action reached may parties israeli class action currently finalizing terms settlement motion approve settlement filed court company established accruals respect product liability litigation associated ethicons pelvic mesh products ethicon physiomesh following june worldwide market withdrawal ethicon physiomesh flexible composite mesh physiomesh claims personal injury made ethicon inc ethicon company alleging personal injury arising use hernia mesh device cases filed federal courts united states organized multidistrict litigation mdl united states district court northern district georgia multicounty litigation mcl also formed new jersey state court assigned atlantic county cases pending new jersey addition matters mdl mcl additional lawsuits pending united states district court southern district ohio part mdl polypropylene mesh devices manufactured cr bard inc lawsuits pending two new jersey mcls formed proceedproceed ventral patch prolene hernia systems lawsuits pending outside united states may ethicon lead counsel plaintiffs entered term sheet resolve approximately physiomesh cases covering approximately plaintiffs pending mdl mcl time master settlement agreement msa entered september includes cases mdl mcl deadlines trial settings proceedings currently stayed pending completion settlement agreement cases subject msa dismissed prejudice ethicon received releases plaintiffs releases continue submitted part settlement process postsettlement cases physiomesh mdl mcl subject docket control orders requiring early expert reports discovery requirements may ethicon entered additional settlement resolve claims physiomesh claimants settlement proceeding releases returned december physiomesh cases mdl new jersey mcl included either settlement remain subject docket control orders claims also filed ethicon company alleging personal injuries arising proceed mesh proceed ventral patch hernia mesh products march new jersey supreme court entered order consolidating cases pending new jersey mcl atlantic county superior court additional cases filed various federal state courts united states jurisdictions outside united states ethicon company also subject claims personal injuries arising prolene polypropylene hernia system january new jersey supreme court created mcl atlantic county superior court handle cases cases involving product also filed federal state courts united states october agreement principle subject various conditions reached settle majority pending cases involving proceed proceed ventral patch prolene hernia system related multilayered mesh products well number unfiled claims litigation activities two new jersey mcls stayed pending effectuation proposed settlement future cases filed new jersey mcls subject docket control orders requiring early expert reports discovery requirements annual report company established accruals respect product liability litigation associated ethicon physiomesh flexible composite mesh proceed mesh proceed ventral patch prolene polypropylene hernia system products innovative medicine risperdal claims personal injury made janssen pharmaceuticals inc company arising use risperdal related compounds indicated treatment schizophrenia acute manic mixed episodes associated bipolar disorder irritability associated autism lawsuits primarily filed state courts pennsylvania california missouri actions pending various courts united states canada product liability lawsuits continue filed company continues receive information respect potential costs anticipated number cases company successfully defended number cases verdicts company including verdict october billion punitive damages related one plaintiff trial judge reduced million january september company entered settlement principle counsel representing plaintiffs matter substantially outstanding cases united states costs associated settlements reflected companys accruals elmiron claims personal injury made number johnson johnson companies including janssen pharmaceuticals inc company arising use elmiron prescription medication indicated relief bladder pain discomfort associated interstitial cystitis lawsuits allege elmiron contributes development permanent retinal injury vision loss filed state federal courts across united states december lawsuits filed federal courts united states including putative class action cases seeking medical monitoring organized multidistrict litigation united states district court district new jersey cases multidistrict litigation active discussions regarding resolution result activity stayed addition cases filed various state courts new jersey coordinated multicounty litigation bergen county well court common pleas philadelphia coordinated granted mass tort designation activity taken place new jersey state court litigation however three bellwether trials set philadelphia march april may addition three class action lawsuits filed canada product liability lawsuits continue filed company continues receive information respect potential costs anticipated number cases company established accruals defense indemnity costs associated elmiron related product liability litigation intellectual property certain subsidiaries company subject time time legal proceedings claims related patent trademark intellectual property matters arising businesses many matters involve challenges coverage andor validity patents various products allegations certain companys products infringe patents third parties although subsidiaries believe substantial defenses challenges allegations respect significant patents assurance outcome matters loss cases could adversely affect ability subsidiaries sell products result loss sales due loss market exclusivity require payment past damages future royalties may result non cash impairment charge associated intangible asset innovative medicine litigation filers abbreviated new drug applications andas companys subsidiaries brought lawsuits generic companies filed andas us fda similar lawsuits outside united states seeking market generic versions products sold various subsidiaries company prior expiration applicable patents covering products lawsuits typically include allegations noninfringement andor invalidity patents listed fdas publication approved drug products therapeutic equivalence evaluations commonly known orange book lawsuits companys subsidiaries seeking order enjoining defendant marketing generic version product expiration relevant patents orange book listed patents event companys subsidiaries successful action automatic statutory stay expires court rulings obtained generic companies involved would ability upon regulatory approval introduce generic versions products market resulting potential substantial market share revenue losses applicable products may result noncash impairment charge associated intangible asset addition fromtime time companys subsidiaries may settle types actions settlements involve introduction generic versions products issue market prior expiration relevant patents inter partes review ipr process united states patent trademark office uspto created america invents act also used times generic companies conjunction andas lawsuits challenge applicable patents xarelto beginning march janssen pharmaceuticals inc bayer pharma ag bayer ag bayer intellectual property gmbh filed patent infringement lawsuits united states district courts generic manufacturers filed andas seeking approval market generic versions xarelto expiration certain orange book listed patents following entities named defendants dr reddys laboratories inc dr reddys laboratories ltd lupin limited lupin pharmaceuticals inc taro pharmaceutical industries ltd taro pharmaceuticals usa inc teva pharmaceuticals usa inc mylan pharmaceuticals inc mylan inc mankind pharma limited apotex inc apotex corp auson pharmaceuticals inc macleods pharmaceuticals ltd macleods pharma usa inc indoco remedies limited fpp holding company llc umedica laboratories pvt ltd aurobindo pharma limited aurobindo pharma usa inc cipla ltd cipla usa inc invagen pharmaceuticals inc following us patents included one cases us patent also consideration uspto ipr proceeding july uspto issued final written decision finding claims patent invalid september bayer pharma ag filed appeal us court appeals federal circuit opsumit beginning january actelion pharmaceuticals ltd actelion pharmaceuticals us inc filed patent infringement lawsuits united states district courts generic manufacturers filed andas seeking approval market generic versions opsumit expiration certain orange book listed patents following entities named defendants sun pharmaceutical industries limited sun pharmaceutical industries inc msn laboratories private limited msn pharmaceuticals inc mylan pharmaceuticals inc following us patents included one cases november company entered confidential settlement agreement msn laboratories private limited msn pharmaceuticals inc december company entered confidential settlement agreement sun pharmaceutical industries limited sun pharmaceuticals industries inc invega sustenna beginning january janssen pharmaceutica nv janssen pharmaceuticals inc filed patent infringement lawsuits united states district courts generic manufacturers filed andas seeking approval market generic versions invega sustenna expiration orange book listed patent following entities named defendants teva pharmaceuticals usa inc mylan laboratories limited pharmascience inc mallinckrodt plc specgx llc tolmar inc accord healthcare inc following us patent included one cases beginning february janssen inc janssen pharmaceutica nv initiated statement claim section patented medicines notice compliance regulations generic manufacturers filed andss seeking approval market generic versions invega sustenna expiration listed patent following entities named defendants pharmascience inc apotex inc following canadian patent included one cases invega trinza beginning september janssen pharmaceuticals inc janssen pharmaceutica nv janssen research development llc filed patent infringement lawsuits united states district courts generic manufacturers filed andas seeking approval market generic versions invega trinza expiration orange book listed patent following entities named defendants mylan laboratories limited mylan pharmaceuticals inc mylan institutional llc following us patent included one cases may district court issued decision finding mylans proposed generic product infringes asserted patent patent invalid mylan appealed verdict symtuza beginning november janssen products lp janssen sciences ireland unlimited company gilead sciences inc gilead sciences ireland uc filed patent infringement lawsuits united states district courts generic manufacturers filed andas seeking approval market generic versions symtuza expiration certain orange book listed patents following entities named defendants lupin limited lupin pharmaceuticals inc msn laboratories annual report private ltd msn life sciences private ltd msn pharmaceuticals inc apotex inc apotex corp following us patents included one cases erleada beginning may aragon pharmaceuticals inc janssen biotech inc collectively janssen sloan kettering institute cancer research ski regents university california filed patent infringement lawsuits united states district courts generic manufacturers filed andas seeking approval market generic versions erleada expiration certain orange book listed patents following entities named defendants lupin limited lupin pharmaceuticals inc zydus worldwide dmcc zydus pharmaceuticals usa inc zydus lifesciences limited sandoz inc eugia pharma specialities limited aurobindo pharma usa inc auromedics pharma llc hetero labs limited unit v hetero usa inc following us patents included one cases reissued december janssen ski voluntarily dismissed case lupin limited lupin pharmaceuticals inc uptravi beginning november actelion pharmaceuticals us inc actelion pharmaceuticals ltd nippon shinyaku co ltd filed patent infringement lawsuits united states district courts generic manufacturers filed andas seeking approval market generic versions uptravi intravenous expiration certain orange book listed patents following entities named defendants alembic pharmaceuticals limited alembic pharmaceuticals inc lupin ltd lupin pharmaceuticals inc cipla limited cipla usa inc msn laboratories private ltd msn pharmaceuticals inc following us patents included one cases november company entered confidential settlement agreement alembic pharmaceuticals limited alembic pharmaceuticals inc spravato beginning may janssen pharmaceuticals inc janssen pharmaceutica nv filed patent infringement lawsuits united states district courts generic manufacturers filed andas seeking approval market generic versions spravato expiration certain orange book listed patents following entities named defendants sandoz inc hikma pharmaceuticals inc usa hikma pharmaceuticals plc alkem laboratories ltd following us patents included one cases stelara november biocon biologics inc filed petition inter partes review uspto seeking review us patent related methods treating ulcerative colitis ustekinumab medtech march abiomed inc abiomed filed declaratory judgment action maquet cardiovascular llc maquet us district court district massachusetts seeking declaration impella infringe certain maquet patents currently us patent nos maquet counterclaimed infringement patents claim construction maquet alleged infringement patent september court granted abiomeds motion summary judgment noninfringement patent september district court entered final judgment favor abiomed patentsinsuit maquet appealed government proceedings like companies pharmaceutical medical technologies industries company certain subsidiaries subject extensive regulation national state local government agencies united states countries operate regulation basis government investigations litigations significant litigation brought investigations conducted government agencies listed possible criminal charges substantial fines andor civil penalties damages could result government investigations litigation medtech july public prosecution service rio de janeiro representatives brazilian antitrust authority cade inspected offices companies including johnson johnson brasil indstria e comrcio de produtos para sade ltda authorities appear investigating allegations possible anticompetitive behavior possible improper payments medical device industry company continues respond inquiries regarding foreigncorrupt practices act united states department justice united states securities exchange commission july us department justice doj issued civil investigative demands company johnson johnson surgical vision inc johnson johnson vision care inc collectively jj vision connection civil investigation false claims act relating free discounted intraocular lenses equipment used eye surgery phacoemulsification laser systems jj vision begun producing documents information responsive civil investigative demands jj vision ongoing discussions doj regarding inquiry innovative medicine july company janssen products lp served qui tam complaint pursuant false claims act filed united states district court district new jersey alleging offlabel promotion two hiv products prezista intelence antikickback violations connection promotion products complaint filed seal december federal state governments declined intervene lawsuit prosecuted relators court denied summary judgment claims december daubert motions granted part denied part january case proceeding trial trial scheduled may march janssen biotech inc jbi received civil investigative demand united states department justice regarding false claims act investigation concerning management advisory services provided rheumatology gastroenterology practices purchased remicade simponi aria august united states department justice notified jbi closing investigation subsequently united states district court district massachusetts unsealed qui tam false claims act complaint served company department justice declined intervene qui tam lawsuit august company filed motion dismiss granted part denied part discovery underway time time company received requests variety united states congressional committees produce information relevant ongoing congressional inquiries policy johnson johnson cooperate inquiries producing requested information general litigation company subsidiaries also parties various proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state local foreign laws primary relief sought companys agreement implement remediation activities designated hazardous waste sites reimburse government third parties costs incurred performing remediation sites october certain united states service members families brought complaint number pharmaceutical medical devices companies including johnson johnson certain subsidiaries united states district court district columbia alleging defendants violated united states antiterrorism act complaint alleges defendants provided funding terrorist organizations sales practices pursuant pharmaceutical medical device contracts iraqi ministry health july district court dismissed complaint january united states court appeals district columbia circuit reversed district courts decision june defendants filed petition writ certiorari united states supreme court february putative class action filed company pension benefits committee johnson johnson certain named officers employees united states district court district new jersey complaint alleges defendants breached fiduciary duties employee retirement income security act erisa allegedly mismanaging companys prescriptiondrug benefits program complaint seeks damages relief medtech october fortis advisors llc fortis capacity representative former stockholders auris health inc auris filed complaint company ethicon inc certain named officers employees collectively ethicon court chancery state delaware complaint alleges breach contract fraud causes action ethicon connection ethicons acquisition auris complaint seeks damages relief december court granted part denied part defendants motion dismiss certain causes action claims individual defendants dismissed trial held january decision pending annual report innovative medicine june united states federal trade commission ftc issued civil investigative demand company janssen biotech inc collectively janssen connection investigation whether janssens remicade contracting practices violate federal antitrust laws company produced documents information responsive civil investigative demand janssen ongoing discussions ftc staff regarding inquiry february united states federal trade commission ftc issued civil investigative demands johnson johnson janssen biotech inc collectively janssen connection investigation whether advertising practices remicade violate federal law janssen produced documents information responsive civil investigative demands janssen ongoing discussions ftc staff regarding inquiry june genmab filed notice arbitration international institute conflict prevention resolution cpr janssen biotech inc seeking milestones extended royalty term darzalex faspro april arbitration panel ruled janssen 's favor dismissed genmabs claims january genmabs appeal dismissal denied october two separate putative class actions filed actelion pharmaceutical ltd actelion pharmaceuticals us inc actelion clinical research inc collectively actelion united states district court district maryland united states district court district columbia complaints allege actelion violated state federal antitrust unfair competition laws allegedly refusing supply generic pharmaceutical manufacturers samples tracleer tracleer subject risk evaluation mitigation strategy required us food drug administration imposes restrictions distribution product january plaintiffs dismissed district columbia case filed consolidated complaint united states district court district maryland december putative class action lawsuit filed company janssen biotech inc collectively janssen united states district court eastern district virginia complaint alleges janssen violated federal state antitrust laws state laws delaying biosimilar competition stelara janssen 's enforcement patent rights covering stelara complaint seeks damages relief june janssen pharmaceuticals inc filed demand arbitration emergent biosol utions inc et al ebsi american arbitration association alleging ebsi breached parties manufacturing services agreement companys covid vaccine july emergent filed answering statement counterclaims hearing scheduled july restructuring fiscal company commenced restructuring actions within innovative medicine medtech segments amounts details current year programs included fiscal company completed prioritization research development rd investment within innovative medicine segment focus promising medicines greatest benefit patients resulted exit certain programs within certain therapeutic areas rd program exits primarily infectious diseases vaccines including discontinuation respiratory syncytial virus rsv adult vaccine program hepatitis hiv development pre tax restructuring expenses million fiscal year included termination partnered nonpartnered development program costs asset impairments estimated costs total activities million million expected completed end fiscal year fiscal company initiated restructuring program orthopaedics franchise within medtech segment streamline operations exiting certain markets product lines distribution network arrangements pretax restructuring expense million fiscal year primarily included inventory instrument charges related market product exits estimated costs total program million million expected completed end fiscal year following table summarizes restructuring expenses fiscal year pretax dollars millions innovative medicine segment medtech segment total programs included million restructuring million cost products sold consolidated statement earnings included million restructuring million cost products sold consolidated statement earnings restructuring reserves december january insignificant annual report kenvue separation discontinued operations may kenvue completed initial public offering ipo resulting issuance shares common stock par value per share kenvue common stock initial public offering per share net proceeds billion excess net proceeds ipo net book value johnson johnson divested interest billion recorded additional paidin capital closing ipo johnson johnson owned approximately total outstanding shares kenvue common stock july noncontrolling interest billion associated kenvue reflected equity attributable noncontrolling interests consolidated balance sheet fiscal second quarter august johnson johnson completed disposition additional ownership kenvue common stock exchange offer resulted johnson johnson acquiring shares companys common stock exchange shares kenvue common stock billion johnson johnson common stock received exchange offer recorded treasury stock following exchange offer company owns total outstanding shares kenvue common stock recorded assets within continuing operations fair market value billion august subsequent changes reflected incomeexpense amounted billion expense december johnson johnson divested net assets billion august accumulated comprehensive loss attributable consumer health business date billion additionally date exchange offer johnson johnson decreased noncontrolling interest billion record deconsolidation kenvue resulted noncash gain exchange offer billion recorded net earnings discontinued operations net taxes consolidated statements earnings fiscal third quarter onetime gain includes gain billion kenvue common stock retained johnson johnson gain exchange offer qualifies taxfree transaction us federal income tax purposes also connection separation johnson johnson kenvue entered separation agreement also entered various agreements provide certain transactions effect transfer assets liabilities consumer health business kenvue govern various interim ongoing relationships kenvue johnson johnson following completion kenvue ipo including transition services agreements tsas transition manufacturing agreements tmas trademark agreements intellectual property agreements employee matters agreement tax matters agreement tsas johnson johnson provide kenvue various services similarly kenvue provide johnson johnson various services provision services tsas generally terminate within months following kenvue ipo additionally johnson johnson kenvue entered tmas pursuant johnson johnson manufacture supply kenvue certain products similarly kenvue manufacture supply johnson johnson certain products terms tmas range initial duration months years amounts related tsas tmas included consolidated statements earnings immaterial fiscal year additionally amounts due kenvue agreements material december results consumer health business previously reported separate business segment well associated gain reflected discontinued operations companys consolidated statements earnings net earnings discontinued operations net taxes prior periods recast reflect presentation result separation kenvue johnson johnson incurred separation costs million million million fiscal years respectively also included net earnings discontinued operations net taxes costs primarily related external advisory legal accounting contractor incremental costs directly related separation activities fiscal part planned separation companys consumer health business company recognized approximately billion net incremental tax costs january assets liabilities associated consumer health business classified assets liabilities discontinued operations consolidated balance sheets details net earnings discontinued operations net taxes follows dollars millions sales customers cost products sold gross profit selling marketing administrative expenses research development expense interest income interest expense net portion capitalized income expense net gain separation kenvue restructuring earnings discontinued operations provision taxes income provision taxes income net earnings discontinued operations company ceased consolidating results consumer health business august date exchange offer continued reflect separation costs incurred part discontinued operations end fiscal fourth quarter following table presents depreciation amortization capital expenditures discontinued operations related kenvue dollars millions depreciation amortization capital expenditures annual report details assets liabilities discontinued operations follows january assets cash cash equivalents accounts receivable trade less allowances doubtful accounts inventories prepaid expenses receivables total current assets discontinued operations property plant equipment net intangible assets net goodwill deferred taxes income assets total noncurrent assets discontinued operations liabilities loans notes payable accounts payable accrued liabilities including accrued taxes income accrued rebates returns promotions accrued compensation employee related obligations total current liabilities discontinued operations longterm debt deferred taxes income employee related obligations liabilities total noncurrent liabilities discontinued operations selected quarterly financial data unaudited selected unaudited quarterly financial data recast discontinued operations years summarized dollars millions except per first second third fourth first second third fourth share data quarter quarter quarter quarter quarter quarter quarter quarter segment sales customers innovative medicine medtech total sales gross profit earnings loss provision taxes income net earnings loss continuing operations net earnings loss discontinued operations net tax net earnings loss basic net earningsloss per share basic net earnings loss per share continuing operations basic net earnings loss per share discontinued operations basic net earnings loss per share diluted net earnings loss per share diluted net earnings loss per share continuing operations diluted net earnings loss per share discontinued operations diluted net earnings loss per share fiscal first quarter includes billion charge related talc matters fiscal third quarter includes noncash gain exchange offer billion recorded net earnings discontinued operations net taxes billion related unfavorable change fair value retained stake kenvue billion related partial impairment idorsia convertible debt change fair value idorsia equity securities held fourth quarter includes favorable changes fair value securities billion fiscal first quarter company recorded intangible asset impairment charge approximately billion related inprocess research development asset bermekimab jnj fiscal fourth quarter includes onetime covid vaccine related exit costs billion annual report report independent registered public accounting firm board directors shareholders johnson johnson opinions financial statements internal control financial reporting audited accompanying consolidated balance sheets johnson johnson subsidiaries company december january related consolidated statements earnings comprehensive income equity cash flows three fiscal years period ended december including related notes collectively referred consolidated financial statements also audited company 's internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion consolidated financial statements referred present fairly material respects financial position company december january results operations cash flows three fiscal years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso basis opinions company 's management responsible consolidated financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinions companys consolidated financial statements company 's internal control financial reporting based audits public accounting firm registered public company accounting oversight board united states pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audits obtain reasonable assurance whether consolidated financial statements free material misstatement whether due error fraud whether effective internal control financial reporting maintained material respects audits consolidated financial statements included performing procedures assess risks material misstatement consolidated financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures consolidated financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation consolidated financial statements audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deterioratecritical audit matters critical audit matters communicated matters arising current period audit consolidated financial statements communicated required communicated audit committee relate accounts disclosures material consolidated financial statements ii involved especially challenging subjective complex judgments communication critical audit matters alter way opinion consolidated financial statements taken whole communicating critical audit matters providing separate opinions critical audit matters accounts disclosures relate us pharmaceutical rebate reserves managed care medicare medicaid described note consolidated financial statements company recognizes revenue product sales obligations terms contract customer satisfied rebates discounts provided customers accounted variable consideration recorded reduction sales liability rebates discounts recognized within accrued rebates returns promotions consolidated balance sheet significant portion liability related rebates sale pharmaceutical goods within us primarily managed care medicare medicaid programs amounted billion december significant rebate programs include us managed care medicare medicaid rebate programs rebates discounts estimated management based contractual terms historical experience patient outcomes trend analysis projected market conditions us pharmaceutical market principal considerations determination performing procedures relating us pharmaceutical rebate reserves managed care medicare medicaid critical audit matter significant judgment management due significant measurement uncertainty involved developing reserves high degree auditor judgment subjectivity audit effort performing procedures evaluating assumptions related contractual terms historical experience patient outcomes trend analysis projected market conditions us pharmaceutical market addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating us pharmaceutical rebate reserves managed care medicare medicaid including controls assumptions used estimate rebates procedures also included among others developing independent estimate rebates utilizing third party information price market conditions us pharmaceutical market terms specific rebate programs historical experience trend analysis actual rebate claims paid ii testing rebate claims processed company including evaluating claims consistency contractual mandated terms companys rebate arrangements iii comparing independent estimates managements estimates litigation contingencies talc described notes consolidated financial statements company records accruals loss contingencies associated legal matters including talc probable liability incurred amount loss reasonably estimated extent adverse awards judgments verdicts rendered company management record accrual loss determined probable reasonably estimated matters management unable estimate possible loss range loss beyond amounts accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions including timing related payments ability make estimates judgments affected various factors including among things whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute procedural jurisdictional issues uncertainty unpredictability number potential claims ability achieve comprehensive multiparty settlements complexity related crossclaims counterclaims andor numerous parties involved management continues believe company strong legal grounds contest talc verdicts appealed notwithstanding managements confidence safety companys talc products certain circumstances company settled cases company recognized total provision approximately billion approximately onethird recorded current liability encompasses actual contemplated settlements recorded amount remains company 's best estimate probable loss dismissal parties yet reached full resolution talc matters company unable estimate possible loss range loss beyond remaining amount accrued principal considerations determination performing procedures relating talc litigation critical audit matter significant judgment management assessing likelihood loss incurred determining whether reasonable estimate loss range loss future existing talc claims made determining timing settlement payments turn led high degree auditor judgment subjectivity effort performing procedures evaluating managements assessment loss contingencies associated litigation annual report addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating managements evaluation talc litigation including controls determining whether loss probable whether amount loss reasonably estimated well financial statement disclosures procedures also included among others gaining understanding companys process around accounting reporting talc litigation ii obtaining evaluating certain executed settlement agreements related talc litigation iii discussing status significant known actual potential litigation settlements activity companys inhouse legal counsel well external counsel deemed necessary iv obtaining evaluating letters audit inquiry internal external legal counsel significant litigation v evaluating reasonableness managements assessment regarding whether unfavorable outcome reasonably possible probable reasonably estimable vi evaluating sufficiency companys litigation contingencies disclosures pricewaterhousecoopers llp florham park new jersey february served companys auditor since least able determine specific year began serving auditor company managements report internal control financial reporting section sarbanesoxley act management required assess effectiveness companys internal control financial reporting end fiscal year report based assessment whether companys internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting companys internal control financial reporting designed provide reasonable assurance reliability companys financial reporting preparation external financial statements accordance generally accepted accounting principles internal controls financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate companys management assessed effectiveness companys internal control financial reporting december making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring companys assessment included extensive documenting evaluating testing design operating effectiveness internal controls financial reporting based companys processes assessment described management concluded december companys internal control financial reporting effective effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein j duato j j wolk joaquin duato joseph j wolk chairman board directors executive vice president chief financial officer chief executive officer annual report shareholder return performance graphs set forth line graphs comparing cumulative total shareholder return companys common stock periods five years ten years ending december cumulative total return standard poors stock index standard poors pharmaceutical index standard poors healthcare equipment index graphs tables assume invested december december companys common stock standard poors stock index standard poors pharmaceutical index standard poors healthcare equipment index dividends reinvested year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnson johnson sp index sp pharmaceutical index sp healthcare equipment index year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index year cagr jj sp sp pharm sp hc equip johnson johnson sp index sp pharmaceutical index sp healthcare equipment index annual report item changes disagreements accountants accounting financial disclosure applicable item controls procedures disclosure controls procedures end period covered report company evaluated effectiveness design operation disclosure controls procedures companys disclosure controls procedures designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified secs rules forms disclosure controls procedures include without limitation controls procedures designed ensure information required disclosed company reports files submits exchange act accumulated communicated companys management including principal executive principal financial officers persons performing similar functions appropriate allow timely decisions regarding required disclosure joaquin duato chairman chief executive officer joseph j wolk executive vice president chief financial officer reviewed participated evaluation based evaluation messrs duato wolk concluded end period covered report companys disclosure controls procedures effective reports internal control financial reporting information called item incorporated herein reference managements report internal control financial reporting attestation regarding internal controls financial reporting included report independent registered public accounting firm included item report changes internal control financial reporting fiscal quarter ended december changes companys internal control financial reporting identified connection evaluation required rules exchange act materially affected reasonably likely materially affect companys internal control financial reporting company continues monitor assess effectiveness design operation disclosure controls procedures company implementing multiyear enterprisewide initiative integrate simplify standardize processes systems human resources information technology procurement supply chain finance functions enhancements support growth companys financial shared service capabilities standardize financial systems initiative response identified deficiency weakness companys internal control financial reporting response initiative company continue align streamline design operation financial control environment item b information securities trading plans directors executive officers fiscal fourth quarter none directors officers defined rule af exchange act informed us adoption termination rule b trading arrangement nonrule b trading arrangement defined item regulation sk item c disclosure regarding foreign jurisdictions prevent inspections applicable part iii item directors executive officers corporate governance information called item incorporated herein reference discussion audit committee caption item election directors board committees material captions item election directors applicable delinquent section reporting proxy statement material caption executive officers registrant part report companys code business conduct covers employees including chief executive officer chief financial officer controller meets requirements sec rules promulgated section sarbanesoxley act code business conduct available companys website wwwjnjcomcodeofbusinessconduct copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment code business conduct waiver code granted chief executive officer chief financial officer controller posted companys website wwwjnjcomcodeofbusiness conduct within five business days retained website least one year addition company adopted code business conduct ethics members board directors executive officers code business conduct ethics members board directors executive officers available companys website wwwinvestorjnjcomgovernancecorporategovernanceoverviewcodeofbusinessconductethics copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment code waiver code granted member board directors executive officer posted companys website wwwinvestorjnjcomgovernancecorporategovernanceoverview codeofbusinessconductethics within five business days retained website least one year item executive compensation information called item incorporated herein reference material captions item election directors director compensation item compensation committee report compensation discussion analysis executive compensation tables proxy statement material incorporated herein reference material caption compensation committee report proxy statement shall deemed furnished filed report shall deemed incorporated reference filing securities act amended securities exchange act amended result furnishing except extent company specifically incorporates reference item security ownership certain beneficial owners management related stockholder matters information called item incorporated herein reference material caption item stock ownership proxy statement note common stock stock option plans stock compensation agreements notes consolidated financial statements item report annual report equity compensation plan information following table provides certain information december concerning shares companys common stock may issued existing equity compensation plans number securities weighted average number securities issued upon exercise price remaining available exercise outstanding future issuance outstanding options equity compensation plan category options rights rights plans equity compensation plans approved security holders equity compensation plans approved security holders total included category following equity compensation plans approved companys shareholders longterm incentive plan longterm incentive plan column excludes shares reflected column number securities issued upon exercise outstanding options rights longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan item certain relationships related transactions director independence information called item incorporated herein reference material captions item election directors related person transactions director independence proxy statement item principal accountant fees services information called item incorporated herein reference material caption item ratification appointment independent registered public accounting firm proxy statement part iv item exhibits financial statement schedules following documents filed part report financial statements consolidated balance sheets end fiscal years consolidated statements earnings fiscal years consolidated statements comprehensive income fiscal years consolidated statements equity fiscal years consolidated statements cash flows fiscal years notes consolidated financial statements report independent registered public accounting firm schedules omitted applicable required information included financial statements notes exhibits required filed item l regulation sk information called item incorporated herein reference exhibit index report item summary registrants may voluntarily include summary information required item company elected include summary information annual report signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized date february johnson johnson registrant j duato j duato chairman board chief executive officer pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signature title date j duato chairman board february j duato chief executive officer principal executive officer j j wolk chief financial officer february j j wolk principal financial officer r j decker jr controller chief accounting officer february r j decker jr principal accounting officer adamczyk director february adamczyk c beckerle director february c beckerle davis director february davis j doudna director february j doudna signature title date hewson director february hewson p johnson director february p johnson h joly director february h joly b mcclellan director february b mcclellan mulcahy director february mulcahy weinberger director february weinberger n west director february n west e woods director february e woods annual report exhibit index reg sk exhibit table description item exhibit agreement plan merger dated october among johnson johnson athos merger sub inc abiomed inc incorporated herein reference exhibit registrants form k current report filed november restated certificate incorporation effective february incorporated herein reference exhibit registrants annual report fiscal year ended january ii certificate amendment certificate incorporation johnson johnson effective april incorporated herein reference exhibit registrant 's form k current report filed april iii bylaws company amended effective june incorporated herein reference exhibit registrants form k current report filed june upon request securities exchange commission registrant furnish copy instruments defining rights holders longterm debt registrant b description securities registered pursuant section securities exchange act incorporated herein reference exhibit registrants form k current report filed august longterm incentive plan incorporated herein reference appendix registrants proxy statement filed march b form stock option certificate longterm incentive plan incorporated herein reference exhibit registrants form q quarterly report quarter ended april c form restricted share unit certificate longterm incentive plan incorporated herein reference exhibit registrants form q quarterly report quarter ended april form performance share unit certificate longterm incentive plan incorporated herein reference exhibit registrants form q quarterly report quarter ended april e global nonqualified stock option award agreement longterm incentive plan incorporated herein reference exhibit registrants form q quarterly report quarter ended april f global restricted share unit award agreement longterm incentive plan incorporated herein reference exhibit registrants form q quarterly report quarter ended april g global performance share unit award agreement longterm incentive plan incorporated herein reference exhibit registrants form q quarterly report quarter ended april h global restricted share unit award agreement granted john reed may longterm incentive plan filed document domestic deferred compensation certificate extra compensation plan incorporated herein reference exhibit g registrants annual report year ended december j amendments certificate extra compensation plan effective january incorporated herein reference exhibit j registrants annual report year ended december k certificates longterm performance plan incorporated herein reference exhibit registrants form q quarterly report quarter ended september l amended restated deferred fee plan directors amended january incorporated herein reference exhibit k registrant 's annual report fiscal year ended january reg sk exhibit table description item exhibit johnson johnson executive income deferral plan amended restated effective january incorporated herein reference exhibit registrants form q quarterly report quarter ended september n johnson johnson excess savings plan amended restated january incorporated herein reference exhibit l registrants annual report fiscal year ended january excess benefit plan johnson johnson affiliated companies amended restated january incorporated reference exhibit n registrants annual report fiscal year ended january p executive life plan agreement incorporated herein reference exhibit registrants annual report fiscal year ended january q executive life plan agreement closure letter incorporated herein reference exhibit registrants form q quarterly report quarter ended march r longterm incentive plan incorporated reference appendix registrants proxy statement filed march severance pay plan johnson johnson us affiliated companies amended restated october incorporated herein reference exhibit registrant 's form q quarterly report quarter ended september first amendment severance pay plan johnson johnson us affiliated companies amended restated effective october incorporated herein reference exhibit registrant 's form q quarterly report quarter ended june u second amendment severance pay plan johnson johnson us affiliated companies amended restated effective october incorporated herein reference exhibit x registrant 's annual report fiscal year ended january v contingent value rights agreement dated december johnson johnson american stock transfer trust company llc incorporated herein reference exhibit registrants form k current report filed december w separation agreement dated may johnson johnson kenvue inc x tax matters agreement dated may johnson johnson kenvue inc employee matters agreement dated may johnson johnson kenvue inc z intellectual property agreement dated may johnson johnson kenvue inc aa trademark phaseout license agreement dated april johnson johnson johnson johnson consumer inc ab transition services agreement dated may johnson johnson kenvue inc ac transition manufacturing agreement dated may johnson johnson kenvue inc ad registration rights agreement dated may johnson johnson kenvue inc ae johnson johnson deferred compensation plan af global performance share unit award agreement annual report reg sk exhibit table description item exhibit ag global restricted share unit award agreement ah global nonqualified stock option award agreement ai amendment one johnson johnson excess savings plan amended restated effective january incorporated herein reference exhibit registrants form q quarterly report quarter ended october aj johnson johnson executive incentive plan amended september incorporated herein reference exhibit registrants form q quarterly report quarter ended october johnson johnson stock trading policy directors executive officers insiders amended april filed document subsidiaries filed document consent independent registered public accounting firm filed document certification chief executive officer pursuant section sarbanesoxley act filed document certification chief financial officer pursuant section sarbanesoxley act filed document certification chief executive officer pursuant section sarbanesoxley act furnished document certification chief financial officer pursuant section sarbanesoxley act furnished document johnson johnson clawback policy effective august filed document exhibit exins instance document instance document appear interactive data file xbrl tags embedded within inline xbrl document exsch inline xbrl taxonomy extension schema excal inline xbrl taxonomy extension calculation linkbase exlab inline xbrl taxonomy extension label linkbase expre inline xbrl taxonomy extension presentation linkbase exdef inline xbrl taxonomy extension definition document exhibit cover interactive data filethe cover interactive data file appear interactive data file xbrl tags embedded within inline xbrl document management contract compensatory plan paper filing certain exhibits schedules omitted pursuant item bii biv regulation sk applicable copy exhibits listed provided without charge shareholder submitting written request specifying desired exhibits secretary principal executive offices company pursuant item b iiia regulation sk company filed exhibits certain longterm debt instruments including indentures total amount securities authorized exceed total assets company subsidiaries consolidated basis company hereby agrees furnish copy instrument sec upon request exhibit h johnson johnson longterm incentive plan global restricted share unit award agreement granted john christian reed grant grant type units scheduled vesting date reed restricted share units reed restricted share units reed restricted share units addition conditions may established committee sole discretion consideration granting award terms johnson johnson longterm incentive plan amended time time plan agree follows grant restricted share units award subject terms conditions global restricted share unit award agreement including countryspecific terms appendix hereto exhibits addendums documents collectively agreement plan johnson johnson new jersey corporation corporation hereby grants abovestated number restricted share units rsus become vested subject terms conditions agreement upon vesting rsu receive one share common stock corporation par value per share common stock cash lieu thereof either case subject accordance terms section agreement except context clearly indicates otherwise capitalized term used herein shall definition assigned agreement extent agreement define capitalized term used herein plan rsus granted herein subject terms conditions plan terms plan hereby incorporated herein reference b conditions grant rsus conditioned electronically accepting grant website plan recordkeeper manner corporation may establish permit time time ii opening maintaining brokerage account permitted use respect awards granted plan case deadline established corporation andor set forth website plan recordkeeper accepting grant rsus confirmedyour acceptance allof terms conditions agreement accept grant rsus applicable deadline grant cancelled vesting rsus competition corporation group general except otherwise provided section rsus granted herein shall become vested abovestated scheduled vesting dates accordance schedule set forth provided respect rsu employed applicable scheduled vesting date employed times since grant date ii complied compliance terms agreement determined corporation sole discretion b termination employment general prior applicable scheduled vesting date cease employed reason except otherwise provided section c certain terminations disability rsus shall forfeited consideration date termination c certain terminations disability termination employment due death die employed rsus shall immediately become vested full date death extent still outstanding already vested estate beneficiary person acquires rsus inheritance devise applicable shall receive number shares common stock cash lieu thereof provided section settlement rsus tax withholding compliance securities laws compliance compensation recoupment policy ii disability become disabled employed shall immediately become vested full rsus extent still outstanding already vested date disability iii termination cause without limiting generality section b notwithstanding provision section c cease employed reason including without limitation result voluntary resignation connection following occurrence event constitutes cause rsus awards hold plan shall immediately forfeited consideration date termination following date termination corporation becomes aware conduct activity occurred following employment would constituted cause rsus portions thereof awards held plan unvested unexercised payments benefits respect thereto date corporation becomes aware conduct activity shall forfeited iv corporation determinations event termination employment determination reason termination applicable treatment section shall made corporation sole discretion competition corporation group order protect corporation groups goodwill investments research development customer businessrelationships prevent disclosure corporation groups confidential trade secret information thereby promoting longterm success corporation groups business agree following employment without prior written consent corporation directly indirectly engage competitive activities ii period eighteen months following date termination without prior written consent corporation directly indirectly perform assist others perform work competitor position geographic location could disadvantage corporation group advantage competitor disclosure use corporation groups confidential trade secret information andor b use corporation groups customer relationships goodwill iii rescission forfeiture understand agree corporation determines violated section di andor section dii andor non competition nonsolicitation agreement member corporation group addition injunctive relief damages equitable legal rights remedies rsus shall forfeited consideration earliest date first violation section di andor section dii noncompetition nonsolicitation agreement member corporation group b upon corporations demand shall immediately deliver corporation number shares common stock equal number rsus vested settled form common stock avoidance doubt without reduction shares common stock may withheld andor sold satisfy applicable withholding taxes ii gross amount cash paid avoidance doubt without reduction amounts withheld satisfy applicable withholding taxes rsus settled form cash case respect rsus vested within twelve month period time immediately preceding earliest date first violation section di andor section dii noncompetition non solicitation agreement member corporation group extent date corporations demand repayment hold number shares common stock sufficient satisfy obligation set forth clause shall pay corporation amount cash equal result x number shares required delivered corporation pursuant clause less ii number shares actually delivered corporation pursuant clause multiplied fair market value per share common stock business day immediately preceding date corporations demand repayment agree deliver execute documents including applicable share certificates corporation may deem necessary effect repayment obligations referred section diiib iv understand agree remedies set forth section diii shall corporation groups exclusive remedies event breach noncompetition obligations set forth section di andor section dii applicable noncompetition nonsolicitation agreement member thecorporation group corporation group reserves rights remedies available law equity e conditions vesting upon following termination employment eligibility vest rsus upon following date termination employment shall subject compliance noncompetition obligations section di andor section dii andor applicable noncompetition nonsolicitation agreement member corporation group ii required member corporation group time termination employment execution separation agreement andor general release claims favor corporation subsidiaries affiliates containing provisions form required corporation group becomes effective prior latest date settlement rsus set forth section earlier date corporation group may require event separation agreement andor release claims required corporation group rsus vest upon date termination ii vesting date falls within period provide release claims b period rsus must settled pursuant section spans two calendar years settlement vested rsus made second calendar year rights common stock prior delivery shares common stock pursuant section applicable shall rights respect shares common stock underlying rsus including limited voting rights right receive dividends dividend equivalents may paid distributions may made respect common stock settlement rsus tax withholding compliance securities laws compliance compensation recoupment policy general subject terms agreement within sixty days following vesting date event later first march th occurring thereafter receive corporation one share common stock rsu vested date discretion committee cash equivalent fair market value vesting date reduced whole shares common stock withheld sold cash withheld satisfy applicable federal state local income taxes social insurance payroll tax fringe benefits tax payment account taxrelated items related participation plan legally applicable deemed applicable taxrelated items amount determined corporation lieu foregoing corporation applicable member corporation group may determine withholding taxrelated items shall satisfied method permitted plan notwithstanding foregoing section officer corporation securities exchange act amended corporation satisfy applicable tax withholding obligations withholding shares common stock upon relevant taxable event withholding obligations determined based applicable statutory withholding rates without regard section c internal revenue code amended unless otherwise determined committee b registration listing notwithstanding section hereof shares common stock shall issued pursuant agreement unless vesting date effect current registration statement amendment thereto securities act asamended covering shares common stock issued upon vesting rsus shares authorized listing new york stock exchange another securities exchange determined corporation nothing herein shall deemed require corporation apply effect obtain registration listing c compensation recoupment policy hereby acknowledge agree rsus including cash andor shares common stock may delivered pursuant rsus subject corporations compensation recoupment policy may amended andor restated time time current copy found corporations website httpwwwinvestorjnjcomgovcompensationrecoupmentpolicycfm terms conditions compensation recoupment policy hereby incorporated reference agreement nontransferability rsus rsus rights granted hereunder may sold transferred assigned pledged hypothecated way whether operation law otherwise laws descent distribution accordance beneficiary designation procedures may established corporation shall rights subject execution attachment similar process accordance terms plan upon attempt sell transfer assign pledge hypothecate otherwise dispose rsus rights granted herein contrary provisions plan agreement upon levy attachment similar process upon rsus rights rsus rights shall election corporation forfeited consideration special employment rights rights awards nothing contained plan agreement shall construed deemed person circumstances bind member corporation group continue employment vesting period period create right employment corporation form amend employment service contract corporation interfere way right member corporation group terminate employment time hereby acknowledge agree plan established voluntarily corporation discretionary nature may modified amended terminated corporation time provided plan ii participation plan voluntary voluntarily accepting grant rsus iii rsus shares common stock subject rsus income value constitute part normal expected compensation salary purposes including limited calculating severance resignation termination indemnities redundancy dismissal endofservice payments bonuses longservice awards pension retirement benefits welfare benefits similar payments event considered compensation way relating past services corporation group iv rsus shares common stock subject rsus income value intended replace pension rights compensation v grant rsus exceptional voluntary occasional create contractual right receive future grants rsus benefits lieu rsus even rsus granted past vi unless otherwise agreed corporation rsus shares common stock subject rsus income value granted consideration connection service may provide director subsidiary corporation vii future value underlying shares common stock unknown indeterminable predicted certainty viii noclaim entitlement compensation damages shall arise forfeiture recoupment rsu resulting termination employment service relationship regardless reason termination whether later found invalid breach employment laws jurisdiction employed terms employment agreement ix shall seek necessary approvals make required notifications comply laws rules regulations applicable ownership rsus applicable shares common stock including currency exchange laws rules regulations x neither corporation subsidiaries affiliates shall liable foreign exchange rate fluctuation local currency us dollar may affect value rsus amounts due pursuant settlement rsus subsequent sale shares common stock acquired upon settlement xi determination form award granted plan made committee sole discretion xii corporation providing tax legal financial advice corporation making recommendations regarding participation plan acquisition sale underlying shares common stock consult personal tax legal financial advisors regarding participation plan taking action related rsus notices unless corporation notifies otherwise writing notices designations payments submitted corporation connection rsus shall addressed equity compensation resources one johnson johnson plaza new brunswick nj usa definitions following capitalized terms shall definitions set forth purposes agreement cause means conviction plea nolo contendere commission felony federal state law ii act corporations opinion constitutes fraud embezzlement dishonesty disclosure confidential information willful deliberate failure perform employment duties material respect conflict interest violation noncompetition obligations set forth section di agreement applicable noncompetition nonsolicitation confidentiality agreement obligation member corporation group violation standards conduct policies policies corporation group subject event inimical contrary best interests corporation group determination cause shall made corporation sole discretion determination shall final binding b committee means compensation benefits committee board directors corporation successor committee person persons committee delegated authority administer construe interpret terms plan pursuant section planc competitor means person entity including limited anyone acting behalf engaged preparing engaged research development production manufacturing marketing selling consulting product process technology machine invention service existence development resembles competes may future compete substituted marketed substitute product process technology machine invention service corporation group existence planned development corporation shall determine whether individual entity competitor sole discretion determination shall final competitive activities means activities including preparations compete intended compete otherwise may adversely affect interfere corporation groups business advantage competitor whether immediately future corporation shall determine whether conduct constitutes competitive activities sole discretion determination shall final e corporation group means corporation subsidiaries affiliates determined corporation f customer means entity client account person including employees agents representatives foregoing entity person participates influences responsibility making purchasing decisions behalf entities clients accounts persons contacted solicited business sold rendered service assigned responsibilities received commissions compensation promoted marketed products services eighteen month period time preceding date termination corporation shall determine whether individual entity customer sole discretion determination shall final g date termination means date employment terminates h disability disabled means determined unable work disability lasts period excess twentysix weeks ii entitles longterm disability benefits longterm disability policy corporation applicable affiliate covered b policy determined disabled similar status corporation applicable affiliate accordance applicable procedures policies notwithstanding foregoing considered incurred disability unless identified disabled similar status accordance personnel andor human resources policies corporation applicable affiliate effect time time ii rsus subject section determined corporation considered incurred disability unless condition also constitutes disability within meaning treasury regulation section ai employed employment means period time employee corporation group good standing determined corporation group accordance applicable practices policies records provided periodyou active employment status corporation group ii corporation groupapproved leave absence determined corporation group sole discretion avoidance doubt shall considered employed x period considered employee good standing pursuant corporation groups practices policies records notice period salary continuation period required contract practice local law garden leave similar period severance period covered severance agreement arrangement z period leave approved corporation group determined corporation group sole discretion j grant date means date rsus granted identified first agreement k vesting date means respect rsu earliest extent applicable applicable scheduled vesting date ii date death event termination employment pursuant section ci termination due death iii date become disabled event disability described section cii disability x date rsus vest become payable pursuant applicable provision plan provided rsus subject section determined corporation payment occur earliest permissible date determined corporation would result accelerated taxation andor tax penalties section miscellaneous amendments except provided herein agreement may amended otherwise modified unless evidenced writing signed authorized representative corporation b thirdparty beneficiaries acknowledge agree affiliates subsidiaries corporation result future acquisition merger assignment otherwise interest employment compliance obligations section competition corporation group entities express thirdparty beneficiaries agreement c binding effect agreement shall inure benefit binding upon parties hereto respective heirs executors administrators successors assigns severability event section competition corporation group agreement invalidated enforced applicable law shall affect validity enforceability remaining provisions agreement plan extent section agreement unenforceable deemed overbroad provision shall applied enforced limited manner fullest extent permissible applicable law understand agree event section agreement declared invalid void overbroad unenforceable whole part reason shall remain bound noncompetition confidentiality nonsolicitation andor nondisclosure agreement previously entered member corporation groupe appendix notwithstanding provisions agreement rsus shall subject additional terms conditions set forth appendix country moreover relocate one countries included appendix additional terms conditions country apply extent corporation determines application terms conditions necessary advisable legal administrative reasons appendix constitutes part agreement f data privacy consent accepting grant hereby unconditionally consent collection use transfer electronic form personal data described document among applicable employing entity employer corporation corporation group exclusive purpose implementing administering managing awards issued plan understand corporation employer may hold certain personal information including limited name home address email address telephone number date birth social insurance number identification number salary nationality job title details rsus entitlement shares stock awarded canceled vested unvested outstanding favor data purpose implementing administering managing grants issued plan understand data may transferred third parties may selected corporation assisting implementation administration management plan fulfillment agreement understand recipients data may located united states elsewhere recipients country may different data privacy laws protections country understand reside outside united states may request list names addresses potential recipients data contacting local human resources representative authorize recipients may assist corporation presently future implementing administering managing plan receive possess use retain transfer data electronic form purposes implementing administering managing grants plan fulfillment agreement understand data held long necessary implement administer manage grants plan agreement understand reside outside united states may time view data request information storage processing data require necessary amendments data refuse withdraw consents herein case without cost contacting writing human resources representative understand consent herein provided purely voluntary basis consent later seek revoke consent employment status service affected consequence refusing withdrawing consent corporation may able grant rsus equity awards administer maintain awards therefore understand refusing withdrawing consent may affect ability participate plan information consequences refusal consent withdrawal consent understand may contact local human resources representative g entire agreement agreement plan constitute entire agreement parties relating subject matter hereof previous agreement understanding parties respect thereto superseded agreement planh section intent parties payments benefits agreement comply section internal revenue code amended regulations guidance issued thereunder section extent subject thereto accordingly maximum extent permitted agreement shall interpreted administered compliance therewith notwithstanding anything contrary plan agreement corporation reserves right revise agreement deems necessary advisable sole discretion without consent comply section otherwise avoid imposition additional tax income recognition section prior actual payment cash shares common stock pursuant rsus however corporation makes representation rsus subject section makes undertaking preclude section applying rsus corporation shall liability plan agreement taxes penalties interest due amounts paid payable pursuant plan agreement including taxes penalties interest imposed section purposes plan agreement extent necessary avoid accelerated taxation andor tax penalties section termination employment shall deemed occurred purposes settlement portion rsus unless termination constitutes separation service within meaning section purposes provision agreement references termination termination employment similar terms shall mean separation service amount paid agreement shall construed separately identified payment purposes section addition notwithstanding anything herein contrary deemed date termination specified employee within meaning term section subject us federal taxation extent settlement rsus following termination employment considered payment nonqualified deferred compensation section payable account separation service exempt section settlement shall delayed date earlier expiration sixmonth period measured date separation service ii date death acknowledgement electing accept agreement acknowledge receipt agreement hereby confirm understanding terms set forth agreement event conflict terms plan agreement terms plan shall control corporation may sole discretion decide deliver documents including without limitation information required delivered pursuant applicable securities laws related current future participation plan electronic means hereby consent receive documents electronic delivery agree participate plan online electronic system established maintained corporation third party designated corporation j language acknowledge proficient english language consulted advisor proficient english language enable understand provisions agreement plan received agreement document related plan translated language english meaning translated version different english version english version controlk imposition requirements corporation reserves right impose requirements participation plan rsus shares common stock acquired plan extent corporation determines necessary advisable order comply local law facilitate administration plan make corrections adjustments deems necessary appropriate require sign additional agreements undertakings may necessary accomplish foregoing l waiver acknowledge waiver corporation breach provision agreement shall operate construed waiver provision agreement subsequent breach grantee governing law agreement shall governed construed accordance laws state new jersey without giving effect conflict laws principles except extent superseded federal law set forth section provided primarily resided worked california connection employment corporation group time accepted agreement participation plan agreement shall governed construed accordance laws state california ii section dii shall apply respect services render california involve use disclosure corporation groups confidential trade secret information n submission jurisdiction waiver jury trial litigation brought party agreement shall brought us federal state court located state new jersey parties submits exclusive jurisdiction courts purpose litigation provided final judgment litigation shall conclusive may enforced jurisdictions suit judgment matter provided law party agrees assert objection may venue us federal state court located state new jersey b claim litigation brought inconvenient forum c claim court jurisdiction respect litigation party waives right trial jury respect matters arising agreement awards granted plan johnson johnson carolyn hoenish carolyn hoenisch senior finance director savings plan pension equity compensation operations johnson johnson one johnson johnson plaza new brunswick nj usa appendix acountryspecific provisions participants outside us certain capitalized terms used defined appendix shall meanings set forth plan andor agreement appendix attached terms conditions appendix includes additional terms conditions govern rsus granted plan applicable law resident deemed resident working one countries listed furthermore additional terms conditions govern rsus granted hereunder may apply transfer employment andor residency one countries listed corporation shall discretion determine extent terms conditions contained herein shall apply notifications appendix also includes notifications relating exchange control securities issues aware respect participation plan information based exchange control securities laws effect respective countries october laws often complex change frequently result corporation strongly recommends rely notifications herein source information relating consequences participation plan information may outdated vest rsus acquire shares common stock plan subsequently sell shares common stock acquired plan addition notifications general nature may apply particular situation corporation position assure particular result accordingly strongly advised seek appropriate professional advice relevant laws country may apply situation finally citizen resident country one currently residing andor working considered resident another country local law purposes information contained herein may applicable may subject provisions one jurisdictions nonus jurisdictions notifications insider trading restrictionsmarket abuse laws acknowledge depending brokers country residence shares common stock listed may subject insider trading restrictions andor market abuse laws may affect ability accept acquire sell otherwise dispose shares common stock rights shares common stock eg rsus rights linked value shares common stock eg phantom awards futures times considered inside information regarding corporation defined laws regulations country local insider trading laws regulations may prohibit cancellation amendment orders placed possessed inside information furthermore could prohibited disclosing inside information third party ii tipping third parties causingthem otherwise buy sell securities keep mind third parties includes fellow employees restrictions laws regulations separate addition restrictions may imposed applicable insider trading policy corporation acknowledge responsibility comply restrictions advised speak personal advisor matter foreign assetaccount reporting country residence may certain foreign asset andor account reporting requirements may affect ability acquire hold shares common stock plan cash received participating plan including sale proceeds arising sale shares common stock brokerage bank account outside country may required report accounts assets transactions tax authorities country also may required repatriate sale proceeds funds received result participation plan country designated broker bank andor within certain time receipt acknowledge responsibility comply regulations understand agree consult personal legal advisor details european union european economic area countries switzerland united kingdom terms conditions data privacy following provision replaces section f data privacy consent agreement entirety corporation principal executive offices one johnson johnson plaza new brunswick new jersey usa controller responsible processing personal data corporation third parties noted data collection usage pursuant applicable data protection laws hereby notified corporation collects processes uses certain personal information legitimate purpose implementing administering managing plan generally administering awards specifically name home address email address date birth hire date rehire date applicable termination date applicable employee identification number work country pay frequency associated legal entity management reporting company shares directorships held corporation details awards entitlement shares common stock awarded canceled exercised vested outstanding favor corporation receives employer personal data granting rsus plan corporation collect process use disclose transfer collectively processing personal data purposes implementing administering managing plan corporations legal basis processing personal data corporations legitimate business interests managing plan administering awards complying contractual statutory obligations well necessity processing corporation perform contractual obligations agreement plan refusal provide personal data would make impossible corporation perform contractual obligations may affect ability participate plan byaccepting rsus voluntarily acknowledge processing personal data described herein b stock plan administration service provider corporation may transfer personal data fidelity stock plan services llc fidelity independent service provider based relevant part united states may assist corporation implementation administration management plan future corporation may select different service provider share personal data another company serves similar manner corporations service provider open account receive trade shares common stock pursuant rsus processing personal data take place electronic nonelectronic means personal data accessible individuals requiring access purposes implementing administering operating plan receiving personal data applicable fidelity provides appropriate safeguards accordance eu standard contractual clauses appropriate crossborder transfer solutions participating plan understand service provider process personal data purposes implementing administering managing participation plan c international data transfers plan rsus administered united states means necessary personal data transferred processed united states transferring personal data united states corporation provides appropriate safeguards accordance eu standard contractual clauses appropriate crossborder transfer solutions may request copy appropriate safeguards fidelity corporation contacting local human resources representative may also contact data protection officer responsible country region applicable emailing emeaprivacyitsjnjcom data retention corporation use personal data long necessary implement administer manage participation plan required comply legal regulatory obligations including tax securities laws period may extend beyond point service corporation longer needs personal data related plan corporation remove systems corporation keeps personal data longer would satisfy legal regulatory obligations corporations legal basis would compliance relevant laws regulations data retention corporation use personal data long necessary implement administer manage participation plan required comply legal regulatory obligations including tax securities laws period may extend beyond point service corporation longer needs personal data related plan corporation remove systems corporation keeps personal data longer would satisfy legal regulatory obligations corporations legal basis would compliance relevant laws regulations e data subject rights extent provided law right subject certain exceptions request access copies personal data corporation processes ii request rectification incorrect personal data iii request deletion personal data iv place restrictions processing personal data v lodge complaints competent authorities country andor vi request list names andaddresses potential recipients personal data receive clarification regarding rights exercise rights may contact local human resources representative also right object grounds related particular situation processing personal data well optout plan herein case without cost contacting local human resources representative writing provision personal data contractual requirement understand however consequence refusing provide personal data corporation may able administer rsus grant awards administer maintain awards information consequences refusal provide personal data may contact local human resources representative writing may also contact data protection officer responsible country region applicable emailing emeaprivacyitsjnjcom may also right lodge complaint relevant data protection supervisory authority argentina terms conditions labor law policy acknowledgement provision supplements section special employment rights rights awards agreement accepting grant rsus acknowledge agree grant rsus made corporation employer sole discretion value rsus shares common stock acquired plan shall constitute salary wages purpose argentine labor law including limited calculation labor benefits including limited vacation pay thirteenth salary compensation lieu notice annual bonus disability leave absence payments etc ii termination severance indemnities similar payments notwithstanding foregoing benefits plan considered salary wages purpose argentine labor law acknowledge agree benefits shall accrue frequently vesting date notifications securities law information neither rsus underlying shares common stock publicly offered listed stock exchange argentina australia notifications tax information plan plan subdivision ac income tax assessment act cth act applies subject conditions act securities law information offer participate plan made division part corporations act cth please note offer shares common stock sale person entity resident australia offer may subject todisclosure requirements australian law consult personal legal advisor regarding disclosure obligations prior making offer belgium terms conditions shareholding agreement current belgian tax law understand may enter agreement corporation hold shares common stock two years date shares acquired upon vesting rsus plan obtain specific tax treatment income received plan interested learning information tax treatment plan income check personal tax advisor understand wish take advantage specific tax treatment review execute shareholding agreement form provided corporation brazil terms conditions compliance law accepting rsus acknowledge agree comply applicable brazilian laws report pay applicable taxes associated receipt vesting rsus sale shares common stock acquired plan payment dividends shares acknowledgement nature plan rsus provision supplements section special employment rights rights awards agreement accepting agreement acknowledge making investment decision ii value underlying shares common stock fixed may increase decrease value vesting period without compensation canada terms conditions form settlement rsus payable common stock notwithstanding discretion plan anything contrary agreement rsus provide right resident canada receive cash payment shall paid shares common stock conditions vesting upon following termination employment provision replaces subsection definition employed employment section agreement period follows date receive written notice termination employment notice period garden leave similar period period pay lieu notice salary continuation period requirement local law including limited statutory law regulatory law andor common lawthe following provisions apply resident quebec data privacy notice consent provision supplements section f data privacy consent agreement resident quebec hereby authorize corporation corporations representative discuss obtain relevant information personnel professional involved administration operation plan authorize corporation employer within corporation group disclose discuss participation plan advisors also authorize corporation employer record information keep employee file finally acknowledge authorize corporation parties involved administration plan use technology profiling purposes make automated decisions may impact administration plan notifications securities law information permitted sell shares common stock acquired plan designated broker appointed plan provided resale shares common stock takes place outside canada facilities stock exchange shares listed shares common stock currently listed new york stock exchange united states america chile notifications securities law information offer conforms general ruling n chilean commission financial market cmf offer deals securities registered registry securities registry foreign securities cmf therefore securities subject oversight issuer obligated provide public information chile regarding foreign securities since securities registered cmf securities shall subject public offering long registered corresponding registry securities chile unless fulfill requirements set forth general ruling n cmf esta oferta se acoge la norma de carcter general n de la comision para el mercado financiero de chile la oferta versa sobre valores inscritos en el registro de valores en el registro de valores extranjeros que lleva la comision para el mercado financiero de chile por lo que tales valores estn sujetos la fiscalizacin de sta por tratar de valores inscritos existe la obligacin por parte del emisor de entregar en chile informacin pblica respecto de esos valores esos valores podrn ser objeto de oferta pblica mientras sean inscritos en el registro de valores correspondiente menos que se cumplan las condiciones establecidas en la norma de carcter general n de la comision para el mercado financiero de chile chinathe following terms apply individuals subject exchange control restrictions peoples republic china prc determined corporation sole discretion terms conditions restriction vesting permitted vest shares common stock unless necessary approvals plan obtained state administration foreign exchange safe remain place determined corporation sole discretion corporation obligation issue shares common stock corporation obtain safe approval safe approval subsequently becomes invalid ceases effect time vest rsus corporation reserves right settle rsus cash termination employment event termination employment corporation group corporation require sale shares common stock may hold shares common stock may hold issued pursuant award granted plan predecessor plan within six months following date termination period may required safe understand agree corporation authorized instruct designated broker assist mandatory sale shares common stock behalf pursuant authorization expressly authorize designated broker complete sale shares understand agree corporations designated broker obligation arrange sale shares particular price also agree sign agreements forms consents may reasonably requested corporation corporations designated broker effectuate sale shares common stock including without limitation transfer proceeds exchange control matters noted otherwise cooperate corporation respect matters provided shall permitted exercise influence whether sales occur upon sale shares common stock corporation agrees pay cash proceeds sale less brokerage fees commissions subject obligation satisfy applicable tax related items designated broker account shares issued upon settlement rsus immediately sold acknowledge required maintain shares common stock account designated broker selected corporation shares common stock sold corporation designated broker corporation changes designated broker acknowledge agree corporation may transfer shares common stock issued plan new designated brokerage firm necessary legal administrative reasons agree sign documentation necessary facilitate transfer shares common stock exchange control requirements understand agree pursuant local exchange control requirements required immediately repatriate cash proceeds sale shares common stock related rsus award granted plan predecessor plan china understand applicable laws repatriation cash proceeds need effectuated special exchange controlaccount established corporation affiliate subsidiary hereby consent agree proceeds sale shares common stock transferred special account prior delivered understand corporation may face delays converting proceeds local currency due exchange control restrictions china proceeds may paid us dollars local currency corporations discretion proceeds paid us dollars required set us dollar bank account china proceeds may deposited account proceeds paid local currency corporation obligation secure particular currency conversion rate understand corporation may face delays converting proceeds local currency due exchange control restrictions china agree bear currency fluctuation risk time shares sold time sale proceeds distributed special exchange account agree comply requirements may imposed corporation future order facilitate compliance exchange control requirements china colombia terms conditions following supplements section special employment rights rights awards agreement labor law policy acknowledgement accepting award rsus acknowledge pursuant article colombia labor code plan related benefits constitute component salary purposes notifications securities law information shares common stock subject rsus registered colombian registry publicly traded securities registro nacional de valores emisores therefore shares common stock may offered public colombia nothing document construed making public offer securities colombia denmark terms conditions danish stock option act acknowledge received employer statement translated danish provided comply danish stock option act amended january france terms conditionsqualified tax treatment rsus may granted pursuant addendum participants france qualified share units qualified performance share units french subplan rsus french subplan rsus modifies terms plan agreement event conflict terms conditions french subplan rsus plan agreement french subplan rsus shall prevail grants made thereunder corporation make undertaking representation maintain qualified status rsus underlying shares common stock conditions vesting settlement granted rsus pursuant french subplan rsus irrespective provisions agreement except case death disability defined french subplan rsus rsus subject agreement shall vest prior date one year grant date shares common stock shall issued settlement vested rsus prior date two years grant date minimum holding period granted rsus pursuant french subplan rsus issued shares common stock pursuant agreement prior two year anniversary grant date must hold shares common stock minimum period two years grant date avoidance doubt twoyear holding period applicable shares common stock vested following two year anniversary grant date sale restriction closed period acknowledge shares common stock issued delivered settlement rsus may sold transferred otherwise disposed periods set forth section french subplan rsus acknowledge agree personally responsible complying specific restrictions termination employment due death notwithstanding anything contrary provided section ci agreement granted rsus french subplan rsus upon corporations receipt within six months following death written request heirs form satisfactory corporation corporation shall transfer shares underlying unvested rsus heirs case shares shall cease immediately subject abovementioned minimum holding period termination employment due disability prior vesting date become disabled employed definition section french subplan rsus shall immediately become vested rsus date disability case shares shall cease immediately subject abovementioned minimum holding period language consent accepting grant confirm read understood plan agreement provided english language accept terms documents accordinglyen acceptant lattribution vous confirmez avoir lu et compris le plan et le contrat qui ont communiqus en langue anglaise vous acceptez les termes de ces documents en connaissance de cause notifications exchange control information must report french customs excise authorities value cash securities transfer france without use financial institution value cash securities equals exceeds certain threshold foreign assetaccount reporting information required report foreign accounts whether open current closed french tax authorities filing annual tax return hong kong terms conditions form settlement rsus payable common stock notwithstanding discretion plan anything contrary agreement rsus provide right receive cash payment rsus shall paid shares common stock sale common stock shares common stock received vesting accepted personal investment event common stock issued respect rsus within six months grant date agree offer public otherwise dispose shares common stock prior six month anniversary grant date notifications securities warning contents document reviewed regulatory authority hong kong exercise caution relation offer doubt contents agreement including appendix plan obtain independent professional advice rsus shares common stock issued respect rsus constitute public offering securities hong kong law available eligible service providers plan agreement including appendix plan incidental communication materials prepared accordance intended constitute prospectus public offering securities applicable securities legislation hong kong rsus documentation related thereto intended solely personal use member award recipient may distributed person indonesia terms conditionslanguage consent notification accepting grant rsus confirm read understood documents relating grant ie plan agreement provided english language ii accept terms documents accordingly iii agree challenge validity document based law national flag language coat arms national anthem implementing presidential regulation issued language consent notification dengan manikin tombol saya menerima atau dengan menandatangani dan mengembalikan dokumen ini yang memuat syarat dan ketentuan pemberian anda anda mengkonfirmasi bahwa anda telah membaca dan mengerti isi dokumen yang terkait dengan pemberian ini yang disediakan untuk anda dalam bahasa inggris ii anda menerima syarat dari dokumendokumen tersebut dan iii anda setuju bahwa anda tidak akan mengajukan keberatan atas keberlakuan dokumen ini berdasarkan undangundang tahun tentang bendera bahasa dan lambang negara serta lagu kebangsaan atau peraturan presiden pelaksana ketika diterbitkan ireland terms conditions acknowledgement nature plan rsus following supplements section special employment rights rights awards agreement accepting agreement understand agree benefits received plan taken account redundancy unfair dismissal claim israel terms conditions provision supplements section agreement tax withholding israel accordance applicable law including tax ruling may received corporation andor israeli subsidiaries following provision applies participants israel grant date trustee arrangement hereby agree rsus extent granted corporation israeli subplan plan shall allocated provisions track referred capital gains track according section b b israeli income tax ordinance shall held trustee trustee periods stated section holding period acknowledge holding period sell shares common stock issued settlement rsus tax treatment differ treatment would apply holding period met consult personal tax advisor regard italyterms conditions acknowledgement nature agreement accepting agreement acknowledge received copy plan agreement appendix reviewed applicable documents entirety fully understand contents thereof accept provisions plan agreement appendix mexico terms conditions acknowledgement agreement accepting rsus granted hereunder acknowledge received copy plan reviewed plan agreement including appendix entirety fully understand accept provisions plan agreement including appendix acknowledge read specifically expressly approve terms conditions section special employment rights rights awards agreement clearly provide follows participation plan constitute acquired right plan participation offered corporation wholly discretionary basis participation plan voluntary corporation subsidiaries affiliates responsible decrease value shares common stock acquired vesting rsus labor law acknowledgement policy statement accepting rsus granted hereunder expressly recognize corporation registered offices one johnson johnson plaza new brunswick nj usa solely responsible administration plan participation plan acquisition shares common stock constitute employment relationship corporation since participating plan wholly commercial basis employer johnson johnson mexico sole employer based foregoing expressly recognize plan benefits may derive participation plan establish rights employer johnson johnson mexico form part employment conditions andor benefits provided johnson johnson mexico modification plan termination shall constitute change impairment terms conditions employment understand participation plan result unilateral discretionary decision corporation therefore corporation reserves absolute right amend andor discontinue participation plan time without liability youfinally hereby declare reserve action right bring claim corporation compensation damages regarding provision plan benefits derived plan therefore grant full broad release corporation affiliates shareholders officers agents legal representatives respect claim may arise spanish translation reconocimiento del contrato al aceptar el otorgamiento de las rsus usted reconoce que ha recibido una copia del plan que ha revisado el plan el contrato incluyendo este apndice en su totalidad que entiende acepta todas las disposiciones del plan del contracto incluyendo este apndice adems usted reconoce que ha ledo que especfica expresamente aprueba de los trminos condiciones de la seccin del contrato que claramente dispone lo siguiente su participacin en el plan constituye un derecho adquirido el plan su participacin en el plan se ofrecen por la corporacin en de manera totalmente discrecional su participacin en el plan es voluntaria la corporacin sus subsidiarias afiliadas son responsables por ninguna disminucin del valor de las acciones en el momento de tener derecho conforme las rsus reconocimiento ley laboral declaracin de la poltica al aceptar el otorgamiento de las rsus usted reconoce expresamente que la corporacin con oficinas registradas en one johnson johnson plaza new brunswick nj eeuu es nicamente responsable por la administracin del plan adems usted reconoce que su participacin en el plan cualquier adquisicin de acciones de conformidad con el plan constituyen una relacin laboral entre usted la corporacin ya que usted est participando en el plan sobre una base totalmente comercial que su empleador johnson johnson mexico es su nico patrn derivado de lo anterior usted reconoce expresamente que el plan los beneficios que le puedan derivar al participar en el plan establecen ningn derecho entre usted su patrn johnson johnson mexico que forman parte de las condiciones de trabajo yo prestaciones otorgadas por johnson johnson mexico que cualquier modificacin del plan la terminacin del mismo constituirn un cambio deterioro de los trminos condiciones de su empleo adems usted entiende que su participacin en el plan es resultado de una decisin unilateral discrecional de la corporacin por lo que la corporacin se reserva el derecho absoluto modificar yo discontinuar su participacin en el plan en cualquier momento sin responsabilidad alguna para con usted finalmente usted declara por la presente que se reserva accin derecho alguno para interponer una reclamacin demanda en contra de la corporacin por cualquier compensacin dao en relacin con cualquier disposicin del plan de los beneficios derivados del plan por lo tanto otorga un amplio total finiquito la corporacin susafiliadas accionistas funcionarios agentes representantes legales con respecto cualquier reclamacin demanda que pudiera surgir notifications securities law information rsus granted shares common stock acquired plan registered national register securities maintained mexican national banking securities commission offered sold publicly mexico addition plan agreement document relating rsus may publicly distributed mexico materials addressed existing relationship corporation subsidiary affiliate corporation eg johnson johnson mexico materials reproduced copied form offer contained materials constitute public offering securities rather constitutes private placement securities addressed specifically individuals present employees johnson johnson mexico made accordance provisions mexican securities market law rights offering shall assigned transferred new zealand notifications securities law information warning offer rights receive shares common stock upon settlement rsus subject terms plan agreement rsus give stake ownership corporation may receive return dividends paid shares common stock corporation runs financial difficulties wound paid creditors paid may lose investment new zealand law normally requires people offer financial products give information investors invest information designed help investors make informed decision usual rules apply offer made employee share purchase scheme result may given information usually required also fewer legal protections investment ask questions read documents carefully seek independent financial advice committing participate plan interest rsus may transferred legally beneficially assigned mortgaged charged encumbered shares common stock quoted new york stock exchange means acquire shares common stock plan may able sell new york stock exchange interested buyers may get less invested price depend demand shares common stocka copy corporations recent annual report recent published financial statements quarterly reports form q auditors report financial statements filed us securities exchange commission available online wwwsecgov well corporations investor relations website httpwwwinvestorjnjcom copy documents sent free charge written request equity compensation resources one johnson johnson plaza new brunswick nj usa noted advised carefully read materials provided making decision whether participate plan also encouraged contact tax advisor specific information concerning personal tax situation regard plan participation philippines terms conditions restriction vesting permitted vest shares common stock unless necessary securities law approvals plan obtained remain place determined corporation sole discretion corporation obligation issue shares common stock corporation obtain necessary securities approval approval subsequently becomes invalid ceases effect time vest rsus corporation reserves right settle rsus cash notifications securities law information aware risks participating plan include without limitation risk fluctuation price shares common stock new york stock exchange nyse risk currency fluctuations us dollar local currency regard note value shares common stock may acquire plan may decrease fluctuations foreign exchange rates local currency us dollar may affect value rsus amounts due upon vesting settlement rsus upon sale shares common stock acquire plan corporation making representations projections assurances value shares common stock future information risk factors impacting corporations business may affect value shares common stock refer risk factors discussion corporations annual report quarterly reports form q filed us securities exchange commission available online wwwsecgov well corporations investor relations website httpwwwinvestorjnjcom permitted sell shares common stock acquired plan designated broker appointed plan broker transfer shares common stock provided resale shares common stock acquired theplan takes place outside philippines facilities stock exchange shares common stock listed eg nyse portugal terms conditions consent receive information english hereby expressly declare full knowledge english language read understood fully accepted agreed terms conditions established plan agreement conhecimento da lingua por meio presente eu declaro expressamente que tem pleno conhecimento da lngua inglesa e que li compreendi e livremente aceitei e concordei com os termos e condies estabelecidas plano e acordo russia terms conditions securities law requirements rsus granted hereunder agreement including appendix plan materials may receive regarding participation plan rsus granted hereunder constitute advertising offering securities russia issuance shares common stock plan registered russia therefore shares common stock may offered placed public circulation russia event shares common stock acquired plan delivered russia shares common stock maintained behalf united states permitted sell shares common stock acquired plan directly russian legal entity resident labor law acknowledgement acknowledge continue hold shares common stock acquired plan involuntary termination employment eligible receive unemployment benefits russia data privacy notice hereby acknowledge read understood terms regarding collection processing transfer data contained section f data privacy consent agreement participating plan agree terms regard upon request corporation employer agree provide executed data privacy consent form employer corporation agreements consents may required employer corporation corporation andor employer may deem necessary obtain data privacy laws country either future understand able participate plan fail execute consent agreement notificationsanticorruption legislation information individuals holding public office russia well spouses dependent children may prohibited opening maintaining foreign brokerage bank account holding securities whether acquired directly indirectly foreign company including shares common stock acquired plan consult personal legal advisor determine whether restriction applies circumstances singapore terms conditions restriction sale transferability hereby agree shares common stock acquired pursuant rsus offered sale singapore prior sixmonth anniversary grant date unless sale offer made pursuant one exemptions part xiii division subdivision section securities futures act chap ed sfa notifications securities law information grant rsus made pursuant qualifying person exemption section f sfa made view rsus subsequently offered sale party plan lodged registered prospectus monetary authority singapore south africa notifications securities law information compliance south african securities law acknowledge notified corporations annual report quarterly reports form q filed us securities exchange commission available online wwwsecgov well corporations investor relations website httpwwwinvestorjnjcom spain terms conditions labor law acknowledgement following supplements section special employment rights rights awards agreement accepting rsus granted hereunder consent participation plan acknowledge received copy plan understand corporation unilaterally gratuitously sole discretion decided grant rsus plan individuals may employees corporation group throughout world decision limited decision entered upon express assumption condition rsu granted economically orotherwise bind corporation affiliates ongoing basis expressly set forth agreement including appendix consequently understand rsus granted hereunder given assumption condition shall become part employment contract either corporation affiliates shall considered mandatory benefit salary purposes including severance compensation right whatsoever understand freely accept guarantee benefit whatsoever shall arise gratuitous discretionary grant rsus since future value rsus underlying shares common stock unknown unpredictable addition understand rsus granted hereunder would made assumptions conditions referred thus understand acknowledge freely accept assumptions mistaken conditions met reason grant rsus right rsus shall null void vesting rsus expressly conditioned active employment status corporation group service terminates rsus may cease vesting immediately forfeited whole part effective date termination employment unless otherwise specifically provided section c certain terminations agreement case example even considered unfairly dismissed without good cause ie subject despido improcedente dismissed disciplinary objective reasons due collective dismissal terminate service due change work location duties employment contractual condition terminate service due unilateral breach contract corporation affiliate corporation consequently upon termination employment reasons automatically lose rights rsus vested date termination employment except described section c agreement acknowledge read specifically accept conditions referred section agreement notifications securities law information offer securities public defined spanish law taken place take place spanish territory agreement including appendix registered comisin nacional del mercado de valores constitute public offering prospectus sweden terms conditions tax withholding provision supplements section agreement without limiting corporations employers authority satisfy withholding obligations taxrelated items set forth agreement accepting rsus authorize corporation withhold shares common stock sell shares common stock otherwise deliverable upon vestingsettlement satisfy taxrelated itemsregardless whether corporation andor employer obligation withhold taxrelated items switzerland notifications securities law information neither document materials relating rsus constitutes prospectus according articles et seq swiss federal act financial services finsa ii may publicly distributed otherwise made publicly available switzerland person employee corporation iii filed approved supervised swiss reviewing body according article finsa swiss regulatory authority including swiss financial supervisory authority finma taiwan notifications securities law information offer participation plan available employees offer participation plan public offer securities taiwanese company turkey notifications securities law information plan made available employees corporation affiliates offer participation plan private offering employees turkey rsus issuance shares common stock plan takes place outside turkey permitted sell shares common stock acquired plan turkey shares common stock currently traded new york stock exchange located outside turkey ticker symbol jnj shares common stock may sold exchange united arab emirates notifications securities law information rsus plan granted select employees corporation affiliates purpose providing equity incentives plan agreement intended distribution employees must delivered relied person conduct due diligence rsus offered pursuant agreement understand contents plan andor agreement consult authorized financial adviser emirates securities commodities authority dubai financial services authority responsibility reviewing verifying documents connection plan neither ministry economy dubai department economic development approved plan theagreement taken steps verify information set therein responsibility documents united kingdom terms conditions tax withholding provision supplements section agreement without limitation section agreement agree liable tax related items hereby covenant pay taxrelated items requested corporation different employer hm revenue customs hmrc tax authority relevant authority also agree indemnify keep indemnified corporation different employer taxrelated items required pay withhold paid pay hmrc behalf tax authority relevant authority purposes agreement tax related items include without limitation employment income tax employee portion health social care levy notwithstanding foregoing director executive officer corporation within meaning section k exchange act understand may able indemnify corporation amount income tax collected paid within ninety days end uk tax year event giving rise tax related items occurs may considered loan therefore may constitute benefit additional income tax national insurance contributions nics health social care levy may payable understand responsible reporting paying income tax due additional benefit directly hmrc self assessment regime paying corporation andor employer appropriate amount employee nics health social care levy due additional benefit may also recovered means referred section agreement uruguay terms conditions data privacy acknowledgement provision supplements section f agreement understand data collected employer transferred corporation one johnson johnson plaza new brunswick nj usa andor financial institutions brokers involved management administration plan understand entities may store data purposes administering participation plan venezuela terms conditionssettlement rsus settlement vested rsus shall made shares common stock provided however corporation discretion settle rsus cash determines cash settlement necessary advisable light changes regulatory requirements venezuela event rsus settled cash amount cash payment upon vesting settlement rsus shall based fair market value determined corporation shares common stock subject vested rsus less applicable taxrelated items investment representation condition grant rsus acknowledge agree shares common stock may acquire upon settlement rsus acquired intended investment rather resale shares common stock conversion shares foreign currency notifications securities law information rsus granted plan shares common stock issued plan offered personal private exclusive transaction subject venezuelan government securities regulationsexhibit johnson johnson stock trading policy directors executive officers insiders federal state laws prohibit insiders defined buying selling securities johnson johnson jj aware material nonpublic information jj passing along tipping information others trade illegal activity commonly referred insider trading individuals trade material nonpublic information tip information others trade liable civil criminal penalties addition legal disciplinary action jj including dismissal cause stock trading policy policy directors executive officers family members living household insiders provides guidelines respect transactions securities jj jj adopted policy regarding securities transactions help prevent insider trading protect reputation integrity ethical conduct policy apply general prohibition general prohibition trading tipping aware material nonpublic information always applicable blackout period starting date two weeks prior end fiscal quarter hours financial results fiscal quarter fiscal year announced insiders may trade jj securities period trading allowed called blackout period example fiscal quarter ends september financial results released edt october trading prohibited policy september edt october ii covered policy section insiders members board directors b members executive committee c corporate controller family members living household section insider see additional guidance section restricted insiders treasurer corporate secretary individual may designated time time general counsel company group chairmen members group operating committees sector leadership teams individuals reporting directly chief financial officer excluding nonfinance staff members certain employees corporate controller 's group involved preparation financial statements determined chief financial officer investor relations professionals family members living household restricted insider see additional guidance section insiders section insiders restricted insiders iii transactions prohibited policy trading jj securities possession material nonpublic information trading jj securities blackout period described section iv gifts jj securities possession material nonpublic information blackout period except otherwise permitted section vii iv transactions prohibited blackout period open market purchase sale jj securities purchase sale jj securities broker unless accordance prearranged preapproved written plans irrevocable instructions see additional guidance section sale exchange jj securities connection exercise stock options including sale shares subject stock option part cashless exercise option sale exchange shares generate consideration needed fund exercise option pay taxes elections make change existing elections dividend reinvestment plan switching existing balances jj stock fund company k savings plan increasing decreasing future contributions jj stock fund company k savings plan gifts jj securities except otherwise permitted section vii v transactions allowed blackout period regular matching contributions jj stock fund company k savings plan regular reinvestment dividends dividend reinvestment plan transfers jj securities trust regular purchase jj securities employee stock purchase planvi preclearance stock transactions section insiders times even blackout period effect purchasing selling jj securities engaging transaction prohibited blackout period section insiders must preclear transactions jj securities including gifts writing notifying general counsel corporate secretary least two business days advance proposed transaction addition chief executive officer notified transaction requests section insiders ii lead director board directors nonexecutive chairman board directors applicable notified transaction requests chief executive officer executive chairman board directors transaction must placed within four business days receipt written preclearance general counsel corporate secretary vii gifts jj securities gifts jj securities may include gifts trusts estate planning purposes well donations charitable organization whether gift securities transaction avoided person making gift possession material nonpublic information may depend various circumstances surrounding gift accordingly encouraged consult legal department contemplating gift section insiders required obtain preclearance gift viii prearranged rule b trading plans insider may trade jj securities including exercise stock options sale exchange shares underlying stock options blackout period accordance certain prearranged written plans irrevocable instructions trading plans meet requirements set forth section viii provided however section insider subject stock ownership guidelines may use trading plan required ownership level met first proposed trading plan must entered good faith time insider possession material nonpublic information blackout period second proposed trading plan must either specify number shares purchased sold specific dates else provide written formula trading third proposed trading plan must preapproved writing general counsel corporate secretary least five business days prior entry trading plan modification thereof fourth proposed trading plan must comply sec rule b cfr b successor rule single plan insider may enter multiple trading plans providing transactions overlapping periods ii trading plan providing openmarket purchase sale total amount jj securities plan single transaction month period foregoing restrictions notapply eligible selltocover transactions sell shares necessary satisfy tax withholding obligations arising exclusively vesting certain types compensatory awards sec rule bciid waiting period first trade made trading plan may take place days following entry trading plan section insiders first trade may take place later days following entry trading plan ii business days following jjs filing form q k sec completed fiscal quarter plan adopted subject maximum days following entry trading plan early termination trading plan deemed terminated upon expiration term sale jj securities subject trading plan trading plan may terminated insider either expiration term sale jj securities subject trading plan early termination receipt written approval general counsel corporate secretary note new trading plan would subject waiting period described early termination strongly discouraged certain limited circumstances general counsel corporate secretary may consider whether early termination plan warranted amendments amendments modifications trading plan may made receipt written approval general counsel corporate secretary addition insider may amend trading plan possession material nonpublic information blackout period ii amendment may effective days section insiders longer waiting period described thereafter amendments strongly discouraged section insider representations new modified trading plan section insider must include representation certifying date adoption plan individual section insider aware material nonpublic information security jj ii adopting plan good faith part plan scheme evade prohibitions sec rule b notwithstanding foregoing adoption trading plan preclude trades outside trading plan otherwise made accordance policy information trading plans please contact corporate secretarys office ix additional guidance people covered policy actual knowledge financial results matter policy applies regardless actual knowledge financial results insider may trade jj securities blackout period even person knowledge current financial results trading knowing material nonpublic information sec rules well jj code business conduct jj code business conduct ethics members board directors executive officers prohibit buying selling jj securities possession material nonpublic information company event anyone covered policy trade jj securities time knowledge ofmaterial information involving company disclosed publicly event insider unsure whether news development information would considered material question whether refrain trading jj securities contact corporate secretary 's office stated section insiders always required preclear trades derivative instruments persons covered policy prohibited times buying selling put call options jj securities short sales hedging transactions types derivative instruments linked performance jj securities family members live household family members people covered policy share household also covered policy extent person covered policy addition children go away college otherwise leave home remain financially dependent considered living household subject policy spouse children jj securities important advise policy family members live insiders household also aware restrictions engage transactions involving jj securities without first discussing insider jj securities insider may control policy applies investment decisions made people covered policy insider power direct purchase sale jj securities virtue position shareholder director officer corporation notforprofit organization trustee trust executor estate purposes policy insider engage transaction jj securities behalf corporation organization trust estate would permitted engaged personal capacity policy exceptions policy exceptions policy may granted extenuating circumstances exception must approved general counsel requires individual possession material nonpublic information urgent unexpected need money defense charges trading material nonpublic information posttermination transaction subject additional terms conditions restrictions may set forth agreement insider jj period time status jj terminates aspects policy including mandatory preclearance transactions jj securities shall continue apply later end first black period following public release earnings fiscal quarter insiders status jj terminates ii beginning second market trading day earlier public disclosure material nonpublic information known insider b time material nonpublic information known insider longer material x contact questions policy please contact office corporate secretary email askcorpsecitsjnjcom questions amended board directors johnson johnson effective april exhibit subsidiaries johnson johnson new jersey corporation us international subsidiaries shown december johnson johnson subsidiary entity name subsidiary jurisdiction us subsidiaries abd holding company inc delaware abiomed commercial llc delaware abiomed rd inc delaware abiomed inc delaware acclarent inc delaware actelion pharmaceuticals us inc delaware albany street llc new jersey alza corporation delaware alza land management inc delaware amo development llc delaware amo manufacturing usa llc delaware amo sales service inc delaware amo spain holdings llc delaware anakuria therapeutics inc delaware aortx inc delaware aragon pharmaceuticals inc delaware asia pacific holdings llc new jersey atrionix inc california aub holdings llc delaware auris health inc delaware bandol merger sub inc delaware benevir biopharm inc delaware biomedical enterprises inc texas biosense webster inc california breethe inc delaware cerenovus inc new jersey charm merger sub inc delaware coherex medical inc delaware cotherix inc delaware cres holdings inc delaware crossroads extremity systems llc tennessee csats inc washington depuy mitek llc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine llc ohio depuy synthes institute llc delaware depuy synthes products inc delaware depuy synthes sales inc massachusetts depuy synthes inc delaware dutch holding llc delaware ecl llc delaware ethicon endosurgery inc ohio ethicon endosurgery llc delaware ethicon llc delaware ethicon us llc texas ethicon inc new jerseyname subsidiary jurisdiction hansen medical international inc delaware hansen medical inc delaware id acquisition corp new jersey janssen biotech inc pennsylvania janssen global services llc new jersey janssen oncology inc delaware janssen ortho llc delaware janssen pharmaceuticals inc pennsylvania janssen products lp new jersey janssen research development llc new jersey janssen scientific affairs llc new jersey janssen supply group llc pennsylvania janssencilag manufacturing llc delaware jevco holding inc new jersey jjhc llc delaware jnj international investment llc delaware jntl russia holdco llc delaware johnson johnson new jersey johnson johnson middle east inc new jersey johnson johnson singapore holdco llc delaware johnson johnson enterprise innovation inc delaware johnson johnson finance corporation new jersey johnson johnson gateway llc new jersey johnson johnson health care systems inc new jersey johnson johnson holdco na inc new jersey johnson johnson innovation jjdc inc delaware johnson johnson innovation llc delaware johnson johnson international new jersey johnson johnson medical devices diagnostics group latin america llc florida johnson johnson se inc new jersey johnson johnson services inc new jersey johnson johnson surgical vision inc delaware johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida jom pharmaceutical services inc delaware laminar inc delaware llt management llc texas medical device business services inc indiana medical devices diagnostics global services llc delaware megadyne medical products inc utah mentor partnership holding company llc delaware mentor texas gp llc delaware mentor texas lp delaware mentor worldwide llc delaware middlesex assurance company limited vermont momenta pharmaceuticals inc delaware netherlands holding company delaware neuwave medical inc delaware nuvera medical inc delaware omj pharmaceuticals inc delaware omrix biopharmaceuticals inc delaware ortho biologics llc delaware ortho biotech holding llc delaware patriot pharmaceuticals llc pennsylvanianame subsidiary jurisdiction percivia llc delaware princeton laboratories inc delaware prosidyan inc delaware pulsar vascular inc delaware regency urban renewal associates new jersey royalty llc north carolina rutan realty llc new jersey scios llc delaware serotiny inc delaware sterilmed inc minnesota synthes usa products llc delaware synthes usa llc delaware synthes inc delaware talco llc texas taris biomedical llc delaware tearscience inc delaware anspach effort llc florida tibotec llc delaware torax medical inc delaware verb surgical inc delaware wh development company llc georgia percivia llc delaware princeton laboratories inc delaware prosidyan inc delaware pulsar vascular inc delaware regency urban renewal associates new jersey royalty llc north carolina rutan realty llc new jersey scios llc delaware serotiny inc delaware sterilmed inc minnesota synthes usa products llc delaware synthes usa llc delaware synthes inc delaware talco llc texas taris biomedical llc delaware tearscience inc delaware anspach effort llc florida tibotec llc delaware torax medical inc delaware verb surgical inc delaware wh development company llc georgianame subsidiary jurisdiction international subsidiaries abiomed australia pty ltd australia abiomed europe gmbh germany abiomed europe gmbh aachen zweigniederlassung zug switzerland abiomed japan kk japan abiomed sarl france abiomed singapore pte ltd singapore abiomed ltd united kingdom actelion pharmaceuticals ltd switzerland actelion pharmaceuticals trading shanghai co ltd china actelion treasury unlimited company ireland ais gmbh aachen innovative solutions germany amo hangzhou co ltd china amo shanghai medical devices trading co ltd china amo asia limited hong kong amo australia pty limited australia amo canada company canada amo denmark aps denmark amo france france amo germany gmbh germany amo groningen bv netherlands amo international holdings unlimited company ireland amo ireland cayman islands amo italy srl italy amo japan kk japan amo netherlands bv netherlands amo norway norway amo puerto rico manufacturing inc cayman islands amo singapore pte ltd singapore amo switzerland gmbh switzerland amo united kingdom ltd united kingdom amo uppsala ab sweden apsis france berna rhein bv netherlands biosense webster israel ltd israel c consumer products denmark aps denmark chromagenics bv netherlands cilag ag switzerland cilag gmbh international switzerland cilag holding ag switzerland cilag holding treasury unlimited company ireland cilagbiotech sl spain cordis de mexico sa de cv mexico corimmun gmbh germany depuy hellas sa greece depuy international limited united kingdom depuy ireland unlimited company ireland depuy mexico sa de cv mexico ecp entwicklungsgesellschaft mbh germany ees holdings de mexico de rl de cv mexico ees sa de cv mexico eit emerging implant technologies gmbh germany ethicon endosurgery europe gmbh germany ethicon sarl switzerlandname subsidiary jurisdiction ethicon women 's health urology sarl switzerland ethnor proprietary limited south africa ethnor del istmo sa panama venezuela bolivarian ethnor farmaceutica sa republic finsbury development limited united kingdom finsbury instruments limited united kingdom finsbury medical limited united kingdom finsbury orthopaedics international limited united kingdom finsbury orthopaedics limited united kingdom fms future medical system sa switzerland gatt technologies bv netherlands gbsc division janssen biologics bv netherlands gh biotech holdings limited ireland gmed healthcare bv belgium guangzhou bioseal biotech co ltd china hansen medical deutschland gmbh germany hansen medical uk limited united kingdom healthcare services shanghai ltd china innomedic gesellschaft fr innovative medizintechnik und informatik mbh germany j j company west africa limited nigeria jj argentina sa argentina jj pension trustees limited united kingdom jj productos medicos farmaceuticos del peru sa peru jc general services bv belgium janssen scientific office egypt janssen biologics bv netherlands janssen cilag farmaceutica sa argentina janssen cilag spa italy janssen cilag spa algeria venezuela bolivarian janssen cilag ca republic janssen egypt llc egypt janssen farmaceutica portugal lda portugal janssen france treasury unlimited company ireland janssen inc canada janssen irish finance unlimited company ireland janssen japan treasury unlimited company ireland janssen korea ltd korea republic janssen mexico treasury unlimited company ireland janssen pharmaceutica proprietary limited south africa janssen pharmaceutica nv belgium janssen pharmaceutical kk japan janssen pharmaceutical sciences unlimited company ireland janssen pharmaceutical unlimited company ireland janssen rd ireland unlimited company ireland janssen sciences ireland unlimited company ireland janssen scientific office syria syrian arab republic janssen vaccines prevention bv netherlands janssen vaccines corp korea republic janssencilag france janssencilag new zealand limited new zealand janssencilag denmark janssencilag ag switzerland janssencilag aktiebolag sweden janssencilag norwayname subsidiary jurisdiction janssencilag bv netherlands janssencilag doo beograd serbia janssencilag de mexico de rl de cv mexico janssencilag farmaceutica lda portugal janssencilag farmaceutica ltda brazil janssencilag gmbh germany janssencilag international nv belgium janssencilag kft hungary janssencilag limited thailand janssencilag limited united kingdom janssencilag nv belgium janssencilag oy finland janssencilag pharma gmbh austria janssencilag pharmaceutical saci greece janssencilag polska sp z oo poland janssencilag pty ltd australia janssencilag sa colombia janssencilag sro czech republic janssencilag sa spain janssencilag sa de cv mexico janssenpharma sl spain jc health care ltd israel jj surgical vision spain sl spain jj surgical vision spain sl sucursal em portugal portugal jjc acquisition company bv netherlands jjsv belgium bv belgium jjsv manufacturing malaysia sdn bhd malaysia jjsv norden ab sweden jjsv norden ab filial finland finland jjsv produtos oticos ltda brazil jnj global business services sro czech republic jnj holding emea bv netherlands johnson johnson angola limitada angola johnson johnson australia pty ltd australia johnson johnson canada inc canada johnson johnson china investment ltd china johnson johnson ecuador sa ecuador johnson johnson hong kong limited hong kong johnson johnson ireland limited ireland johnson johnson kenya limited kenya johnson johnson mozambique limitada mozambique johnson johnson namibia proprietary limited namibia johnson johnson new zealand limited new zealand johnson johnson philippines inc philippines johnson johnson private limited zimbabwe johnson johnson trinidad limited trinidad tobago johnson johnson vietnam co ltd vietnam johnson johnson ab sweden johnson johnson ag switzerland johnson johnson bulgaria eood bulgaria johnson johnson doo slovenia johnson johnson de chile sa chile johnson johnson de mexico sa de cv mexico johnson johnson de uruguay sa uruguayname subsidiary jurisdiction johnson johnson brasil industria e comercio de produtos para saude ltda brazil johnson johnson dominicana sas dominican republic johnson johnson european treasury unlimited company ireland johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson export import llc egypt johnson johnson gt sociedad annima guatemala johnson johnson healthcare spc kuwait johnson johnson hemisferica sa puerto rico johnson johnson holding gmbh germany johnson johnson holdings austria gmbh austria johnson johnson innovation limited united kingdom johnson johnson international singapore pte ltd singapore johnson johnson international financial services unlimited company ireland johnson johnson irish finance company limited ireland johnson johnson kk japan johnson johnson kazakhstan limited liability partnership kazakhstan johnson johnson kft hungary johnson johnson llc russian federation johnson johnson management limited united kingdom johnson johnson medical china ltd china johnson johnson medical proprietary ltd south africa johnson johnson medical shanghai ltd china johnson johnson medical suzhou ltd china johnson johnson medical bv netherlands johnson johnson medical gmbh germany johnson johnson medical greece single member sa greece johnson johnson medical korea ltd korea republic johnson johnson medical limited united kingdom johnson johnson medical mexico sa de cv mexico johnson johnson medical nv belgium johnson johnson medical products gmbh austria johnson johnson medical pty ltd australia johnson johnson medical sa argentina johnson johnson medical spa italy johnson johnson medical sas france johnson johnson medical saudi arabia limited saudi arabia johnson johnson medical taiwan ltd taiwan province china venezuela bolivarian johnson johnson medical scs republic johnson johnson medikal sanayi ticaret limited sirketi turkey johnson johnson medtech thailand ltd thailand johnson johnson medtech colombia sas colombia johnson johnson medtech cr limitada costa rica johnson johnson mena rhq limited saudi arabia johnson johnson middle east scientific office united arab emirates johnson johnson middle east fzllc united arab emirates johnson johnson morocco societe anonyme morocco johnson johnson nordic ab sweden johnson johnson pakistan private limited pakistan johnson johnson pharmaceutical ltd china johnson johnson poland sp z oo poland johnson johnson private limited india johnson johnson romania srl romania johnson johnson se doo croatianame subsidiary jurisdiction johnson johnson sdn bhd malaysia johnson johnson sociedade previdenciaria non profit brazil johnson johnson surgical vision india private limited india johnson johnson taiwan ltd taiwan province china johnson johnson trading limited saudi arabia johnson johnson uk treasury company limited united kingdom johnson johnson ukraine ii llc ukraine johnson johnson vision care australia pty ltd australia johnson johnson vision care shanghai ltd china johnson johnson vision care ireland unlimited company ireland johnson johnson vision korea ltd korea republic johnson johnson lda portugal johnson johnson sa spain johnson johnson sro czech republic johnson johnson sro slovakia johnson johnson sihhi malzeme sanayi ticaret limited sirketi turkey la concha land investment corporation philippines mcneil panama llc panama medos international sarl switzerland medos sarl switzerland medos srl succursale de neuchtel branch switzerland menlo care de mexico sa de cv mexico mentor bv netherlands mentor deutschland gmbh germany mentor medical systems bv netherlands neuravi limited ireland obtech medical mexico sa de cv mexico obtech medical sarl switzerland omj holding gmbh switzerland omrix biopharmaceuticals ltd israel omrix biopharmaceuticals nv belgium orthospin ltd israel orthotaxy france precardia france proleader sa uruguay pt johnson johnson indonesia two indonesia respivert ltd united kingdom serhum sa de cv mexico spectrum vision limited liability partnership kazakhstan surgical process institute deutschland gmbh germany synthes costa rica scr limitada costa rica synthes gmbh germany synthes gmbh switzerland synthes holding ag switzerland synthes holding limited united arab emirates synthes medical immobilien gmbh germany synthes medical surgical equipment instruments trading llc united arab emirates synthes produktions gmbh switzerland synthes smp de rl de cv mexico synthes tuttlingen gmbh germany uab johnson johnson lithuania vision care finance unlimited company ireland xian janssen pharmaceutical ltd chinaname subsidiary jurisdiction xo limited united kingdomexhibit consent independent registered public accounting firm hereby consent incorporation reference registration statements form nos form johnson johnson report dated february relating financial statements effectiveness internal control financial reporting appears form k spricewaterhousecoopers llp florham park nj february exhibit certification chief executive officer pursuant section sarbanesoxley act joaquin duato certify reviewed annual report fiscal year ended december report johnson johnson company based knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report companys certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules af df company designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change companys internal control financial reporting occurred companys recent fiscal quarter companys fourth fiscal quarter case annual report materially affected reasonably likely materially affect companys internal control financial reporting companys certifying officers disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information b fraud whether material involves management employees significant role companys internal control financial reporting joaquin duato joaquin duato chief executive officer date february exhibit certification chief financial officer pursuant section sarbanesoxley act joseph j wolk certify reviewed annual report fiscal year ended december report johnson johnson company based knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report companys certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules af df company designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change companys internal control financial reporting occurred companys recent fiscal quarter companys fourth fiscal quarter case annual report materially affected reasonably likely materially affect companys internal control financial reporting companys certifying officers disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information b fraud whether material involves management employees significant role companys internal control financial reporting joseph j wolk joseph j wolk chief financial officer date february exhibit certification chief executive officer pursuant section sarbanesoxley act undersigned joaquin duato chief executive officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies best knowledge company 's annual report fiscal year ended december report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company joaquin duato joaquin duato chief executive officer dated february certification furnished sec report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended otherwise subject liability sectionexhibit certification chief financial officer pursuant section sarbanesoxley act undersigned joseph j wolk chief financial officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies best knowledge company 's annual report fiscal year ended december report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company joseph j wolk joseph j wolk chief financial officer dated february certification furnished sec report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended otherwise subject liability sectionexhibit johnson johnson clawback policy board directors board johnson johnson company determined appropriate company adopt clawback policy policy applied executive officers company effective date definitions purposes policy following definitions shall apply committee means compensation benefits committee board b company group means company subsidiaries applicable c covered compensation means incentivebased compensation granted vested paid person served executive officer time performance period incentivebased compensation received effective date nyse listing standard section ii person became executive officer iii time company class securities listed national securities exchange national securities association effective date means august e erroneously awarded compensation means amount covered compensation granted vested paid person fiscal period applicable financial reporting measure relating covered compensation attained exceeds amount covered compensation otherwise would granted vested paid person amount determined based applicable restatement computed without regard taxes paid ie pretax basis covered compensation based stock price total shareholder return amount erroneously awarded compensation subject mathematical recalculation directly information restatement committee determine amount covered compensation constitutes erroneously awarded compensation based reasonable estimate effect restatement stock price total shareholder return upon covered compensation granted vested paid committee shall maintain documentation determination provide documentation nyse f exchange act means securities exchange act g executive officer means officer company defined rule af section exchange act shall deemed include individuals identified company executive officers pursuant item b regulation sk exchange act current former executive officers subject policy accordance terms h financial reporting measure means measure determined presented accordance accounting principles used preparing companys financial statements measures derived wholly part measures may consist gaap nongaap financial measures defined regulation g exchange act item regulation sk exchange act ii stock price iii total shareholder return financial reporting measures may may filed sec may presented outside companys financial statements managements discussion analysis financial conditions result operations performance graph required item e regulation sk exchange act home country means companys jurisdiction incorporation j incentivebased compensation means compensation granted earned vested based wholly part upon attainment financial reporting measure k lookback period means three completed fiscal years plus transition period less nine months within immediately following three completed fiscal years results change companys fiscal year immediately preceding date company required prepare restatement given reporting period date earlier date board committee board officer officers company authorized take action board action required concludes reasonably concluded company required prepare restatement ii date court regulator legally authorized body directs company prepare restatement recovery erroneously awarded compensation policy dependent restatement actually filed l nyse means new york stock exchange received incentivebased compensation deemed received companys fiscal period financial reporting measure specified otherwise relating incentivebased compensation award attained even grant vesting payment incentivebased compensation occurs end period n restatement means required accounting restatement company financial statement due material noncompliance company financial reporting requirement securities laws including correct error previously issued financial statements material previously issued financial statements commonly referred big r restatement ii correct error previously issued financial statements material previously issued financial statements would result material misstatement error corrected current period left uncorrected current period commonly referred little r restatement within meaning exchange act rule nyse listing standard section changes companys financial statements represent error corrections thencurrent relevant accounting standards notconstitute restatements recovery erroneously awarded compensation policy dependent fraud misconduct person connection restatement sec means united states securities exchange commission p subsidiary means domestic foreign corporation partnership association joint stock company joint venture trust unincorporated organization affiliated company directly indirectly one intermediaries controlling controlled common control company control purpose means possession direct indirect power direct cause direction management policies person whether ownership voting securities contract otherwise recoupment erroneously awarded compensation event restatement erroneously awarded compensation received lookback period prior restatement thenoutstanding yet paid shall automatically immediately forfeited b paid person shall subject reasonably prompt repayment company group accordance section policy committee must pursue shall discretion waive forfeiture andor repayment erroneously awarded compensation accordance section policy except provided notwithstanding foregoing committee committee composed entirely independent directors majority independent directors serving board may determine pursue forfeiture andor recovery erroneously awarded compensation person committee determines forfeiture andor recovery would impracticable due following circumstances direct expense paid third party example reasonable legal expenses consulting fees assist enforcing policy would exceed amount recovered following reasonable attempts company group recover erroneously awarded compensation documentation attempts provision documentation nyse ii pursuing recovery would violate companys home country laws adopted prior november provided company obtains opinion home country counsel acceptable nyse recovery would result violation provides opinion nyse iii recovery would likely cause otherwise taxqualified retirement plan benefits broadly available employees company group fail meet requirements usc usc regulations thereunder means repayment event committee determines person shall repay erroneously awarded compensation committee shall provide written notice person email certified mail physical address file company group person person shall satisfy repayment manner terms required committee company group shall entitled set repayment amount amount owed person company group require forfeiture award granted company group person take necessary actions reasonably promptlyrecoup repayment amount person case fullest extent permitted applicable law including without limitation section internal revenue code regulations guidance thereunder committee specify repayment timing written notice described applicable person shall required repay erroneously awarded compensation company group wire cash cashiers check later thirty days receipt notice indemnification person shall indemnified insured reimbursed company group respect loss compensation person accordance policy shall person receive advancement expenses disputes related loss compensation person accordance policy person shall paid reimbursed company group premiums paid person thirdparty insurance policy covering potential recovery obligations policy purpose indemnification includes modification current compensation arrangements means would amount de facto indemnification example providing person new cash award would cancelled effect recovery erroneously awarded compensation event shall company group required award person additional payment restatement would result higher incentive compensation payment miscellaneous policy generally administered interpreted committee determination committee respect policy shall final conclusive binding interested parties determinations committee policy need uniform respect persons may made selectively amongst persons whether persons similarly situated policy intended satisfy requirements section doddfrank wall street reform consumer protection act may amended time time related rules regulations promulgated sec nyse including additional new requirements become effective effective date upon effectiveness shall deemed automatically amend policy extent necessary comply additional new requirements provisions policy intended applied fullest extent law extent provision policy found unenforceable invalid applicable law provision applied maximum extent permitted shall automatically deemed amended manner consistent objectives extent necessary conform applicable law invalidity unenforceability provision policy shall affect validity enforceability provision policy recoupment erroneously awarded compensation policy dependent upon company group satisfying conditions policy including requirements provide applicable documentation nyse rights company group policy seek forfeiture reimbursement addition lieu rights recoupment remedies rights recoupment may available company group pursuant terms lawgovernment regulation stock exchange listing requirement policy code conduct employee handbook employment agreement equity award agreement plan agreement company group amendment termination extent permitted manner consistent applicable law including sec nyse rules committee may terminate suspend amend policy time discretion successors policy shall binding enforceable persons respective beneficiaries heirs executors administrators legal representatives respect covered compensation granted vested paid administered persons entities